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Abstract
Ph.D.
Development of Bioinformatics Tools for Biomedical High-Throughput
Analyses
by Markus List
Despite of improvements in treatment and diagnosis, breast cancer is still the major
cause of death in women world-wide. Highly resilient breast cancer stem cells have been
implicated in treatment resistance, metastasis and tumor relapse, demanding the devel-
opment of new targeted therapies. The combination of large-scale functional genomics
techniques and high-throughput screening (HTS) is a powerful approach to systematically
discover drug targets and novel agents. In one application of HTS, the eect of silencing
each individual gene in the genome is studied via RNA interference. A dierential screen
in triplicates involves approximately 120,000 samples, which can be further utilized in a
secondary readout on the protein level. Here, each sample is typically spotted more than
20 times in a dilution series on so-called reverse-phase protein arrays (RPPAs). Inter-
rogating these for only 10 cancer markers thus leads to 24 million sample spots. Pivotal
to the success of drug target discovery strategies are ecient bioinformatics methods for
sample management, data processing and analysis, as well as systems biology methods to
generate new testable hypotheses. To address these challenges, suitable bioinformatics
web applications were developed in the frame of this thesis.
OpenLabFramework (OLF) is a laboratory information management system covering
all aspects of experimental documentation and sample management in high-throughput
functional genomics. OLF is linked to Sample Management and Visual Analysis of HTS
(SAVANAH ), which provides sample management of molecular libraries and thousands
of microtiter plates. Raw HTS data is normalized, accounting for known sources of vari-
ation, and evaluated in RNAi and compound screen evaluation (RNAice). Furthermore,
RNAice provides functional enrichment analyses and addresses particular challenges for
microRNA and small compound screens, where target genes need to be determined
prior to analysis. Finally, Microarray R-based Analysis of Complex Lysate Experiments
(MIRACLE ) allows for management and analysis of RPPA data, addressing particular
challenges in this technology to obtain protein concentration estimates from dilution
series.
In conclusion, the tools presented here enable researchers to handle millions of samples
across dierent high-throughput platforms. Sample management is streamlined and
highly ecient and in addition, functions for processing, analysis, and visualization are
available. Each of the developed tools can be used alone or as integral part of a high-
throughput drug discovery platform, which has the potential to signicantly accelerate
the development of new treatment options in breast cancer.
Dansk Resume
Ph.d.
Etablering af Bioinformatiske Vrktjer til Biomedicinisk
High-Throughput Data Analyse
fra Markus List
Til trods for fremskridt inden for behandling og diagnosticering, er brystkrft stadig
hovedarsagen til ddsfald blandt kvinder verden over. Srligt eksible brystkrftstam-
celler er blevet impliceret i behandlingsresistens, metastasedannelse, samt tilbageven-
dende tumorer, hvilket krver udvikling af nye malrettede behandlingsstrategier. Kom-
binationen af omfattende funktionelle genomteknikker og high-throughtput screening
(HTS) er en eektiv tilgang til systematisk at identicere gener til malrettet behan-
dling. I en anvendelse af HTS, undersges eekten nar alle individuelle gener i genomet
hmmes enkeltvis via RNA interferens. Et dierentielt screen i triplikater indeholder ca.
120.000 prver, hvilke yderligere kan anvendes til sekundr udlsning pa proteinniveau.
Her spottes hver prve typisk mere end 20 gange i en fortyndingsserie af sakaldte reverse-
phase protein arrays (RPPAs). Dette resulterer i 24 millioner prver, safremt hver enkelt
skal undersges for bare 10 cancermarkrer. Afgrende for succesen af denne strategi
til identikation af behandlingsmuligheder er eektive metoder inden for bioinformatik
til at varetage prverne, databehandling og analyse, samt system biologi til at generere
nye hypoteser. For at gribe disse udfordringer an, udvikledes egnede bioinformatiske
webapplikationer i omfanget af denne disputats.
OpenLabFramework (OLF) er et administrationssystem til laboratorieinformation, hvilket
dkker over alle aspekter af eksperimentel dokumentation same varetagelse af prver fra
high-throughput funktionelle genomteknikker. OLF er koblet til Sample Management
and Visual Analysis of HTS (SAVANAH ), hvilket srger for varetagelsen af molekylre
biblioteker og tusindvis af mikrotiterplader. Ra HTS data normaliseres for at tage
hjde for kendte variationskilder og evalueres i RNAi and compound screen evaluation
(RNAice). Ydermere, muliggr RNAice funktionelle berigelsesanalyser og adresserer
srlige udfordringer for screening af microRNA og kemiske forbindelser, hvor malgenerne
skal fastslas fr analysen. Endeligt tillader Microarray R-based Analysis of Complex
Lysate Experiments (MIRACLE ) administration og analyse af RPPA data, hvor srlige
udfordringer i denne teknologi adresseres for at opna estimater for proteinkoncentra-
tioner fra fortyndingsserier.
Afslutningsvis stter disse vrktjer forskere i stand til handterer millioner af prver
over forskellige high-throughput platforme. Varetagelsen af prver er strmlinet og
srdeles eektiv og i tilgift er funktioner til behandling, analysering, og visualisering
tilgngelige. Hvert af de udviklede vrktjer kan anvendes alene eller som integrered del
af en platform til high-throughput identikation af behandlingsmidler, hvilket potentielt
set signikant kan accelerere udviklingen af nye behandlingsmuligheder i brystkrft.
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Chapter 1
Introduction
1.1 Motivation
Despite of recent advances in prognosis and therapy, breast cancer remains the second
most common cause of cancer-related death in women, accounting for 23% of total cancer
cases and 14% of cancer deaths [1].
Traditional therapies, such as surgical intervention, chemotherapy, and radiation therapy
often fail to capture all tumor cells, leading to tumor recurrence and metastasis, in which
the cancer cells enter the blood stream to spread to other organs with fatal outcome [2].
So-called cancer stem cells (CSCs) are suspected to be the main reason for treatment
resistance. In addition, dierent molecular breast cancer subtypes exist, which dier in
prognosis and treatment requirements [3]. Classifying breast cancer patients into these
subtypes enables precision medicine in which molecular properties of the disease are
exploited with the aim of increasing specicity and ecacy of treatment [4].
To facilitate the development of precision medicine, a better understanding of cancer de-
velopment is needed. Systematic high-throughput approaches are well suited to identify
causal cancer genes, for example, from next-generation sequencing (NGS) or messen-
ger RNA (mRNA) expression data. Such functional genomics approaches are feasible
through advanced cell manipulation techniques. These allow creating large panels of
isogenic cell lines that only dier in the molecular change under investigation. These ap-
proaches are particularly powerful in combination with high-throughput screening (HTS),
in which a large number of experiments can be performed in parallel to study phenotyp-
ical changes and / or to identify genotype-selective vulnerabilities of cancer cells. Mas-
sive amounts of experimental data from these and other high-throughput approaches
can then be analyzed individually or in combination to gain new insights into driving
molecular mechanisms and potential new therapeutic strategies for cancer.
1
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However, a common theme of high-throughput approaches in general is that they demand
advanced bioinformatics methods for sample management and data analysis. Therefore,
the goal of the project underlying this thesis was to deliver intuitive and ecient bioin-
formatics tools to cover several challenges reaching from functional genomics studies
to HTS and array-based proteomics using reverse-phase protein arrays (RPPAs). In-
tegrating these approaches into a drug discovery pipeline will, in addition, reduce the
eorts necessary to keep track across several complex experiments. In this chapter, we
illuminate some basics of the current knowledge of cancer development, as well as some
key obstacles in the treatment of breast cancer, which is the focus of this work.
1.2 Cancer
1.2.1 Development
As they continue to replicate, cells inevitably suer from damage to the DNA, which
is typically detected and repaired. In cancer cells, however, genes involved in DNA
repair are frequently mutated. This allows cancer cells to accumulate mutations and
genetic variations such as insertions, deletions, gene duplication and chromosomal aber-
rations [5]. However, most of the mutations in a cancer cell are passenger mutations
that do not have a signicant eect on cell behavior. Cancer development is triggered
by a set of so-called driver mutations responsible for a step-wise failure of the regula-
tion of various cellular processes. Commonly, dysfunctional cells are programmed to die
from apoptosis. Resisting this process is thus one of the most important hallmarks of
cancer [6, 7]. Other hallmarks include the ability to sustain unlimited cell replication,
to evade the immune system and to manipulate the local environment, for instance,
by stimulating the growth of new blood vessels. While the tumor grows, some cancer
cells may enter the bloodstream through a process, where epithelial to mesenchymal
transition (EMT) could play a role. An EMT causes the cells to change to an invasive
phenotype that is eventually suited for the conditions found in the vascular system. This
process, together with the reverse process, mesenchymal to epithelial transition (MET),
is considered as important for metastatic spread [8]. A better understanding of cancer
progression is imperative to develop drugs that specically target cancer vulnerabilities.
However, cancer is a heterogeneous disease that ideally requires treatment optimization
on a case by case basis. This is in essence the future promise of precision medicine
(Chapter 1.3). In current clinical practice, dierent cancers are divided into subtypes
dened through morphological and molecular characteristics of the malignant cells. The
following chapter will elaborate on known subtypes in breast cancer and their links to
the natural development of mammary tissue.
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1.2.2 Breast Cancer Subtypes
Breast cancer is a heterogeneous disease, in which both treatment and prognosis depend
largely on the subtype of the tumor. Due to its morphology, breast cancer can be
divided into the basal and luminal subtype. The histological status of estrogen and
progesterone receptor, as well as HER2 expression, are used as diagnostic markers to
further dierentiate luminal A, luminal B and the HER2 overexpressing subtype from the
basal subtype, which is also known as triple-negative subtype [9]. A better understanding
of the dierences between these subtypes was achieved through the analysis of gene
expression data, which lead to the distinction of ve major subtypes, i.e. luminal A and
B, basal, HER2 as well as the normal-like subtype [10, 11]. Subtyping based on gene
expression was subsequently successfully commercialized leading to clinical tests such
as Oncotype DXTM (Genomic Health Inc., Redwood City, CA, USA), MammaPrintTM
(Agendia, Amsterdam, NL) or PAM50TM (Prosigna, Seattle, WA, USA). These tests rely
on a set of 50-70 genes that were shown to have prognostic potential with regards to the
clinically relevant subtypes. Larger sample numbers allowed later studies to dene more
ne-grained subtypes, which, however, remain poorly described such that the research
focus remains on the established subtypes [12], with the notable exception of the claudin
low subtype [13].
Progress in understanding the development of normal mammary tissue allowed linking
the dierent molecular subtypes of breast cancer to various types of mammary cells
(Figure 1.1) [14]. Here, the most aggressive subtypes, such as claudin-low and basal
breast cancer, closely resemble stem cells and progenitor cells in their gene expression
prole. In contrast, the less aggressive luminal types resemble the more dierentiated
epithelial and myoepithelial cells. Moreover, the frequency of the dierent subtypes
matches the relative abundance of these cell types in breast tissue, making luminal A
breast cancer the most frequent subtype. Evidence suggests that the breast cancer
subtypes originate from mutations and genetic rearrangements occurring in stem or
progenitor cells [15, 16]. In theory, this establishes a link between the origin of the breast
cancer subtypes and the cancer stem cell model introduced in the following chapter.
Although this link is controversial, it could be shown that the cancer stem cell content
in fact correlates with the level of dierentiation inherent to the dierent subtypes [17].
1.2.3 Cancer Stem Cells
Cancer stem cells (CSCs), also known as tumor initiating cells, have been implicated
in treatment resistance and tumor relapse. CSCs represent a small sub-population of
cancer cells that share properties of normal stem cells, such as asymmetric cell division,
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Figure 1.1: Breast cancer can be divided into molecular subtypes that are linked
to the dierent stages of cellular development of the mammary tissue. Moreover, the
frequency and aggressiveness of the subtypes is reected by the dierentiation and
relative abundance of these cell types. Adopted from [14].
which allows them to grow new tumors in which the majority of cells are again non-
CSCs (Figure 1.2) [7, 18]. CSCs have been shown to express EMT markers [19], which
makes them the primary suspects for the cause of the metastatic spread of the disease.
The fact that EMT and MET have been observed in stem cells and progenitor cells
in embryonic development indicates that this is a naturally occurring phenomenon that
escaped regulation in cancer progression [20].
There is consensus that future therapies must target CSCs to fully eradicate the pri-
mary tumor and to prevent metastasis [3]. Several factors complicate such an endeavor.
CSCs appear to exist in multiple forms and have even been shown to emerge through
de-dierentation of bulk tumor cells [22]. This requires a set of highly specic drugs
that act in combination to eradicate all types of tumor cells by exploiting their genetic
vulnerabilities.
Chapter 1. Introduction 5
Self-renewal 
Assymetric 
Cell Division 
Stem 
cell 
Progenitor 
cell 
Differentiated 
cell 
Mutation 
Cell fate conversion 
Figure 1.2: The cancer stem cell (CSC) model suggests that mutations in stem or
progenitor cells lead to CSCs, which have the ability to grow a tumor through asymmet-
ric cell division. The resulting tumor consists of a few self-renewing CSCs and a bulk
of more dierentiated tumor cells. The stem-cell properties of CSCs implicate them
in treatment resistance, tumor relapse and metastatic spread of the disease. Adopted
from [21].
1.3 Precision Medicine
While some of the commonly de-regulated pathways in cancer are already known, it is
not clear, without knowledge of the DNA sequence and the epigenetic patterns of the
tumor, which particular mutations and epigenetic alterations caused a tumor to emerge
and which of several redundant molecular mechanisms are aected. This has tremendous
impact for selecting an eective treatment strategy, since the molecular properties of the
tumor need to be understood on a patient-by-patient basis. Originally, this principle
was therefore coined personalized medicine. However, since this can be misleading, the
term precision medicine has been suggested as a replacement, highlighting that instead
of oering a dierent drug for each patient, molecular properties of the patient's tumor
are exploited more eciently than in the past [23].
With the rise of NGS technologies and the steady decrease in both time and costs nec-
essary to sequence a human genome, obtaining the full sequence of a patient's tumor
will soon be a feasible option and thus enter clinical practice [24]. First of all, however,
a better understanding of exploitable tumor properties, and of CSCs in particular, is
needed. This is the goal of drug target screening and is intended to lead to the develop-
ment of novel drugs that can then be used to eradicate all tumor cells, including CSCs,
with high precision [3]. The key obstacle in this, is to make sure that non-cancerous
cells remain mostly unharmed. To this end, the concept of synthetic lethality can be
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utilized [25].
1.4 Synthetic Lethality
In synthetic lethality, two factors, such as two genes, are exploited in combination to
achieve a lethal outcome. Let us assume a pair of genes provides the same essential
function. Let us further assume that one of the two genes can be inactivated, e.g.
through a drug. In this case the remaining active gene can still provide the essential
functionality to the cell and the cells can continue to survive. If, however, both genes
were inactivated simultaneously, no compensation mechanism would be left to provide
the essential functionality and the cells would die.
Cancer is a disease in which cellular regulation mechanisms are disturbed, a fact neces-
sary for cancer to develop. To maintain this status, cancer cells depend on mutations
in molecular key pathways, which suggests that it is possible to nd a scenario where
one of two synthetic lethal factors is already inactivated through a mutation. Such a
mutation may lead directly or indirectly to the hyperactivation of so-called oncogenes,
i.e. genes that are implicated in cancer development and progression. This phenomenon
is also referred to as oncogene addiction, due to the importance of these genes for cancer
survival, and can be exploited for targeted anti-cancer therapy [26]. Synthetic lethal
screening aims at nding a drug that can kill cancer (stem) cells specically and to leave
healthy (stem) cells intact (Figure 1.3). For a subset of breast cancer patients, this strat-
egy proved already successful. Here, one of two DNA repair mechanisms is inactivated
due to a mutation in the BRCA1/2 genes. Inhibiting the gene PARP through a drug
removes the only alternative DNA repair mechanism, which causes cancer cells to die
leading to tumor regression [27]. In the past, however, the discovery of such synthetic
lethality scenarios proved dicult due to a lack of suitable techniques for cell manipula-
tion at the genetic level [28]. Such techniques are presently available and allow for large
scale functional genomics studies.
1.5 High-Throughput Functional Genomics
The aim of functional genomics is to study the function of genes at a substantial sys-
tematic scale. In this context, the term gene can refer to protein coding genes, as well
as to microRNAs (miRNAs) or long non-coding RNAs (lncRNAs). In general, func-
tional genomics can be divided into loss-of-function (LOF) and gain-of-function (GOF)
studies [29]. In the following, the major methods for functional genomics studies are
presented.
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Figure 1.3: In the concept of synthetic lethality, two genes A and B provide an
essential function to the cell in a redundant fashion. Inactivating one of the two genes
will thus not aect healthy cells, but might prove lethal for cancer cells that do not
possess an active copy of the second gene for compensation.
1.5.1 Loss-of-function Studies
LOF studies allow functional characterization by blocking either the expression or the
function of a gene. In a gene knock-out experiment, a gene is rendered permanently
dysfunctional. This can be achieved using transposons or retroviruses that target DNA
sequences through homologous recombination to introduce a mutation. Alternatively, a
gene knock-down, implying a transient inactivation of a gene, can be performed. Tran-
sient inactivation can be achieved by RNA interference (RNAi), while permanent in-
activation or introduction of point mutations can be achieved via more sophisticated
genome editing methods.
1.5.1.1 RNA interference (RNAi)
The RNAi pathway was rst observed in 1990 in plants, where a trans-gene was sus-
pected to have a gene silencing eect [30]. Nearly ten years later, Fire et al. could
unravel the mechanism of RNAi and the role of double-stranded RNA in Caenorhabditis
elegans, for which they received the Nobel prize in 2006 [31]. RNAi is a cellular process
aimed at regulating the endogenous levels of messenger RNA (mRNA) in a cell and thus
eectively regulates the amount of protein that can be translated. The RNAi pathway is
mainly triggered by endogenous so-called miRNAs, which can down-regulate or silence
up to several hundreds or even thousands of target genes by repressing the translation
of the gene's transcribed messenger RNA. This makes miRNAs the most important key
players in cellular regulation next to transcription factors. Apart from miRNAs, the
RNAi pathway can be triggered by small interfering RNAs (siRNAs), which naturally
occur in the defense against viral DNA. In contrast to miRNAs, siRNAs typically have
a specic target. It was soon discovered that this can be exploited to achieve nearly
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complete gene knock-downs in LOF studies. The RNAi pathway is illustrated in Figure
1.4 and will be explained in more detail in the following two chapters.
1.5.1.2 MicroRNAs
Changes in miRNA expression have been implicated in breast cancer progression [32]
and several miRNAs have been shown to be of major importance in breast cancer [33].
This suggests a potential not only as diagnostic and prognostic biomarkers, but also for
the development of targeted therapies after successful drug target screening [34].
Mature miRNAs are 19 to 25 nucleotide long non-coding RNAs that function in the
endogenous RNAi mediated repression of mRNAs. After transcription, miRNAs are
generated via a series of processing steps. Primary miRNAs (pri-miRNAs) are rst
transcribed by RNA Polymerase II, leading to 70-100 nucleotide long hairpins known
as precursor miRNA (pre-miRNA). Overhanging single stranded ends are subsequently
cleaved by the endonuclease Drosha, before the precursors are transported from the
nucleus into the cytoplasm by Exportin-5. In the cytoplasm, the loop structure is
cleaved by the endonuclease Dicer, such that only a short-lived miRNA duplex remains.
Only one of the two strands in this duplex, either the 3p or 5p variant, is usually active
and is integrated as guide strand in the RNA induced silencing complex (RISC). The
complementary strand, also known as passenger strand, is usually degraded. In the
RISC complex, the guide strand interacts with the mRNA target site by base pairing.
Perfect or almost perfect complementarity is only achieved in the so-called seed region
at the 5' end of the miRNA, while a bulge seems to be required in the central region
of the miRNA-mRNA duplex. Moreover, a good complementarity at the 3' end of the
miRNA is advantageous to nally mediate the endonucleolytic cleavage of the mRNA
through a member of the Argonaute protein family, which is part of the RISC complex.
The miRNA-mediated post-transcriptional control is explained exhaustively in [35].
1.5.1.3 Small interfering RNAs
As described in the previous chapter, miRNAs achieve perfect complementarity only in
the seed sequence. This allows them to target a large number of dierent genes. In
contrast, siRNAs achieve perfect complementarity to their target mRNA over the entire
length. Naturally, they occur as non-coding RNA duplexes or hairpins of the same length
as miRNAs. They have been implicated in the cell's defense against viruses, which often
operate through double stranded RNAs to manipulate their host cells. After their initial
discovery, it became soon clear that synthetic siRNAs can be utilized to specically
silence genes [36]. This triggered a massive research interest in siRNAs for inuencing
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cellular gene expression, as well as their potential use for targeted therapeutics. They
proved particularly useful for HTS scenarios and have been successfully applied in many
genome-wide LOF studies [37, 38]. However, caution is advised, since several studies
indicate that siRNAs can suer from o-target eects. This implies that a change in
phenotype can not always be clearly attributed to the target gene that was intended
to be inactivated [39]. Several strategies have been proposed to circumvent this issue,
including pooling siRNAs with dierent sequences, control experiments to detect true
and false positives, as well as several bioinformatics approaches. These strategies are
reviewed in detail in [40].
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mRNA 
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Target mRNA cleavage 
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Figure 1.4: The RNA interference (RNAi) pathway is utilized by miRNAs and other
RNAi reagents. Single stranded ends of the pri-miRNA are cut by Drosha. The re-
sulting pre-miRNA is exported out of the nucleus, where Dicer cleaves the loop away.
The short-lived double stranded miRNA is separated and the active miRNA strand
enters the RISC complex, where it leads to the recognition of a target mRNA se-
quence and to translational repression. In contrast to miRNAs, which recognize up to
several hundreds of target genes through imperfect matching, small interfering RNA
(siRNA) show perfect complementarity to the target sequence and lead to cleavage
and immediate degradation of the mRNA. SiRNAs can start as small hairpin RNAs,
long double-stranded RNA (dsRNA), synthetic siRNA (siRNA), or endoribonuclease-
prepared siRNA (esiRNA). Adopted from [40, 41]
1.5.1.4 Genome Editing Methods
In the past few years, genome editing methods have become an attractive alternative,
which can be used to modify or edit existing genes directly within a living cell. One
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example of such a method are transcription activator-like eector nucleases (TALENs).
These bind to genomic sequences anking a target site and introduce double strand
breaks. In consequence, a repair method known as nonhomologous end-joining is trig-
gered, which, however, is error-prone and introduces small insertions or deletions in
the target sequence. The resulting frame shifts are likely to cause a knock-out of the
gene [42]. Alternatively, a donor template can be used to trigger a homology-directed re-
pair pathway. The gene at this locus can thus be edited, allowing for a specic mutation
to be studied. Moreover, this technique can in principle be used to repair dysfunctional
genes by exchanging a mutated site with a non-mutated template, suggesting a huge
potential for gene therapy. Another example of a similar genome editing method are
zinc-nger nucleases (ZFNs), which consist of two domains, a zinc-nger domain that
facilitates targeting to a specic DNA site as well as a nuclease domain that also intro-
duces a double strand break triggering DNA repair [43]. A more recent genome editing
method is the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9
system.
1.5.1.5 CRISPR/Cas9
CRISPR are a central part of a bacterial defense system in which invading DNA from
viruses or plasmids is cut into small fragments and incorporated into a CRISPR locus
anked by a series of short repeats of around 20 base pairs in length. Transcripts of this
locus are processed to generate CRISPR RNAs (crRNAs), which, together with a trans-
activating crRNA (trRNA) serves as a guide for endonucleases. Three similar CRISPR
mechanisms are known to date. In contrast to type I and III, however, type II depends
only on a single eector protein, an endonuclease called Cas9. The crRNA facilitates
targeted cleavage of the invading DNA through sequence complementarity, together with
a short conserved sequence of 2 - 5 nucleotides length known as protospacer-associated
motif (PAM), which follows immediately 3' of the crRNA complementary sequence.
Jinek et al. were able to recruit this mechanism as a tool for functional genomics by
combining crRNA and trRNA into a single synthetic single-guide RNA (sgRNA) [44].
The simplicity of the method has quickly made the CRISPR/Cas9 system a popular
choice for LOF studies. Mutated versions of Cas9 allow for further applications, such
as Cas9D10A, which cuts only one of the strands and can be used for homologous
directed DNA repair via a donor template [45]. Another promising application allows
in-vivo visualization using a version of Cas9 that has been fused with an enhanced green
uorescence protein [46]. In contrast to TALENs and ZFNs, where the DNA-protein
interface needs to be adapted for each target gene, the CRISPR/Cas9 system requires
only the design of a suitable sgRNA. This makes it easy to engineer and thus a powerful
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alternative to RNAi technology for genome-wide LOF screening. Considering the issue
of potential o-target eects, Mohr et al. suggest to complement RNAi screening with
CRISPR/Cas9 to achieve a higher condence in the observed eects [40].
1.5.2 Gain-of-function Studies
In contrast to LOF studies, GOF studies employ an over-expression system to study the
eect of expressing a particular gene beyond its natural expression level or to express
genes that do not yet exist in the target organism's genome. The process of delivering
DNA or RNA through target's cell membrane is called transfection. Even naked DNA
or RNA can be transfected through physical methods such as micro injection or electro-
poration. Chemical methods involve wrapping the negatively charged nucleic acids in a
positively charged complex using, for instance, suitable lipids. Even though the details
are not known, it is believed that these complexes can then enter the cells through en-
docytosis and phagocytosis and translocate to the nucleus. Finally, biological methods
allow virus or transposon-mediated transfection. Depending on the transfection strat-
egy, the target DNA or RNA can either be integrated into the genome and henceforth be
expressed stably across generations / cell cycles or in case of a transient transfection be
expressed over a limited period of time. A detailed review about transfection methods
can be found in [47].
1.5.3 Isogenic Cell Lines
A particularly useful technique in functional genomics is targeted transfection, in which
a cell line receives an acceptor vector that is integrated into the genome. The role of the
acceptor vector is to facilitate site-specic recombination. To this end, a secondary vector
system, which carries a gene ormiRNA, is integrated at the acceptor site. Dierent types
of secondary vector systems allow for genes to be expressed in a stable or inducible
fashion. This allows researchers to generate a panel of isogenic cell lines that dier only
by the gene of interest, which makes them ideal for studying the eect and function
of a gene and for drug screening in general [48]. In principle, two dierent acceptor
vectors can be used to create double recombinants with two dierent genes. These are
particularly suitable for studying scenarios of synthetic lethality.
1.5.4 Sample Management
In the past, functional genomics tools have already proven essential for the discovery and
characterization of potential oncogenes, e.g. genes that are known to cause cancer, and
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potential tumor suppressors [49]. It is clear that large-scale functional genomics studies
accumulate not only a signicant amount of data, but, independent of the techniques em-
ployed, lead to the creation of several thousands of samples representing various stages
of the experiment. For example, the maintenance of a vector library for all human genes
would already amount to more than 20,000 samples. If a subset of these genes was to
be used for stable transfection of a panel of dierent cell lines, the number of samples
would already increase dramatically. It is therefore imperative for any high-throughput
functional genomics laboratory to establish and maintain a laboratory information man-
agement system (LIMS) to keep track of these samples and the associated experimental
data. OpenLabFramework (OLF), which is a novel LIMS system tailored towards high-
throughput functional genomics, was implemented during this thesis and is presented in
Chapter 3.
1.5.5 Assay Types
Subsequent to the selection and application of a genome perturbation method, a large
number of possible experimental assays are available for functional characterization of
the perturbed gene. These assays can be divided into the observations of signature
changes and observation of phenotypical changes. The most common type of signature
data is gene expression data, which allows to compare the relative abundance of mRNA
levels between samples or conditions. Originally, gene expression was measured with
microarray technology, in which oligonucleotides are immobilized on a glass slide and
serve as bait for the mRNA. However, this technology is slowly being replaced by NGS ,
which also allows measuring mRNA levels in so-called RNA-seq [50]. Using the same
techniques, the expression of miRNAs or lncRNAs can also be determined. Moreover,
variations of these methods enable researchers to obtain epigenetic signature informa-
tion by measuring DNA methylation. Finally, a protein expression signature can be
established using RPPAs (Chapter 1.7) or mass spectrometry. Phenotypic assays can
complement signature information by providing additional information on the capabil-
ity of cells to proliferate, to change appearance or to cause metastasis, for instance.
Phenotypic assays are suitable for HTS .
1.6 High-Throughput Screening
In 1999, shortly before the completion of the human genome project, Evans et al. pointed
out that the combination of functional genomics and HTS was expected to drive future
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pharmacological studies [51]. This eld, also called pharmacogenomics, aims at unrav-
eling the underlying mechanisms of drug action, which is a crucial step for the advance-
ment of precision medicine in cancer. Obviously, a drug utilizing specic genetic traits
is of no use if those traits are not found in a particular tumor. Therefore, to know if a
drug can be eective, the drug targets need to be identied. Most drugs, however, act
through more than one gene, making such studies challenging and highlighting the need
for high-throughput approaches that can also deal with polygenic scenarios. Moreover,
LOF studies require large-scale experimental setups to sequentially test the eect of
silencing genes on a genome-wide level.
1.6.1 Automation and Miniaturization
Formerly applied exclusively by pharmaceutical companies, industrial-scale HTS is nowa-
days entering more and more academic institutions, which often seek to extend the appli-
cation beyond traditional chemical compound screening. HTS is generally characterized
by a high degree of automation, which allows several thousands of experiments to be
performed each day. This is achieved through miniaturization as well as through the ex-
tensive use of robotics. Experiments are typically performed in microtiter plates carrying
between 96 and 1536 wells. A robotic station for high-throughput drug screening usually
consists of an assembly of machines such as plate hotels, incubators, freezers, pipetting
stations and instruments for various readouts, which are fully integrated through con-
veyor belts and robotic arms to achieve full automation.
1.6.2 Types of Readouts
The result of an HTS experiment is typically captured with plate readers, which are
used to quantify the outcome of an experiment via absorbance, uorescence, or lumi-
nescence. These instruments are often capable of multiple readouts on several wave
lengths, allowing for several parameters of an experiment to be measured or to conduct
several experiments in parallel. Typical applications are assays that reect cell viability
or metabolic activity. The focus on the numeric output of a plate reader distinguishes
HTS from high-content screening (HCS), in which automated microscopes are used for
image acquisition. For a more detailed review of the development of the HTS eld
see [52].
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1.6.3 Types of High-Throughput Drug Target Screens
In most HTS studies, cultured cell lines serve as an in vivo model system. HTS was
originally developed by the pharmaceutical industry to be able to test large libraries
of small molecules and chemical compounds for drug discovery. Nowadays, many HTS
studies utilize libraries of, for instance, siRNAs, small hairpin RNAs (shRNAs), sgRNAs
or miRNA inhibitors / mimics to study the eect of a large number of genes up to the
genome-wide level. Even though the latter represents a more controlled and targeted
approach, chemical compound screening is still very relevant since small molecules can in
many cases be engineered into eective drugs, while reagents targeting genes still suer
from the lack of an ecient and specic drug delivery system that can be considered
safe in humans [53].
Nevertheless, gene-targeting LOF screens are eective tools for identifying putative
drug targets irrespective of how these can later be used for successful treatment. The
interrogation of two or more cell lines with the same screening library allows researchers
to establish not only vulnerabilities of a single cell-line, but to focus on cell line specic
vulnerabilities. The idea is that one cell line serves as a baseline, i.e. genes that prove
lethal here are not disease-specic but are generally important for survival and can be
disregarded. In this way, dierential screening between several cell lines can be helpful to
uncover potential scenarios for synthetic lethality [54]. A gene knock-down or knock-out
that is lethal in only one of two or more cell lines might point to a synthetic lethal target
gene. Possible examples of dierential screens include comparisons between cancerous
and non-cancerous cell lines, between cell lines representing dierent molecular subtypes
or between cell lines enriched in CSCs and cell lines that consist mainly or exclusively
of bulk tumor cells. Due to its versatility, the same HTS platform can also be used to
study ecacy of a specic drug on a large number of samples or to test the ecacy of
novel drug delivery systems.
1.6.4 Sample Management
Irrespective of the type of HTS experiment, it is clear that sample management is a
key issue in the eld. Hundreds or even thousands of individual plates need to be
tracked eciently, together with detailed sample information for up to 1536 individual
experiments per plate. Moreover, the sample information needs to be linked with one
or several types of measurements obtained, e.g. through plate readouts. To deal with
these challenges, Sample Management and Visual Analysis of HTS (SAVANAH), was
developed (Chapter 5).
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1.6.5 Data Analysis
HTS data generally suers from variation caused by, for instance, plate, batch, library,
and positional eects [55, 56]. The robust identication of putative hits, e.g. samples
with a desired phenotype, from a single screen or the comparison of several independent
screens thus crucially depends on normalizing these data appropriately. Unfortunately,
there is currently no standard for processing HTS data, since dierent normalization
strategies can lead to largely varying results. The inherent problem is that dierent
data sets suer from dierent types of variation to a varying degree. Moreover, control
samples that are utilized in some normalization methods do not always perform as
expected. Therefore, no single normalization method is ideally suited for all data sets.
This poses a signicant hurdle for the analysis of HTS data in general and for secondary
and comparative analyses in particular [57]. Additionally, advanced normalization and
hit detection strategies can be dicult to apply due to a lack of suitable analysis software.
To mitigate this, an intuitive and user-friendly tool named RNAi and Compound Screen
Evaluation (RNAice) was implemented (Chapter 6).
The versatility of a HTS platform makes it indispensable for drug target discovery.
However, even though it is in principle possible to employ several readout strategies in
parallel, the amount of information available from a single experiment is limited. Fur-
thermore, HTS experiments cause considerable costs and experimental eorts, such that
it is desirable to reuse the treated samples for additional high-throughput experiments.
One possibility to gain additional information on the protein level is presented in the
following chapter.
1.7 Reverse-Phase Protein Arrays
Reverse-phase protein arrays (RPPAs) are typically nitrocellulose covered glass slides on
which crude lysates of tissue samples or treated cell lines are spotted. Each single slide
can carry several thousand spots. Notably, only very small amounts of lysate in the range
of a few cell equivalents are required for each spot. Consequently, several hundred slide
copies can be created at minimal sample consumption, each of which can be interrogated
with a dierent protein-specic antibody. This allows high-throughput measurement of
the relative abundance of proteins in up to several thousand samples. Parallel processing
of large sample numbers discerns RPPAs from forward phase arrays, where probes are
immobilized on a slide, and mass spectrometry, which are both suitable methods for
the analysis of many proteins in small sample numbers. Due to the support of large
sample numbers, RPPAs are well suited as secondary readout for HTS , since they can
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signicantly increase the amount of information gained from each single experiment. In
cancer research, RPPAs allow to measure the abundance of known oncogenes on the
protein level, establishing a link between the observed eects of silencing a gene and
known mechanisms of cancer biology. Measuring these eects on the protein level is
a huge advantage over detection methods that measure the mRNA level, since mRNA
levels do not necessarily reect actual protein amounts.
The eld of RPPAs has shown steady growth since its introduction in 2001 [58]. Sev-
eral studies have applied this technology successfully to protein and signaling pathway
analyses in cancer [59{62], as well as for cancer classication in general, cancer subtype
classication and prognosis of disease progression [63{66]. The relevance of RPPA data
for multi-OMICS and high-throughput projects is also highlighted by its inclusion into
The Cancer Genome Atlas (TCGA) [67], which already lead to a large pan-cancer study
using 181 antibodies for 128 dierent proteins in 3,467 samples [68].
Experimental challenges involved in this technology, such as antibody selection, sample
preparation and optimization of staining conditions have been addressed successfully
in the past [69{73]. However, a comprehensive solution addressing bioinformatics chal-
lenges emerging from the RPPA technology was missing.
1.7.1 Sample Management and Data Analysis
Using a state-of-the-art spotting device, a single RPPA slide of approximately 12 cm2
can easily carry up to approximately 15,000 spots. Each of these spots corresponds to
a sample that needs to be tracked back to one of several microtiter plates that serve as
sample source for the spotter. In a scenario where RPPAs are used as a secondary read-
out, these plates typically originate directly or, if a reformatting step becomes necessary,
indirectly from an HTS experiment. Samples are often spotted in varying numbers of
depositions and in a dilution series. The various combinations of dilutions and deposi-
tions guarantee that a broad dynamic range can be covered for signal detection. This,
however, also increases the complexity of the experiment tremendously. Moreover, even
single experiments often span several slides, where each slide is spotted in dozens of
dierent copies. This is necessary, since each copy can be stained with a dierent an-
tibody to measure the abundance of a large number of dierent proteins. Antibodies
can be produced that recognize specic isoforms or post-transcriptional modications,
allowing more ne grained studies. Thus, the number of samples that need to be tracked
on RPPAs virtually explodes in a high-throughput setting. This demands for a sample
tracking solution tailored towards the characteristics of RPPAs. Due to the fact that
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samples are spotted in a dilution series, RPPAs have unique requirements for data anal-
ysis. Furthermore, the fact that each protein is measured on a dierent slide with a
dierent antibody leads to dierent signal distributions, creating additional challenges
for comparing samples across dierent proteins. A web application tailored towards
the specic needs of RPPA sample management and data analysis was lacking in the
eld [74]. This was the motivation to develop Microarray R-based Analysis of Complex
Lysate Experiments (MIRACLE), which addresses both sample management and anal-
ysis challenges for customized arrays in general and RPPAs in particular (Chapter 7).
In conclusion, RPPA technology is an appropriate end-point for HTS experiments and
contributes essential knowledge for characterizing putative drug targets. The combi-
nation of functional genomics, HTS and RPPA therefore constitutes an ecient drug
discovery platform.
1.8 An Integrated Functional Genomics Platform for Drug
Discovery
High-throughput functional genomics studies combine next-generation cell manipulation
techniques with the power of a HTS screening platform. This allows large-scale drug
target discovery experiments, aimed at, for instance, identifying disease specic vulner-
abilities. Adding a secondary readout at the protein level strengthens this approach
considerably in enabling a better characterization of the identied drug targets in the
context of established biological knowledge. This constitutes a drug target discovery
platform that has the potential to deal with the complexity of multi-factorial diseases
and polygenic scenarios such as that of synthetic lethality (Figure 1.5A). Such a platform
is thus ideally suited to identify cancer vulnerabilities in general, as well as to discover
genes or miRNAs that may serve as a basis for developing drugs targeting, for instance,
CSCs with high specicity. Fully harnessing the power of this approach requires not
only ecient bioinformatics tools that deal with the specic technological and analysis
challenges of functional genomics, HTS and RPPA, but also the tight integration of
these tools. This enables researchers to eciently track large scale experiments across
various high-throughput technologies, even though the sample complexity increases in
each step. Most importantly, the accumulated information captured by this platform
establishes a broad view on gene and miRNA function. Combined with other systems
biology resources such as protein-protein interaction networks, these data permit inves-
tigating bio-medical questions on a genome-wide level as was already demonstrated in
previous studies [75, 76]. Such integrated approaches hold the potential to shed light
onto open questions, as, for example, the origin of CSCs and their role in treatment
resistance, metastasis and in the emergence of the dierent cancer subtypes. Moreover,
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this can lead to a better understanding of disease biology, which can in turn be exploited
to make future drug screening eorts more focused and ecient [77].
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High-Throughput 
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Reverse-Phase Protein 
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Primary 
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Chapter 6 
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Figure 1.5: A: Setup of the Drug Discovery Pipeline proposed in this thesis. Exist-
ing high-throughput data and biological knowledge can be used to generate testable
hypotheses. Functional genomics methods can subsequently be used to design exper-
iments based on gain-of-function or loss-of-function. These alterations can be tested
in high-throughput screening setups, which allow drug target discovery at the genome-
wide level. Potential drug targets can be characterized at the proteomics level through
RPPA technology. This generates new knowledge that again serves as basis for the
design of further experiments. B: The thesis structure is inspired by the drug discovery
platform. Chapter 2 illustrates how publicly available OMICS data can be used to gen-
erate leads for high-throughput experiments. Chapter 3-7 present software tools that
solve bioinformatics challenges inherent to the respective domains of the platform.
1.9 Thesis Structure
The thesis structure shown in Figure 1.5B is based on the drug target discovery platform
introduced above.
 Chapter 1: The current chapter provides a general introduction to high-throughput
functional genomics, HTS , as well as the RPPA technology.
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 Chapter 2: A major application of this platform is to widen our knowledge of
the emergence of breast cancer and its various molecular subtypes. Therefore,
an initial study investigates the issue of correctly classifying breast cancer sub-
types from sample data by combining two prominent and widely available types
of OMICS data, namely gene expression and DNA methylation, in a statistical
learning approach.
 Chapter 3: In functional genomics research several hundreds or thousands of
samples, such as vector constructs or genetically engineered cell lines, need to be
tracked eciently. Due to a lack for a suitable LIMS for functional genomics re-
search, we developed OpenLabFramework (OLF ), a modular and extensible system
suitable for functional genomics and other research domains.
 Chapter 4: Here, OpenLabNotes, an extension to OLF that allows it to also serve
as an electronic laboratory notebook (ELN), is presented.
 Chapter 5: This chapter introduces Sample Management and Visual Analysis of
HTS (SAVANAH ), a sample management system suited to deal with particular
challenges that arise when routinely performing HTS experiments, such as the
management of extensive molecular screening libraries.
 Chapter 6: SAVANAH is complemented by RNAi and Compound Screen Evaluation
(RNAice), which deals with challenges in data normalization, visualization and hit
detection in HTS data. Moreover, downstream functional analysis is provided for
several types of HTS experiments.
 Chapter 7: The drug target discovery platform is completed with MIRACLE,
which addresses challenges specic to RPPA experiments. This includes sample
management, which is complicated by the complex spotting process and data anal-
ysis challenges, such as obtaining a single protein concentration estimate from each
dilution series on a slide.
 Chapter 8: Details about the implementation of the various tools are presented
in this chapter. Common as well as unique elements and software design strategies
are pointed out.
 Chapter 9: This chapter provides a summary of the eorts described in this
thesis, as well as a general discussion and conclusion.
 Chapter 10: An outlook on future developments and extensions of this drug
discovery platform is described in this chapter.
 Appendix A-D: The appendix includes references, lists of gures, tables and
abbreviations, as well as supplemental tables (Chapter A), gures (Chapter B) and
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information about the availability of the source code, additional documentation,
and demo applications (Chapter C), and supplemental methods (Chapter D).
Chapter 2
Classication of Breast Cancer
Subtypes by Combining Gene
Expression and DNA Methylation
Data
z
Objective of this Chapter
Here, we investigate, if DNA methylation data can contribute positively to
breast cancer subtype classication. To this end, the performance of four
dierent machine learning models is compared:
 A control model based on the expression of 50 gold standard genes.
 A model based on gene expression data.
 A model based on DNA methylation data.
 A model based on both types of data.
The correct diagnosis of breast cancer subtypes is of great importance for optimal treat-
ment selection and a crucial rst step for the successful application of precision medicine.
Discovering and utilizing subtype specic vulnerabilities of cancer, however, requires
knowledge of robust biomarkers as well as suitable methods that allow one to quickly
assess the subtype of a particular tumor. So far, the dierences between breast cancer
subtypes were mostly studied based on gene expression data [78], even though there
is clear indication for the involvement of epigenetic eects [79]. Therefore, the follow-
ing study that was published in [80] investigates, if DNA methylation data can make
21
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a positive contribution to the performance of breast cancer subtype classication. To
this end, we will rst highlight the current state of the art in breast cancer subtyping,
before investigating how supervised machine learning models could benet from DNA
methylation data.
2.1 State of the Art
In contrast to the subjective histological classication through pathologists, gene expres-
sion proling is considered an objective, accurate and robust alternative [81]. To nd
a set of genes with prognostic properties, Perou et al. performed a systematic charac-
terization of expression proles of histologically determined subtypes [10]. Srlie et al.
subsequently identied an \intrinsic" set of 427 genes that was signicantly associated
with disease outcome [11]. In 2009, Parker et al. suggested a more concise set of 50
genes (referred to as PAM50) with good prognostic performance that currently serves
as a gold standard for subtype classication [82]. In recent years, various supervised
and unsupervised machine learning methods were applied to extract a subset of genes
allowing for robust classication of subtypes, including support vector machines [83] and
random forests [84]. Furthermore, Daemen et al. exposed a panel of 70 breast cancer
cell lines to 90 dierent therapeutic reagents with the goal to identify prognostic mark-
ers that would allow for predicting treatment response using copy number aberration,
mutation, gene and protein expression, as well as methylation data. They conclude that
no single data set was optimal (25% success rate for transcription data) for delivering
prediction markers, emphasizing that multiple data types should be used together (65%
success rate).
Online resources such as The Cancer Genome Atlas (TCGA) [67] provide open access
to multiple types of breast cancer related OMICS data. This suggests to combine the
prognostic potential of gene expression data with data from other OMICS technologies.
In this thesis, the focus was on DNA methylation data, which has been shown to play
a major role in many cellular processes and in cancer development [85]. Several studies
have already shown that random forest models based on gene expression proles can
be used for successful breast cancer subtype classication [78, 84, 86]. Since DNA
methylation patterns also dier for breast cancer subtypes [79, 87] and since they can
signicantly alter the gene expression dynamics [85], it can be expected that DNA
methylation data can be applied similarly. Moreover, it can be hypothesized that an
integrated model, using DNA methylation and gene expression proles alike, is superior
to the individual models.
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2.2 Material & Methods
2.2.1 Data
Gene expression and DNA methylation data were downloaded from TCGA [67] in pro-
cessed and normalized form. Along with these data, TCGA provided a subtype classi-
cation of all gene expression samples via the gold standard PAM50. The gene expression
data set contained samples of 547 breast cancer patients. Three samples were marked
as metastatic and removed. We could match all but one of the remaining 544 samples
to the methylation data set, resulting in a total of 543 samples for analysis. It should
be noted that of the 30 samples recognized as normal by PAM50, only 22 were actual
non-tumor samples according to the sample identier used by TCGA.
2.2.2 Classication
2.2.2.1 Random Forest and Bootstrapping
We applied the varSelRF R package [78] to perform random forest classication on (1)
the gene expression dataset (gene expression model), (2) the DNA methylation data set
(methylation model), (3) a combination of both datasets (combined model) and (4) a
reference model, in which we applied random forest using only the 50 genes used in the
PAM50 classier (control model). The combined feature space was created by appending
all feature columns of the methylation to the gene expression feature matrix, allowing
the random forest method to use both sources for feature selection (Figure 2.1).
Recursive Feature Elimination:
For each model, we applied varSelRF with default settings. Initially, 5000 trees were
constructed, in order to remove the bulk of features that were not relevant for classi-
cation. For each tree the square root of the number of features of the current feature
space were selected for construction. Subsequently, the feature set was further reduced
in several additional random forest runs with 2000 trees each, while the set size was con-
tinuously reduced by dropping the 20% least important features. This so-called recursive
feature elimination was repeated until a tree with only two splits was left. Afterwards,
the model with the lowest out-of-bag error (OOB) was returned as solution.
Bootstrapping:
In order to assess how results between several independent runs agreed and how much
our models suered from overtting, we applied the .632 bootstrap method [88]. This
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Figure 2.1: Four dierent models were created using gene expression data (1), DNA
methylation data (2), a combination of both (3), and a gene expression data subset
of 50 genes that are part of the gold standard PAM50, which also delivered the class
labels [82] (4). The R package varSelRF was applied in 10 independent bootstrap runs
(using the .632 bootstrap rule) to obtain a minimal set of features for classication. To
this end, the feature space was recursively reduced by removing insignicant features.
method is similar to cross validation, since only one part of the data set is used for
training the model, while the other part is kept for model validation. In contrast to
cross validation, however, the .632 bootstrap method creates datasets of the same size
as the original dataset through sampling with replacement and is therefore sometimes
also referred to as smoothed cross validation. Following 10 iterations of bootstrapping,
we calculated the .632 bootstrap error, which is dened as the weighted average of (1)
the classication error on the training data and (2) the so-called leave-one-out bootstrap
error, where samples that were not part of the training data (the ones \left out") were
used to validate the model [78].
2.2.2.2 Feature Importance
The most signicant features were extracted through sorting of all feature lists for the
mean decrease of the gini index or gini coecient, which is an established measure of
feature importance in random forests [89]. In a binary decision tree T for two classes A
and B, the gini index i(n) is dened for any given node n 2 T as follows:
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i(n) = p(Ajn)  p(Bjn) (2.1)
= p(Ajn)  (1  p(Ajn)) (2.2)
where p(Ajn) is the proportion of cases of class A in node n and p(Bjn) is the proportion
of cases of class B in node n respectively. The gini index is thus a measure of node
impurity. It can be generalized for an arbitrary number of classes j
i(n) =
X
j
(p(jjn)  (1  p(jjn))) (2.3)
The decrease in gini index in a split at node n in a decision tree is dened recursively
as a function of its own gini index and that of its children k, i.e.
i(n) = i(n) 
X
k
(p(k)i(k)) (2.4)
where p(k) is the proportion of samples sent to child k and i(k) the gini index of child k
respectively. Applied to a random forest, this measure is averaged across all decision trees
to provide a summarized measure of the importance of a given feature. The decrease in
gini index is large for features that separate samples well into the pre-dened classes j
and small otherwise.
2.2.2.3 Model Evaluation
Traditionally, the classication performance of random forests is assessed through re-
ceiver operator characteristics (ROC) curves and summarized by the area under the
ROC curve (AUC). This solution, however, is only applicable to binary classication,
since the two dimensions of such a plot fail to capture more than two classes. As an al-
ternative, we calculated the average AUC (AAUC), sometimes referred to as multiclass
AUC , based on all pair-wise class combinations as described by Hand and Till [90].
Bootstrapping allowed us to evaluate the performance of the dierent models via the
.632 bootstrap error. However, since these models were based on part of the data only,
we applied a nal random forest run with 5000 trees using only the previously selected
features of the bootstrap solution, but the complete dataset. This allowed us to assess
the overall classication error of each model by computing the confusion matrix and the
AAUC .
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2.2.3 Evaluation of Feature Lists
We evaluated how the feature lists overlap with each other and with a list of 373
known breast cancer genes downloaded (01/17/2014) from the Network of Cancer Genes
(NCG) [49], as well as with the intrinsic gene list of 1918 genes that have been aggre-
gated by Parker et al. during their eort to develop the PAM50 classier [82]. In order
to deal with synonymous gene symbols, we parsed all symbols to their unique entrez
identiers.
2.3 Results
Following our hypothesis that epigenetic data can make a valuable contribution to im-
proving the classication of breast cancer subtypes, we compared dierent random forest
models. In the following, we show how these models performed in terms of accuracy,
which features made the most signicant contribution to the classication, and how the
selected features overlap with known breast cancer genes.
2.3.1 Classication Performance of the Dierent Models
As shown in Figure 2.2, the gene expression model performed best with a very low
bootstrap error of less than 10% and an AAUC of close to 100%, which was also the
case for the combined model and the control model. The methylation model performed
slightly worse, achieving a bootstrap error of 20% and an AAUC of 88%.
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Figure 2.2: The .632 bootstrap error over 10 iterations (left), AAUC (middle), and
the distribution of the number of variables across bootstrap iterations (right) after
applying random forests to the dierent feature matrices. For comparison, the AAUC
of the control model is also shown.
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As shown in Figure 2.3, all random forests models converged on their optimal classi-
cation performance within the rst 1000 trees. The gene expression and the combined
model could separate all subtypes with a classication error varying between 1 and ap-
proximately 30%. The best classication performance was achieved for the basal and
luminal A subtype, whereas the worst performance was found for the HER2 subtype and
samples labeled as normal. The methylation model yielded similar results with generally
higher error rates between 6 and 50%.
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Figure 2.3: The classication and out of bag error (OOB) of each subtype for the
control model (A), gene expression model (B), methylation model (C) and the combined
model (D) depending on the number of trees already created by the random forest
algorithm.
In contrast to the other two models, the methylation model showed the worst classica-
tion performance for the luminal B instead of the HER2 subtype. This is illustrated in
more detail in the confusion matrices (Table 2.1), which shows which pairs of subtypes
were mainly confused by each model. All models confused the two luminal types A and
B. HER2 was mostly confused with the luminal B subtype.
2.3.2 Analysis of Misclassication by the Control Model
A total of 30 samples were labeled as normal by the PAM50 classier. Our results
(Table 2.1) show, however, that 8 of these samples had been assigned to dierent breast
cancer subtypes, leading to a high classication error for the normal class. A possible
explanation for this was oered by the TCGA barcodes linked to these samples, which
indeed identied them as originating from tumors. We therefore repeated the analysis
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Model PAM50
Basal Her2 LumA LumB Normal class.error
Basal 97 1 0 0 0 0.01
Her2 1 46 0 11 0 0.21
LumA 0 1 221 7 1 0.04
LumB 0 1 22 104 0 0.18
Normal 1 0 5 1 23 0.23
Basal Her2 LumA LumB Normal class.error
Basal 97 1 0 0 0 0.01
Her2 2 39 2 15 0 0.33
LumA 0 1 212 16 1 0.08
LumB 0 3 23 101 0 0.20
Normal 1 0 5 1 23 0.23
Basal Her2 LumA LumB Normal class.error
Basal 91 1 2 3 1 0.07
Her2 3 32 9 14 0 0.45
LumA 2 2 200 26 0 0.13
LumB 1 7 55 64 0 0.50
Normal 3 0 4 1 22 0.27
Basal Her2 LumA LumB Normal class.error
Basal 97 1 0 0 0 0.01
Her2 2 38 2 16 0 0.34
LumA 0 0 216 13 1 0.06
LumB 0 1 23 103 0 0.19
Normal 1 0 5 1 23 0.23
Model PAM50 Random forest predicted class
Control
Gene
Expression
DNA
Methylation
Combined
Basal
Her2
LumA
LumB
Normal
Basal
Her2
LumA
LumB
Normal
Basal
Her2
LumA
LumB
Normal
Basal
Her2
LumA
LumB
Normal
Table 2.1: Confusion matrices of control model, gene expression model, methylation
model, and combined model respectively. Rows correspond to class predictions origi-
nating from the PAM50 method, while columns correspond to class predictions of the
random forest models.
excluding these samples. This led to comparable results as illustrated in Supplemental
Figures B.4 and B.5. The only dierence we found concerned the number of selected
features, which was generally higher in the gene expression models when excluding these
samples.
2.3.3 Most Important Features
Figure 2.4 depicts, for each of the models, the features with the highest mean decrease
in gini index. In other words, these were the 15 features with the highest importance
for the classication. Among the selected features stemming from gene expression data
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we nd many known cancer genes. The top four hits overlap between the control model,
the gene expression model, and the combined model. As expected, we identied the
estrogen receptor (ESR1), which is the most relevant marker for breast cancer subtyping
in histochemistry, as one of the top features. The other top features are FOXA1, which
has been identied as a tumor suppressor [91] and MLPH, which is not known to be
associated with breast cancer, but has an experimentally veried interaction to RAB27A,
which was shown to promote proliferation in human glioma cells [92]. Furthermore, we
identied FOXC1 as a top feature, which is of the same family of transcription factors
as FOXA1 and which was shown to play a role in NF-B signaling in basal breast cancer
cells [93].
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Figure 2.4: The 15 most important features determined by the mean decrease in gini
index for models based on control model (A), gene expression model (B), methylation
model (C) and combined model (D).
The top hits of the methylation model showed no overlap with the gene expression
derived features. The top ve features include Dynamin-3 (DNM3), which is a novel
tumor suppressor candidate in hepatocellular carcinoma [94], TNFRSF10A, which is a
member of the tumor necrosis factor receptor superfamily, Sorcin (SRI), which several
studies could connect to multi-drug resistance in cancer [95], TBX19 (also known as
TPIT), which has not yet been associated with cancer, and TFF1, which is known to
be regulated by DNA methylation and which is a predictive factor for poor survival in
gastric cancer [96]. The trefoil factor family is characterized by a 40 amino acid motif and
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interestingly TFF1 and another member of this family, TFF3, are found in the feature
list of the combined model. TFF3 expression is positively correlated with the status of
the estrogen receptor in adenocarcinoma [97] and TFF3 is furthermore associated with
breast cancer invasion and metastasis [98], as well as treatment resistance [99]. For each
model, the importance of the top 50 genes is shown in Supplemental Figures B.1 to B.3.
The number of selected features varied across bootstrap runs (Figure 2.2). The combined
model selected the highest number of features, followed by the methylation and the
gene expression models. The superior performance of the gene expression model is also
reected in the nal feature list of the combined model, which consists almost exclusively
of features derived from the gene expression part of the matrix. Furthermore, these
feature lists show very strong overlap and consequently, the two models perform equally.
Even though the feature lists across dierent runs were not identical and varied in size,
the same features were always found at the top in slightly changing order.
2.3.4 Overlap of Feature Lists
Figure 2.5 depicts how the dierent features selected by the dierent methods overlap
with each other and with the PAM50 gene list. Only 13 of the 38 features from the
methylation model were reported by the combined model. In contrast, all 53 features
of the gene expression model were included. 32 PAM50 genes were included in the
combined model, out of which 14 were also found in the gene expression model. Only a
single gene, namely MIA, was found by the methylation model, as well as in the PAM50
list.
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Figure 2.5: Venn diagram showing the overlap of the feature lists selected by each of
the random forest models and the PAM50 genes that serve as gold standard.
A comparison of the methylation and combined model with NCG and intrinsic lists
(Figure 2.6) reveals that only 10 of the 278 genes in the combined model, and none of
38 features of the methylation model were listed in the NCG list. 127 of the genes of
the combined model and 8 genes from the methylation model could also be found in the
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intrinsic gene list by Parker et al. The intrinsic gene list and the NCG query list show
an overlap of 48 genes.
1687
43
321
4
0
0
5
5
21
0
0 4
118
134
9
Methylation Combined
Parker2009 NCG query list
Figure 2.6: Venn diagram showing the overlap of the features selected by the combined
model with a list of known breast cancer genes (downloaded 01/17/2014) from the
Network of Cancer Genes [49] and with the list of intrinsic genes reported by Parker et
al. [82].
2.4 Discussion & Conclusion
Both, gene expression and DNA methylation are typically measured through microar-
rays comprising thousands of probes. Most of the probes, however, can be considered
as background, since the fold change of the represented genes is negligible after nor-
malization [100]. One of the most crucial tasks in microarray data processing is thus
identifying probes that show signicant dierential signal between dierent conditions
or groups, e.g. between dierent breast cancer subtypes. Machine learning algorithms,
such as random forests, are able to handle the noise in the data while providing both,
good accuracy and a manageable run time [86]. The original implementation of random
forest by Breiman [89] struggles with microarray data, since a large number of probes
will make a small but negligible contribution to a successful classication. As a result,
each new run of the algorithm will lead to large feature lists with little overlap. Using
the varselRF R package [78] allowed us to address this problem by recursively removing
features with low signicance from the feature list, such that subsequent trees had a
higher likelihood of incorporating signicant features. In this way, we could show that
random forests are suitable for extracting relevant features from both, gene expression
and DNA methylation data.
In our analysis, the performance of the gene expression model was superior in consistency,
which was measured through .632 bootstrapping, as well as in accuracy, which was
determined through an AAUC and classication error rates. Consequently, the feature
elimination process removed most of the methylation derived features in the combined
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model. Both models showed a similar classication error and AAUC as the control
model.
It should be noted that the control model does not achieve a perfect classication, due
to the fact that the PAM50 classication is based on the method of shrunken centroids,
while we use the same 50 genes as input for creating a random forest model. Furthermore,
class labels may ip even in the shrunken centroid method, when samples have the same
correlation distance to two dierent centroids, such as luminal A and luminal B [82].
The generally high classication error with the HER2 subtype can be explained by the
fact that the training data was highly unbalanced in favor of the basal and luminal
subtypes. Another explanation might be that even though this subtype is identied
through HER2 (also known as ERBB2) expression, the combined model did not select
this gene, but interestingly EGFR, ERBB3 and ERBB4, which belong to the same
protein family as HER2.
The imbalance of the training data might also oer an explanation for the classication
error found for samples labeled as normal. Here, we could, however, determine via the
TCGA provided sample information that 8 out of 30 samples were in fact originating
from tumor tissue. Removing these samples prior to the analysis lead to comparable
results with a higher number of features selected for the gene expression model, indicating
that these samples might in fact have perturbed the feature selection. Finally, the
confusion matrices (Table 2.1) clearly show that all models had diculties separating
the two luminal subtypes, indicating that they are highly similar on a transcriptomic
and epigenetic level.
All feature lists obtained in this analysis showed very little overlap with the list of known
breast cancer genes derived from the NCG . This agrees with previous ndings that gene
selection remains a challenge in which dierent, or even the same methods, can lead
to highly disparate results [86]. This is also emphasized by the high variability in the
number of selected features in all models, reaching from as few as 8 up to more than
300 features (Figure 2.2).
The relatively large overlap of our combined model with the intrinsic list of Parker et al.
and the PAM50 gene list can be explained through the fact that the TCGA classication
of the samples was performed using PAM50. This, however, is an inherent problem of
supervised learning that we cannot easily overcome. Assumptions about the current
classication system have already been challenged by unsupervised learning methods
that have extracted clusters that only partially agree with known breast cancer subtypes.
In the TCGA publication on breast cancer subtypes itself [67], 13 distinct breast cancer
subtypes were found on gene expression data using a method called SigClust [101], while
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for the methylation data, the authors were able to extract ve clusters using a recursively
partitioned mixture model [102]. As depicted in the supplemental material of [67], these
clusters do not agree with the classical subtype scheme. This highlights that clustering
of methylation data might reveal other dierences than the ones that can be explained
by the established subtypes. Our analysis showed, however, that at least some of the
features can be used for successfully classifying tumor samples according to clinically
relevant subtypes.
In conclusion, gene expression data appeared to be superior to DNA methylation data
for breast cancer subtype classication. It remains unclear, however, if using the PAM50
gene expression discriminator as the gold standard still allowed a fair comparison. Fur-
thermore, the imbalance in the training data made it dicult to identify features suitable
to discriminate HER2 from other subtypes. These issues could in the future be addressed
by either generating a more balanced data set or by compensating with class weights.
The small overlap of the feature lists found here and the intrinsic gene list with the NCG
query list emphasizes that genes that are known to play an important role in cancer might
not necessarily be the ones most suitable for breast cancer subtype classication.
Finally, we expect that further research into the most promising features of the methyla-
tion model might lead to a better understanding of breast cancer subtype dierences on
an epigenetic level. A good example for this is Sorcin, which is not only the most promi-
nent feature in the methylation data, but also appears to play a major role in resistance
to cancer treatment. In contrast to the well studied genes found in gene expression data,
many of the genes found here, such as TBX19, have not yet been linked to breast cancer
and would thus be ideal candidates for functional genomics experiments to study their
role in cancer development in the dierent subtypes and to investigate their potential
as drug targets.

Chapter 3
OpenLabFramework: A
Laboratory Information
Management System with Focus
On Functional Genomics
z
Objective of this Chapter
Development of a modular and extensible laboratory information manage-
ment system (LIMS) to cover functional genomics work-ows, including
 sample tracking in hierarchical storage structures.
 QR barcode label printing and scanning.
 support of mobile devices.
 document management.
In functional genomics, researchers utilize powerful methods to study the eect of knock-
down, knock-out or over-expression of a gene to be able to establish its function, its role
in a disease, and its suitability as a drug target (Chapter 1.5). With the develop-
ment of these sophisticated cell manipulation techniques, functional genomics has seen
a paradigm shift from small projects involving single or few researchers towards large-
scale projects involving several laboratories and often hundreds or thousands of samples.
Sample management is therefore a growing issue, especially since most laboratories still
attempt to keep track of their samples using spreadsheet tools. A high turn-over of
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academic sta coupled with maintenance of individual les that are often locked or out-
dated, as well as inconsistent nomenclature and labeling, can lead to tedious repetition of
previously existing work. The signicant amount of time that is often spent on locating
samples would be better used for performing experiments. Moreover, expensive storage
space is wasted, since samples are often not labeled properly and cannot be identied.
Even if a label is given, it usually does not include a standardized minimal amount of
information that allows unambiguous identication of the materials or the experiments
they were derived from. These issues can be overcome by introducing and maintaining a
suitable LIMS . Existing LIMS already cover a large variety of experimental work-ows,
mostly focusing on a particular eld of research with specic requirements. To be useful
across various disciplines, LIMS needs to be implemented in a exible and extensible
way, covering a broad range of possible use cases. In this chapter, we will rst identify
common requirements for a LIMS system and subsequently, we will analyze to what
degree these requirements are already fullled by existing solutions. This analysis is fol-
lowed by a detailed description of OpenLabFramework (OLF ), a novel LIMS that was
developed during this thesis to better accommodate the needs of the functional genomics
community. OLF was previously published in [103], which is the main source of this
chapter.
3.1 Requirements
Any LIMS that involves sample management on a large scale should in our opinion fulll
a number of requirements listed in the following as R1-15. These requirements are the
basis for a comprehensive comparison with existing solutions in Supplemental Table A.2.
3.1.1 Implementation
A LIMS for an academic environment needs to be open-source (R1), in order to save
costs and to allow for adaptation to the specic requirements of a given scientic eld
and laboratory. Since adaptation can be a dicult and time-consuming task, a LIMS
that is modular and extensible by design (R2) would be most appropriate. Although
dicult to assess for existing projects, a LIMS should be reliable and its implementation
simple. Existing frameworks and software packages that are maintained and tested by
a large community are often more reliable than individual solutions and should thus be
incorporated.
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3.1.2 Data Handling
Dealing with a large number of samples in a library or biobank requires ecient mech-
anisms for sample management (R3) and physical sample tracking over several hierar-
chical levels (R4). Since related information and experimental results are usually stored
in additional documents, a management system, where les can be linked to an arbi-
trary number of samples (R5), would be most useful. Another requirement is that raw
data previously entered into the system can be exported to various le formats. This
requirement is usually met through an integrated reporting mechanism (R6).
3.1.3 Flexibility in Deployment
Academic laboratories are often part of an existing IT infrastructure, but support is
in many cases limited, e.g. to a single database management system (DBMS), such as
MySQL1. LIMS deployment should thus be as exible as possible, not be bound to a
specic operating system or DBMS . While the rst requirement is fullled by all LIMS
considered here, multiple database support remains an issue (R7). Furthermore, if a
suitable server is not available, deployment locally (R8) or to a cloud service (R9) is
advantageous.
3.1.4 User Acceptance and Excess Value
Triplet et al. have identied approachability as a major hurdle in the acceptance of a
LIMS [104]. Modern web-technologies allow for a more responsive and intuitive user
interface, which in turn improves the user experience and reduces the learning period.
User acceptance can also be improved by oering an excess value over traditional spread-
sheet tools, for instance by incorporating the use of barcodes (R10), label printing (R11),
and mobile devices, such as smartphones (R12). This is particularly useful in case ex-
perimental data from experiments can be uploaded to the system. Finally, a crucial
requirement for a successful adaptation of a LIMS is good documentation (R13). A
further advantage would be the incorporation of data analysis tools directly within the
LIMS (R14).
3.1.5 Security
LIMS typically address security concerns by restricting access through secure user log-
ins and dierent user roles. Security would also be enhanced by audit logging features
1https://www.mysql.com/ (access date: 06/01/2015)
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(R15), where a version number is added to each database entry. Any change will then
result in a copy of the entry with a new version number, so that accidentally overwritten
entries can be restored.
The requirements identied here allow assessing how well existing solutions cover the
needs of the functional genomics research community.
3.2 State of the Art
While a large number of laboratories continue to rely on spreadsheet tools, it is obvious
that a powerful LIMS is advantageous in handling the large number of samples that are
regularly created in a functional genomics laboratory. This also holds true for most other
bio-medical research areas, which has led to the development of countless new LIMS
platforms in the past 20 years. Notably, there are a number of commercial providers
like Labvantage R that oer adaptable systems for a large number of use cases. The
licensing costs for these systems, however, are usually not aordable for a typical mid-
sized laboratory. We therefore focus on available open source alternatives that have
been developed within the scientic community.
Existing LIMS are often tailored towards specic types of research data, as for instance
genotyping [105{107], protein production [108, 109], protein-protein-interaction [110],
2D gel electrophoresis [111], or protein crystallography [112] data. Some generic LIMS
target specic laboratory tasks, such as sample management [104, 107, 113], laboratory
work-ows and protocols [106, 114{116], documentation, management of lab stocks, or
clinical studies [117]. Additional solutions exist for molecular genetics and the creation
of vector libraries [118]. There is, however, no dedicated LIMS for handling samples typ-
ically generated in functional genomics studies. The complete list of currently available
LIMS is provided in Supplemental Table A.1. However, only those LIMS that support
sample management were considered for a detailed requirement analysis, which can be
found in Supplemental Table A.2.
Summary:
None of the existing solutions provides the necessary exibility to be easily adaptable to
new sample types. Moreover, the existing systems have typically very strict requirements
for their deployment. Despite their usefulness, barcode generation is only supported by
two and label printing by one tool. The possible advantages of incorporating mobile
devices in the laboratory work-ow have not been tested in any of the existing LIMS .
The lack of exibility and supported features motivated the development of OLF to
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provide a LIMS that is equipped to face the sample management and documentation
challenges of the functional genomics community.
3.3 Results
OLF is primarily targeted at advanced sample and storage management in mid-sized
laboratories with less than 50 users. It facilitates a seamless integration of virtual
and real world storage handling by making use of mobile devices, which are carried by
lab personal anyways, in combination with cheap and fully integrated barcode labeling
technology. In the following we shed a light on how OLF fullls the LIMS requirements
that we have identied before (R1-R15) (Supplemental Table A.2).
3.3.1 Modularity and Extendibility
OLF was published under an open source license (R1) and, due to its modular struc-
ture, it can be adapted to dierent types of laboratory data and sample types (R2)
(Figure 3.1).
Frontend Barcoding 
Module 
Storage 
Module 
GeneTracker 
Module 
File 
Attachments 
Module 
? 
Backend 
Figure 3.1: OLF is built in a strictly modular fashion. A back-end module provides
the basic functionality, including project and user management, as well as base classes
for other modules. Additional modules (depicted exemplary as ?) extend the base
classes and integrate with existing ones. Finally, the front-end module creates views
for all dened content and allows for interaction through a responsive web-interface.
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3.3.2 Sample Management
The OpenLabGeneTracker module is intended to fulll requirements specic to the hi-
erarchical organization of genes, gene variants, vector constructs, and genetically engi-
neered cell lines (R3). The organization of these samples is further supported through
OLF 's built-in user and project management features.
3.3.3 Sample Storage
The OpenLabStorage module adds options for tracking and organizing samples in a cus-
tomizable storage infrastructure (R4). This infrastructure is hierarchical, starting from
buildings and rooms and ending in individual freezers and storage boxes. Interactive
grids help the user to assess the content of a storage box at a glance. Together with
OpenLabGeneTracker, samples can be added or removed from storage in an intuitive
manner, while providing an overview of remaining copies and related samples.
3.3.4 File Uploads
The OpenLabFileAttachments module allows users to up- and download arbitrary les,
enabling users to upload and organize their results and documents. Files are stored
with a combination of timestamp and original le name to avoid conicts arising from
identical le names. Files are uploaded to a congurable folder on the server and not
to the database itself. They can be linked to an arbitrary number of samples, so that
other users can quickly obtain an overview of les relevant to a sample (R5).
3.3.5 Reporting
OLF can export lists of samples to various le formats, including Excel (XLSX), Open
Document Spreadsheets (ODS), PDF, and comma separated values (CSV). This feature
is currently available for lists of genes, vector constructs, and cell lines. The storage
hierarchy and individual boxes can also be exported to a spreadsheet format (R6).
3.3.6 Deployment
OLF is not bound to a specic DBMS and will also work with non-SQL systems, such as
MongoDB2 (R7). OLF is compiled either as WAR le, which is suitable for deployment
2https://www.mongodb.org/ (access date: 06/01/2015)
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on a large number of Java-based web containers, or as locally executable JAR le, which
comes packed with its own web container and le-based SQL solution (R8). Finally, OLF
is also suitable for cloud deployment, using, for instance the VMware CloudFoundry
service3 (R9).
3.3.7 Barcode and Label Support
The functionality of the OpenLabStorage module is complemented by the OpenLabBar-
code module, with which a user can create and print barcode labels (R10,11). These can
later be used to locate a sample in OLF by scanning the barcode using a USB-connected
scanner or a mobile device (R12). The Barcode module currently requires a connected
DYMO R label printer but can be extended in the future to support other devices.
3.3.8 Web Application Interface and Documentation
OLF oers a modern web-interface that is clearly organized and intuitive (Figure 3.2),
and allows for responsive user interaction. At the top, a navigation menu provides direct
access to all features contributed by OLF and its modules. The search functionality
allows users to locate required information quickly and conveniently. Samples in OLF
can be grouped in projects, which are accessible through a tree structure shown on the
left-hand side. Modules can contribute so-called add-ins to OLF . These can be arranged
freely by the user in a column on the right-hand side. Add-ins can react to the main
content shown in the middle of the screen through an event-based system. An example
for this is the barcode add-in, which will oer label printing options when a sample is
shown, or show a barcode scanner view otherwise. OLF distinguishes mobile clients
from desktop clients. If a mobile device is detected, a dierent view is shown that is
tailored for the small-sized screen and touch-screen interaction (R12). Finally, OLF
comes with online documentation that introduces the system to users, administrators,
and software developers (R13).
3.3.9 Typical Work-Flow
Users can develop eective laboratory work-ows using the sample tracking feature to-
gether with barcode labels and mobile devices (Figure 3.3). Only administrators can
add master data, such as cell lines or vectors, which can then be utilized by normal
users to create samples. OLF validates all user entered data for validity and will, where
applicable, provide a list of viable options in form of select boxes. In this way, OLF
3http://www.cloudfoundry.com/ (access date: 06/01/2015)
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Figure 3.2: The web-interface of OLF is divided into four main parts. (A) The header
contains a menu and a search eld for navigation. (B) A hierarchical project tree found
in the left column can also be used for navigation. (C) The main panel is used to render
the actual page. It can be further divided into a central panel (1), where properties
can be altered, an object history box (2), an operations box with additional links (3),
and at the bottom a set of tabs (4) where related information is available and can be
interacted with. (D) Additional interaction possibilities are provided through add-ins
that can be customized by each user in the right column.
eectively avoids ambiguity and ensures consistency of sample data. Once a sample, for
instance, a vector construct or a cell line, has been created, OLF will oer the possi-
bility to print a barcode label. The user can then apply the label and add the sample
to physical, as well as virtual storage. At a later point, the barcode can be used for
ecient retrieval and updating of sample information. Moreover, new gene variants and
passages can be added with respective new labels and storage locations conveniently.
Files and documents can be added to samples and genes, in order to make experimental
results and additional information such as related publications, available to other users
3.4 Discussion & Conclusion
Numerous commercial and open-source LIMS exist today. However, since commercial
licenses are expensive and lack the possibility to be adapted to specic needs without
additional costs, academic laboratories usually focus on nding an open-source solution
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Storage* 
Vector* Cell-Line* 
Add Variants Add Passages Read Barcode 
Figure 3.3: A typical work-ow in OLF : Initially, the administrators set up master
data, such as vectors, cell-lines, medium compositions, as well as the storage infras-
tructure (*). Users then create projects and link genes to them. Vector clones are
created from the genes, which in turn can be used to create cell-line recombinants.
OLF supports printing of barcode labels, which can be scanned at a later point to
modify existing or to add new samples.
to their sample management issues. Moreover, none of the existing solutions seems
optimal for all given tasks (Supplemental Table A.2). For example, none of the tools
supports the samples and work-ow typically encountered in a functional genomics lab-
oratory. Particularly support for printing and scanning of barcoded labels would be
a desirable feature to increase productivity. Naturally, most LIMS are dedicated to a
specic eld of research and are thus not generally suited for other elds. Some so-
lutions, on the other hand, focus on certain general aspects of laboratory work, such
as sample tracking, protocols, or work-ows. Acknowledging that many LIMS remain
limited to their research domain, we created OLF in a strictly modular and extensible
fashion, with dedicated modules for sample tracking, le management, and barcoded
label printing. We expect that OLF can be adapted to other research elds and bioma-
terials with minimal developmental eort by implementing a content module similar to
OpenLabGeneTracker, which is then complemented by plugging in additional features
as needed. Since the successful publication of OLF , the power of this modular approach
could already be demonstrated by the addition of OpenLabNotes, which is a module that
adds ELN functionality to OLF (Chapter 4). The integration of an ELN into a LIMS
is a novelty among open-source ELNs and is expected to further increase productivity
by enabling OLF users to maintain all experimental details, including documentation
they are legally required to maintain, in a single place.
The introduction of OLF allows controlling sample logistics eectively, which is a partic-
ular challenge upon movement, turn-over of lab sta, and improper labeling of samples.
OLF may further increase productivity by including modern technologies so far disre-
garded by most other open-source LIMS , such as printing and reading barcode labels.
The high degree of automation and standardization that can be achieved by this may
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substantially reduce user-caused errors in sample assignment. A web-layer for mobile
devices provides an additional advantage. In this way, samples can now be removed
from physical and virtual storage at the same time, thus limiting the risk of forgetting
this step after the work with the sample is completed. As illustrated in Figure 3.3, the
implementation of OLF in a laboratory environment can lead to a signicantly more
productive work-ow.
Unlike most LIMS , OLF is not bound to a specic database or web-container. It can
be coupled with a large number of database management systems, including non-SQL
solutions like MongoDB. If a suitable server is not available, OLF can be installed
locally, on a server, or even be deployed to the cloud. This exibility, together with the
online documentation, will reduce technical hurdles in the introduction of OLF to a new
laboratory.
Basic reporting capabilities are available, but could be substantially improved by al-
lowing for customized reports, where information from several instances is pooled.
This would also help in establishing data analysis directly within OLF . Finally, OLF 's
database security would benet from the introduction of an audit logging feature, which
could, for example, prevent sample data from being accidentally deleted.
In conclusion, OLF oers ecient and user-friendly management of sample information
and location in the eld of high-throughput biology and functional genomics. Being
extensible, it can be further adapted to satisfy additional requirements with little devel-
opmental eort. An example for this is presented in the following chapter.
Chapter 4
OpenLabNotes: An Electronic
Laboratory Notebook Extension
for OpenLabFramework
z
Objective of this Chapter
Development of an electronic laboratory notebook (ELN) extension for
OpenLabFramework, including
 a user-friendly document editor.
 content protection through access control and digital signatures.
 links to existing samples and documents.
In laboratory research, experimental work is typically documented in paper laboratory
notebooks (PLNs). This does not only help researchers to keep track of the details of
their experiments, but also protects their interests, and those of their institutions, in
legal disputes. For a long time, electronic data storage was not considered a legally
acceptable alternative, since information could be falsied more easily than in PLNs.
Therefore, electronic laboratory notebook (ELN ) were only considered as a supplement,
but not as a substitute for PLNs. However, ELNs have clear advantages compared to
their paper-based pendants. Laboratories are open environments and thus documents
can get accidentally destroyed, lost, or, in the worst case, stolen. ELNs, on the other
hand, are typically paired with an automated and reliable backup system. Time stamps
and additional meta information can further contribute to the reliable documentation
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of costly experimental eorts. Moreover, there are immediate advantages in daily use,
such as full text search, which allows researchers to retrieve information quickly and
to share documents with their colleagues. In this way, ELNs can signicantly increase
productivity and make it easier to keep track of experimental details despite of frequent
turn-over in laboratory sta [119]. Thus, when the U.S. Federal Drug Administration
introduced a guideline for electronic information storage (CFR21 part 111), ELNs slowly
began to replace PLNs in many laboratories. This leads to a list of general requirements
an ELN should fulll, which are denoted in the following as R1-18 and which can also
be found in Supplemental Table A.3.
4.1 Requirements
In order to follow the regulations, an ELN needs to guarantee that documents are safely
stored. The history of a document, such as the creation date and the author, must be
traceable (R1). To have credibility in a law case, documents must be protected from
changes. This implies that a document in the ELN should be signed by its author
(R2). Ideally, it is possible for a colleague or a supervisor to countersign a document
to further increase its credibility (R3). The latter is particularly important when it
comes to patenting, since a countersigned document that includes a timestamp can be
considered strong legal proof for an invention. In a typical software system, a user
proves his identity by securely logging into a system with a unique username and a
secret password. However, instead of merely marking a document as signed by a logged
in user, a so-called digital signature should be used to prevent scientic fraud not only
on the application, but also on the database level. Digital signatures rely on a pair of
asymmetric keys, a private key, to sign the document, and a public key, to validate the
document [120].
To enable researchers to collaborate eectively, an ELN should enable its users to or-
ganize documents in notebooks (R4) and projects (R5), as well as to share them with
other users (R6-7). Moreover, it would be advantageous if users could comment on or
to annotate documents (R8) and upload additional les (R9). A user-friendly interface
(R10) and a rich text editor (R11-12) allows users to document their experimental re-
sults conveniently. Various sort and lter options guarantee that crucial information can
be quickly located (R13-15). Export to local le formats should be possible (R16-17).
ELNs focus on the thorough documentation of experimental procedures, including ap-
plied methods, consumables, as well as experimental results. Another type of electronic
1http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11 (ac-
cess date: 06/01/2015)
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system that can increase productivity in laboratories is the laboratory information man-
agement system (LIMS ), which is mostly concerned with sample management. Inte-
grating an ELN with a LIMS enables researchers to link experimental documentation
directly to the samples that were part of the experiment (R18). This is particularly use-
ful, if an experiment is to be repeated or continued by another researcher not familiar
with the experiment.
4.2 State of the Art
A large number of commercial ELNs are already on the market [121]. However the costs
for these systems can typically not be covered by small to mid-sized laboratories. Free
alternatives range from general note-keeping tools to dedicated ELNs. A comprehensive
list of commercial and free ELNs can be found online2. The majority of the free systems,
however, do not suciently protect the documents to prevent scientic fraud. Moreover,
many of these are web applications that are only accessible online and cannot be deployed
in a local network. Thus, researchers using these systems might be in violation of strict
data protection rules found in many academic institutions. Voegele et al. found that
none of the existing ELNs could suciently fulll the requirements found in a typical
laboratory and thus developed a new open-source ELN based on WordPress [122]. Their
IARC ELN prevents scientic fraud on the application level by user authentication and
on the database level by securing and monitoring database access. The lack of digital
signatures in this system, however, may pose a problem in case of patenting, where
it is advantageous if a document describing an experiment that led to an invention is
actively signed and protected by an ocially recognized digital signature algorithm.
Finally, none of the available open-source ELNs, including the IARC ELN , feature the
integration with a LIMS . We thus sought to extend OLF to close this gap. A detailed
comparison between the features of the IARC ELN and OpenLabNotes can be found in
Supplemental Table A.3.
4.3 Results
We realized that experimental documentation in OLF (Chapter 3) through uploading
additional les or through using comment elds was not a convenient solution. More
importantly, this solution fell short of the legal requirements an ELN is expected to
fulll. OpenLabNotes is a module for OLF that closes this gap by implementing ELN
functionality (Figure 4.1). This module was initially developed during an individual
2http://www.atriumresearch.com/html/eln.htm (access date: 06/01/2015)
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study activity by Michael Franz3 and later extended by the author. In OpenLabNotes, a
rich text editor allows documents, which are called notes, to be created with the various
formatting options that a user typically expects from a modern text editor. Images can
be placed within the text and will be stored as part of the note. Each note can be
edited until it is nalized by the user (draft status). In this case, the note, as well as
a timestamp, are digitally signed with the private key and password of the user (nal
status). When signing a note, the user needs to appoint a supervisor, which can then
countersign it (signed status). These signatures are subsequently validated each time a
note is shown to a user. In order to document the origin and current location of material
used in an experiment, notes can be linked to arbitrary samples in OLF . Moreover, notes
can be attached to specic projects or organized in notebooks, which are user-dened
collections of notes. The documentation of an experiment can be further complemented
by uploading additional les. Frequently, notes need to be accessible to researchers
other than the author or the assigned supervisor. To this end, each user with access to
a note can also grant access to other users. To retrieve notes, several types of lists are
available, including a list of authored notes, a list of accessible notes, a list of notes that
were signed in the role of a supervisor and most importantly, a list of notes a supervisor
still has to sign. Lists can be ltered by author, data, and project. Each list includes a
preview of the notes and can also be exported to various formats, including XLSX, ODT,
DOC, and PDF. When browsing samples, a list of linked notes is shown in a dedicated
tab. Most importantly, notes can be retrieved through the search functionality, which
extends to entire text of the note. Finally, notes can be printed or exported to either
PDF or DOCX format.
4.4 Discussion & Conclusion
ELNs revolutionize the way in which experimental notes are kept by making them more
secure, accessible and shareable. The requirements to data safety make ELNs more
reliable than their paper based pendants and it can be expected that researchers will
be required to use ELNs in the future [119]. The choice of an appropriate solution,
however, is dicult. The market oers a wide variety of products resulting in a large
choice of attractive and reliable products that are mostly superior to free alternatives.
As a disadvantage, these solutions are often not aordable to laboratories. Moreover,
it is unclear if a company will endure in the competition and still be able to provide
support in a long term perspective. It might therefore become necessary to migrate
from one ELN to another, which is complicated by the lack of a common data format
3Computational Biology Group, Department of Mathematics and Computer Science, University of
Southern Denmark
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Figure 4.1: The show note view in OpenLabNotes. A: The menu allows to select
dierent types of lists or to create a new note. B: The history of the note, including
checkmarks for valid signatures. C: Notes can be linked to samples, projects or note-
books. Moreover, les can be uploaded and attached and notes can be shared with
other users. D: Here, the note is shown in a read only viewer. E: The note can be
exported to PDF or DOCX les.
for ELN data storage and the fact that some products do not oer a backup mechanism
in the rst place. We therefore consider open source ELNs an attractive alternative to
commercial products.
OpenLabNotes is an open source ELN extension for OLF that comes with advantages
typically found in state-of-the-art note keeping tools, such as sharability, full text search,
a reliable backup system, and a modern text editing experience. Using HTML for storing
notes simplies data export, long term storage, and the potential migration to another
ELN . To our knowledge, OpenLabNotes is the rst open source solution to provide a
digital signature mechanism to prevent scientic fraud. Being open source, it can also be
easily adapted to use alternative digital signature methods should the legal requirements
change. The intended work-ow suggests that each note is signed by two authors, which
serves to protect the researchers in a potential law case.
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A common issue when introducing electronic data storage to a laboratory is that of-
ten not only an ELN , but also an ecient sample management solution is required.
Tightly integrating an ELN with a LIMS allows experimental information to be linked
eciently, thus increasing experimental documentation overall. While any open source
ELN can be integrated with some developmental eort into a LIMS or vice versa, a
single solution oers the advantage of reduced maintenance eort. If two independent
systems are connected, an update of one system might lead to incompatibility with the
other system. A fully integrated system such as OLF is likely to include updates to all
related functional parts at once.
In conclusion, OpenLabNotes is a powerful and user-friendly alternative to costly com-
mercial ELNs. The digital signature mechanism implemented here follows accepted
standards and should thus be suitable to fulll legal requirements for data protection.
Finally, the addition of OpenLabNotes to OLF eectively closes the gap between experi-
mental documentation and sample management, making OLF a comprehensive solution
for functional genomics studies.
Despite its exibility, OLF is not ideally suited to deal with HTS data, where sam-
ples are typically included in several plates belonging to the same screening library. A
web application specically accommodating this type of data is thus presented in the
following chapter.
Chapter 5
SAVANAH: Sample Management
and Visual Analysis of
High-Throughput Screens
z
Objective of this Chapter
Development of a sample management system for high-throughput screen-
ing, covering
 management of molecular screening libraries
 tracking of diluted library copies and assay plates and corresponding
readouts.
 user-friendly and interactive sample management.
 data export to suitable analysis software.
High-throughput screening (HTS ) extends functional genomics and drug screening to
large- or ultra-large scale (Chapter 1.6). The basis for this are molecular libraries,
i.e. sets of plates containing the samples or reagents to be tested. A genome-wide
siRNA screen, for instance, spans more than 200  96 well or more than 50  384 well
plates. The elaborate process of generating and delivering screening libraries is addressed
by a number of pharmaceutical companies such as DharmaconTM. The preparation,
delivery, and storage of screening libraries, however, is costly. Libraries are therefore
manufactured in a highly condensed form. Hypothetically, the solubilized reagents in a
library plate can simply be resuspended, allowing for small amounts to be extracted to
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produce a single set of assay plates. However, the quality of subsequent screens might be
aected, since reagents will slowly degrade with each freeze / thaw cycle. Consequently,
library plates need to be diluted in as few freeze / thaw cycles as possible. Assay plates
obtained in this way can then be thawed and directly utilized for a screen when needed.
However, fully diluting an entire library would lead to a very large number of plates that
typically have to be stored at -20C. This poses a storage problem, since freezer space
is expensive and limited. To circumvent these problems, library plates are typically
diluted in several steps (Figure 5.1). At rst, each library plate is diluted and samples
are divided between a number of master plates. These sets of plates, each representing
the full library, are then stored in a freezer, except for one set of master plates, which
is processed further. Again, the samples are diluted and transferred to a number of
so-called mother plates. Only a single set of mother plates is in turn processed further
and diluted into a number of daughter plates. Master, mother, and daughter plates are
thus technically identical and only dier in the concentration of the sample, where only
daughter plates are appropriately diluted for screening. Each set of daughter plates, also
called assay plates, covers an entire screen. This process allows for a large portion of the
screening library to be kept in a concentrated form, while reducing freeze / thaw cycles
to a minimum. Depending on the actual concentrations, a screening library can thus be
used for dozens of screens. A more comprehensive overview of the HTS procedure can
be found in [123]. Over time, the thousands of samples found in a library are distributed
across hundreds or thousands of plates. This demands a systematic solution for sample
management.
Library 
… 
Master 
Plates 
… 
… 
Mother 
Plates 
Daughter 
Plates 
Experimental 
Information 
Sample 
Information 
Figure 5.1: HTS screening libraries are typically delivered in a highly concentrated
form. To keep the number of freeze / thaw cycles low and to minimize the freezer space
needed for the entire library, plates are diluted step-wise via master and mother plates,
down to daughter plates, which can nally be used as assay plates in a screen.
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5.1 Requirements
A suitable system for supporting HTS needs to fulll a number of requirements listed in
the following as R1-28. These requirements are the basis for a comprehensive comparison
with two existing applications in Supplemental Table A.4.
A sample management system for HTS should be open source (R1) to allow for adapting
the system to the particular requirements of individual screening facilities. Moreover,
access should be restricted based on dierent user roles (R2). The system should be
able to handle the samples found in molecular screening libraries (R3). The multitude
of plates representing dierent dilution stages of a library requires an ecient plate
tracking system. Consequently, a HTS sample management system should model the
entire library dilution process in a user-friendly way (R4). In addition, the system
should keep track of empty wells in the library plates that are reserved for controls
(R5). Occasionally, it might be necessary to allow the user to transfer samples to a
dierent plate format, e.g. from 96 to 384 well plates (R6). Apart from monitoring the
well volumes (R7), it would be advantageous to avoid considering inactive or deprecated
samples. The system should thus allow for the corresponding well to be agged as
deprecated (R8) or even automatically assess the activity of all samples across dierent
screens (R9). The sample information for all sets of diluted plates is identical, which
suggests to avoid entering and keeping this information in the system redundantly (R10).
Finally, only the fully diluted daughter plates are actually used as assay plates in a
screen. For those plates, the sample information of each well needs to be linked to data
originating from one or several experimental readouts (R11). Apart from information
about an individual sample, experiment parameters need to be tracked that are often
shared across a batch or an entire screen (R12). This includes, for instance, reagents
that have been used or the cell lines that have been tested. Secondary screening can be
guided by so-called cherry-picking (R13), where the most promising hits are transferred
in silico to a new assay plate. Ideally, an automated mechanism for randomizing the
sample position is included to avoid clustering similar reagents (R14). The system
should cover typical use-cases like RNAi screens (R16), small compound screens (R17),
as well as miRNA inhibitor and mimics screens (R18). All samples should be searchable
(R19) and be linked to external databases (R20) to provide additional information to the
user. Data should be visualized (R21-22) and subjected to quality control (R23). After
appropriate normalization to counter known sources of variation (R24), hit discovery
(R25) can be performed to lter for active samples that show an eect. In a typical
screen, each sample is considered an independent experiment. There are, however, other
types of HTS with related experiments, such as dose-reponse (R26) or time-series (R27)
experiments, which would benet from dedicated features. Finally, HTS readout data
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can in theory be followed up in a secondary readout with RPPAs, suggesting to include
support for linking such data (R28).
5.2 State of the Art
Most software systems that have been developed for HTS focus on the aspect of data
processing and analysis and do not address the issue of sample management. Few LIMS
have been developed in the past to accommodate small compound and RNAi screens.
OpenBIS [124] is a general purpose LIMS that includes support for high-content screen-
ing (HCS ), where the focus is mainly on image acquisition and processing. In HTS ,
however, only numeric readouts are produced. One system accommodating this type of
data is Screensaver, which has been developed at the Harvard Medical School to manage
siRNA as well as compound screens [125]. The system keeps track of screening libraries
including the remaining volume of the wells. Reagents are linked to external databases
to provide additional information. Furthermore, Screensaver provides cherry picking,
which allows promising hits to be selected and to be assembled for secondary screen-
ing. Plates can be randomized and wells can be agged as deprecated to exclude them
from future screens. Normalization and hit detection are not supported and have to be
performed externally. However, the results of such an analysis can subsequently be up-
loaded back into the system. An alternative to Screensaver is MScreen, which has been
developed at the University of Michigan [126]. MScreen provides similar features and
in addition supports dose-response curves, quality control, normalization, and hit detec-
tion. However, neither MScreen nor Screensaver support miRNA mimics or inhibitor
libraries. In both systems, all sample information is uploaded via externally dened
les. While this is an appropriate strategy to upload information about a screening
library, which is only necessary once, it would be advantageous if users were oered a
convenient and interactive interface to design smaller experiments manually. This moti-
vated us to develop Sample Management and Visual Analysis of HTS (SAVANAH ), an
advanced sample management system for microtiter plates supporting small customized
experiments as well as large-scale HTS . A comprehensive feature comparison between
SAVANAH, Screensaver, and MScreen is provided in Supplemental Table A.4.
5.3 Results
SAVANAH aims at simplifying HTS data management for screening data, supporting
both small experiments involving manually created plates, as well as HTS . To achieve
the latter, SAVANAH oers a set of features for managing screening libraries eciently.
Chapter 5. SAVANAH 55
5.3.1 Plate Layouts
In many cases, experiments involve several replicate plates to accommodate technical and
biological variation. To avoid redundancy, SAVANAH thus separates the so-called plate
layouts holding the sample information from the actual plates. This has the advantage
that changes applied to the layout will automatically be propagated to the respective
plates. To avoid long and cryptic sample names, sample information is divided in several
categories shown in Figure 5.2. Each property is modeled as a distinct layer of the plate
layout, which provides a clear data structure to the system. The user can conveniently
change which sample property to edit, which will bring up the corresponding sample
layer together with a box that allows the user to select a specic attribute. The user
can apply attributes to individual wells or to multiple wells by drawing a box with the
mouse. This mechanism enables users to quickly and eciently design an experiment
once the necessary sample properties have been entered into the system.
Figure 5.2: Plate layouts capture sample information in several layers and can be
conveniently edited by the user.
5.3.2 Plates and Readout Import
In contrast to plate layouts, which hold sample information, plate objects identify phys-
ical plates by properties such as its plate type or its barcode. Moreover, plates can be
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linked to measurements, where readout data can be uploaded for each plate individually
or as a batch import. For the latter, the user is required to add all readout les to a
zip le in which each le is named after the unique barcodes of the plate. SAVANAH
accepts XLSX, comma, tab and semicolon separated les as input for readouts. During
the import, the columns of the input le can be mapped to the expected properties, such
as the well position and signal value. For convenience, this column mapping can also be
stored as a so-called ResultFileCong. The uploaded readout data can subsequently be
visualized as a scatter plot or a heatmap (Figure 5.3).
Figure 5.3: SAVANAH visualization of readout data. A: As a heatmap, where signal
intensities are indicated by a color gradient in which red corresponds to a high signal
and yellow to a low signal. B: As a scatter plot, where signal intensity is shown on the
y-axis and the sample name on the x-axis. Only a few sample names can be shown
to avoid overlays. However, both types of plots are interactive and provide additional
information when hovering the mouse over a data point or tile.
5.3.3 Projects and Experiments
To keep a growing number of plate layouts organized, users are encouraged to group
them into experiments, which in turn can be grouped into projects. First of all, this will
make it easier to apply the search function eciently. Moreover, a lter is available in
the navigation menu. Here, a specic experiment and / or project can be selected by
the user. Whenever the user opens a list view, e.g. a list of plate layouts or a list of
plates, only items that are associated with the selected experiment and / or project will
be displayed.
5.3.4 Screening Libraries
5.3.4.1 Import Library
A screening library comprises a set of library plates with hundreds or thousands of
molecules to be tested. For each of them, information about the plate and well location,
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as well as sample and product identiers needs to be added to the system. To this end, a
tab separated le can be uploaded. SAVANAH expects this le to have a specic header
(Supplemental Table A.5). SAVANAH will process this information and create a library
together with the corresponding library plates. To avoid multiple database entries for
the same sample, the system will check if an existing entry can be used by looking up the
sample name and sample accession in the database. This functionality, together with
the aforementioned function for importing readout data, have been implemented during
an individual study activity by Martin Dissing-Hansen1.
5.3.4.2 Browse Library
After successful upload, the content of the library can be browsed conveniently in a
tree structure (Figure 5.4). To nd a specic entry of the library, the use of the search
function in the navigation bar is recommended.
Figure 5.4: Once uploaded to the system, libraries can be browsed in a tree view
where wells are shown as children of plates. Clicking on a well provides information
about sample it carries.
5.3.4.3 Library Dilutions
Prior to use, library plates are serially diluted via master and mother plates to daughter
plates, which are also called assay plates. Consequently, a large number of library
plate copies need to be tracked. To avoid burdening the user with creating and linking
these plates individually, SAVANAH introduces the concept of library dilutions. Each
library dilution represents a full copy of the original library and can either be of type
\Master", \Mother", or \Daughter". In addition, diluted libraries of type \Mother"
and \Daughter" keep track of their respective source. Diluted libraries are represented
as a tree (Figure 5.5), where additional diluted libraries can be added at an arbitrary
level. To this end, the user rst selects an existing library or diluted library to be used
as source. In addition to the number of additional diluted libraries to be created, the
1Computational Biology Group, Department of Mathematics and Computer Science, University of
Southern Denmark
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system needs to be able to identify the corresponding physical plates unambiguously.
To this end, proper labeling is imperative, which is typically achieved using barcodes.
Ideally, the barcode contains information about the lineage of a plate, e.g. its index
in the library, as well as indices identifying the diluted libraries the plates were derived
from. To facilitate this during the creation of a set of diluted libraries, a barcode pattern
needs to be specied. This pattern is required to include certain place-holders that are
later substituted with the corresponding indices (Figure 5.5, right hand side). In the
next step, the user can follow a step-by-step guide to use sets of daughter plates as
replicates in a screen.
Figure 5.5: The dilution of screening libraries leads to a large number of plates that
need to be tracked. SAVANAH uses the concept of diluted libraries to bundle all plates
that belong to a single copy of a library. The lineage of each diluted library is shown
in a tree view, where new copies can be added conveniently. In addition to the number
of copies, the user is required to dene a barcode pattern, which includes the library
plate index and the indices of all diluted libraries that gave rise to a particular copy.
5.3.5 Create Experiment from Library
Experiments can either be created manually or from a screening library. For the latter,
the user is guided through a number of selection steps (Figure 5.6). After selecting a
library, the user can choose from all diluted libraries of type \Daughter" that have not
been used in an experiment yet. Several diluted libraries can be selected at once to serve
as replicates. Subsequent to selecting default properties, such as the cell line to be tested,
the user is given the option to manually dene a control sample for arbitrary wells. This
is useful, since libraries typically have one or several empty rows or columns to be used
for this purpose. Prior to assigning these control wells to the plates, the system will
check if the corresponding well is empty. When the selection process is complete, the
experiment will be created along with the following other objects (Figure 5.7). For
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each library plate, a plate layout is created, which holds the sample information of the
library and, in addition, the sample information entered by the user. Moreover, for each
diluted library plate, a corresponding replicate plate is created. As mentioned before,
replicate plates thus share the sample information. This allows users to edit the plate
layout instead of editing each replicate plate individually. To equip the plates in this
experiment with readout data, the user can now utilize the aforementioned batch import
functionality.
Figure 5.6: Creating an experiment using a library in SAVANAH . A: The user enters
details about the experiment and selects a library. B: A number of diluted libraries of
type \Daughter" is selected to serve as assay replicate plates. Diluted libraries that
were previously used are not shown. C: Default sample properties that will apply to
the entire screen. D: The user can specify, which control samples should be placed in
the empty wells of the plates.
5.3.6 Data Analysis
The data analysis, including normalization, quality control, and hit detection is currently
not part of SAVANAH . Instead, the user can choose to export data directly to RNAice
(Chapter 6), which is a dedicated R based web application suited for this task.
5.4 Discussion & Conclusion
A major challenge for any screening center that regularly performs HTS is the con-
tinuously growing number of plates and sample information that needs to be tracked
eciently. To make this elaborate task easier for the user, SAVANAH bundles diluted
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Figure 5.7: Libraries that consist of library plates give rise to diluted libraries and
diluted library plates. In an experiment, several diluted libraries can be selected as
replicates for a screen. In this process, each library plate is rst converted to a new plate
layout holding the information of the library and in addition, experimental information,
such as the cell line that was used. Moreover, for each replicate, a plate is created. These
share the experimental information provided by the plate layout and can be linked to
an arbitrary number of readouts.
copies of library plates as abstract entities and handles the bulk of the plate setup auto-
matically. This separates SAVANAH from similar tools such as Screensaver orMScreen.
Another unique feature is the distinction between plate layouts and actual plates, which
makes it possible to edit the sample information for all replicates at once. Finally, the
interactive plate layout editor makes sample information accessible and editable in a
convenient way. In addition to its support for HTS , SAVANAH is also ideally suited
for designing and managing small customized experiments. This makes the system also
attractive for laboratories that do not perform HTS , but deal with a large number of
custom plate designs. The multi-level sample management may at rst be considered
as a burden, since users have to tediously add sample information before they can be-
gin designing plate layouts and experiments. However, once this process is complete,
sample properties can be applied quickly and eciently, while the data model ensures
consistency and ecient information retrieval. Finally, the possibility to export data to
RNAice for further data processing and in depth analysis is a clear advantage compared
to systems such as Screensaver that currently require manual data export.
In conclusion, SAVANAH provides plate based sample information for an entire labo-
ratory in one place, which is a tremendous advantage over scattered spreadsheet les
with cryptic and ambiguous sample identiers. In contrast to comparable solutions, it
streamlines the creation of library dilutions and the creation of screens with replicates.
The powerful plate layout editor and the search functionality enable users to eciently
retrieve and edit all related sample information quickly. Additional plots and an in-
depth analysis are facilitated through exporting data to RNAice, which is described in
the following chapter.
Chapter 6
RNAice: High-Throughput RNAi
and Compound Screen Evaluation
for R
z
Objective of this Chapter
Development of an interactive analysis tool for high-throughput screening
data, covering
 normalization of raw data to account for known sources of variation.
 quality control and data visualization.
 hit discovery and consensus hit lists based on several normalization
strategies.
 determination of microRNA and drug targets.
 downstream functional enrichment analysis.
High-throughput screening (HTS ) experiments produce a wealth of data that allows
for functional analysis on the genome scale. The challenges in automation and minia-
turization have been successfully addressed in the past, such that HTS is no longer
exclusively used by pharmaceutical companies, but readily adopted by more and more
academic institutions. HTS data analysis, however, is a challenging task complicated
by the complexity of adapting cell culture conditions to the necessary experimental
scale (Chapter 1.6). Individual plates or batches may suer from quality issues, where
transfection protocols are occasionally ineective. In general, variation between batches,
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plates and well positions complicate the robust identication of active samples. Spread-
sheet tools, such as Microsoft Excel R, are still commonly used to tackle these challenges,
but are unsatisfactory, since they are not suitable to deal with the large number of data
points. Moreover, these tools oer only limited support for the advanced statistical
methods required to normalize HTS data appropriately. Even if suitable macros were
available, they would not provide the user with an ecient graphical user interface,
which is better suited to guide the user through the dierent steps of the analysis.
6.1 Requirements
In the following, we dene requirements an HTS analysis tool should fulll. These
requirements are denoted in more detail as R1-R39 in an exhaustive comparison found
in Supplemental Table A.6.
6.1.1 Data Input
Even though reporting guidelines for HTS experiments such as Minimal Information
About an RNAi Experiment (MIARE)1 have emerged to standardize meta data, there
is no such standard for HTS raw data. Even public databases such as PubChem2 or
ChEMBL3 only provide minimal standardization. The common denominator is that raw
data is typically reported as XLSX, comma, or tab separated le with interchangeable
column names. At a minimum, such a le includes, for each well, an unambiguous
identier of the sample, a unique plate identier, a well position, a replicate number (if
replicates were included), and a signal value. To utilize this information, any analysis
tool needs to include a column mapping step (R1) upon data import. Special care
has to be taken of the way in which well positions are reported, which can either be
alphanumeric (e.g. A01, A02, ..., B01, ...), numeric or with separate column and row
indices (R2). Finally, it would be advantageous if screening data could be directly
imported from public databases using identiers such as the PubChem Assay ID (AID)
(R3).
6.1.2 Quality Control
Subsequent to the import of the data, a visual inspection should be possible (R4),
including, for instance, plots for signal distribution, correlation of replicates and the
1http://www.miare.org (access date: 06/01/2015)
2https://pubchem.ncbi.nlm.nih.gov/ (access date: 06/01/2015)
3https://www.ebi.ac.uk/chembl/ (access date: 06/01/2015)
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variation between plates, batches, columns, and rows. Typically positive, negative,
and transfection controls are incorporated on each plate to monitor the ecacy of cell
transfection or treatment. Quality measures (R5-6) for the performance of positive and
negative controls need to be included to allow experimenters to exclude plates that do
not provide the necessary separation between active and inactive samples.
6.1.3 Normalization and Hit Discovery
Dierent normalization strategies should be provided to deal with the specic challenges
presented by a particular dataset, including control-based (R7-8) and plate-based meth-
ods (R9-18). Moreover, the tool should oer various methods for hit discovery, including
variance based methods (R19-20) and more sophisticated methods utilizing replicate and
experiment-wide information (R21-22). The goal of hit discovery is to produce a list of
active samples that qualify for further analysis both in vitro and in silico. Such a list
should be exportable (R23) and visualization of the corresponding data (R24) should be
oered. Here, interactive visualization (R25) is preferable over static plots, since this is
better suited to present complex data without overwhelming the user. The analysis of
several experiments or readouts in combination in so-called dierential or multi-channel
screening (R26) is advantageous to extract hits that show a specic eect. This could
be, for example, the combination of a plus and a minus drug screen to exclude hits that
generally cause toxicity. Since each normalization method has advantages and disad-
vantages, there is generally no unique method that can address all issues. Therefore, a
consensus hit list (R27) should be oered, in which the hit lists of dierent normalization
methods can be compared and aggregated.
6.1.4 Downstream Analysis
6.1.4.1 MicroRNAs
Optimally, additional resources are integrated to provide more information about the
selected hits. This information can either be part of the tool or retrieved from public
databases. In case of miRNA screens, additional information about mature miRNA
identiers, miRNA family membership (R28), disease-specic information, e.g. from
miRcancer [127] (R29), as well as a mapping of miRNA hits to putative and experimen-
tally validated target genes (R30) is advantageous.
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6.1.4.2 Small Compounds
In case of a small compound or drug screen, a plot of the chemical structures (R31), a
list of similarly structured compounds in the screen (R32), and a list of putative drug
target genes would be desirable (R33).
6.1.4.3 Functional Enrichment Analysis
All screen types would benet from a systematic functional enrichment analysis on the
level of pre-dened gene sets that are associated with biological processes, functions,
or pathways (R34-35). Finally, including de novo network enrichment (R36), in which
potentially unknown pathways are extracted from existing interaction networks, such as
BioGrid [128], is particularly suitable to generate new hypotheses and to identify the
most promising hits in a screen.
6.1.5 User Interface
To make the analysis of HTS data easily accessible to users, a graphical or a web browser
interface should be oered to guide to provide features for data input (R37) as well as for
the presentation of results (R38). Moreover, it would be advantageous to implement the
analysis following a reactive design, in which parameters of the analysis can be changed
in the user interface without the need to reiterate the entire analysis process (R39).
6.2 State of the Art
A number of tools have been developed in recent years to deal with challenges typically
encountered in analyzing HTS experiments. Even though commercial solutions like
Spotre R or Pipeline Pilot R support HTS data, we focus on non-commercial tools de-
veloped within the academic community. Here, analysis of genome-wide RNAi screens is
supported by two dierent R Bioconductor packages. RNAither [129] and cellHTS2 [130]
each provide features to process and normalize RNAi screening data. Both packages have
the ability to produce HTML reports that allow the user to interact with the results in
a user-friendly way. Moreover, a web service called web cellHTS2 has been established
that provides convenient access to the analysis work-ow of cellHTS2 without requiring
a local installation of R. Furthermore, both packages can link identied genes to gene
ontology terms [131] and test for gene set enrichment [132]. While both tools support
gene ontology analysis, only cellHTS2 results can be subjected to more sophisticated
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functional enrichment analysis via the HTSanalyzeR package [133]. Another notewor-
thy tool is HiTSEE KNIME [134], which focuses on the analysis of small compound
screens. While it lacks many common features in data normalization and hit discovery,
it oers a powerful user interface to explore small compound data, including structural
comparisons and the ability to explore the so-called neighborhood of a compound, which
consists of structurally similar compounds.
In summary, RNAither and cellHTS2 provide excellent support for RNAi screening
experiments, but fail to accommodate alternative screen types such as small compound or
miRNA screens. Moreover, they lack hit discovery methods that optimally utilize sample
replicates, such as the Bayesian hit detection method suggested by Zhang et al. [135].
The strict separation between input parameters and results does not allow the user
to explore dierent thresholds and data processing strategies interactively and without
manually repeating large parts of the analysis procedure. We envision that a more
responsive web application would motivate users to explore and compare alternative data
processing strategies and thus to better accommodate the unique challenges that come
with each individual experiment. This motivated us to develop RNAi and Compound
Screen Evaluation (RNAice), which in addition to RNAi and CRISPR/Cas9 screens
also oers support for small compound and miRNA screens with their unique challenges
in downstream analysis. A comprehensive comparison between cellHTS2, RNAither,
and RNAice can be found in Supplemental Table A.6.
6.3 Methods
Processing HTS data involves a number of steps. Raw signal data needs to be normalized
to account for known sources of variation. the quality of the screening data needs to be
assessed by visual inspection of the signal distribution and by measuring the separability
of included controls. The major goal of primary HTS is to obtain a list of hits, i.e.
samples that show a signicant change in phenotype. Various methods are available to
make this distinction. A detailed overview can be found in [136] and [55]. Methods
implemented in RNAice are briey introduced in the following.
6.3.1 Normalization of Raw Signal
While some hits are easily spotted both visually and statistically due to their extreme
eect, there are typically many hits with moderate yet signicant eect. The specicity
and sensitivity for identifying these hits depends largely on the ability to remove noise
from the raw data. In general, two types of normalization methods exist, namely control
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based and plate based normalization.
6.3.1.1 Control Based Normalization
Control based normalization methods rely on a series of wells containing negative control
samples that demonstrate little or no eect and positive control samples that exhibit a
strong eect. Control samples can be used as a reference point to measure the relative
eect observed in samples located on the same plate as the controls. This allows for
inter-plate comparisons even if absolute values vary signicantly between plates and
batches, since the control normalized values express the signal of the various plates as a
percentage of eect strength. Two control based normalization methods are presented
in the following.
Percentage of control (POC): Here, only a single control type is needed to establish
a reference point, i.e.
POC =
xi
c
 100 (6.1)
where c corresponds to the control mean and xi corresponds to the sample value.
Normalized percentage inhibition (NPI): Here, two controls establish an eect
range that can be computed as a percentage, i.e.
NPI =
c+   xi
c+   c   100 (6.2)
where c  corresponds to the mean of the negative control and c+ corresponds to the
mean of the positive control, respectively.
6.3.1.2 Plate Based Normalization
Control based normalization is often considered inappropriate, since the number of con-
trol wells is typically kept small to reserve more space for samples. Moreover, control
wells are typically located on the outer wells, where the signal is often strongly biased
by evaporation. Most importantly, control samples may occasionally not perform as
expected, e.g. in cell viability assays, where negative controls may prove lethal for a
particular cell line or where a cell line may be resistant towards a normally lethal pos-
itive control [137]. A viable alternative is plate based normalization, which operates
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under the assumption that the majority of reagents do not demonstrate any signicant
eect. Consequently, most wells in a plate qualify as negative controls, which largely
increases the number of wells contributing to a virtual reference point. A control reagent
may show unexpected behavior in some scenarios, while the plate-based normalization
is more robust due to the large number of contributing samples [136]. Plate based nor-
malization, however, is limited to primary screening. Follow-up screens are typically
conrmation screens of hits found in the primary screen, where this assumption does
not hold. Consequently, control wells are typically included in primary screening even
when only plate based normalization methods are considered. The control wells will
then be used at a later stage to compare the eect strength between primary and sec-
ondary screening results. Finally, screening libraries are sometimes not randomized but
clustered. In this case, it is quite likely that groups of wells on a plate demonstrate
comparable eects. Examples are small compound libraries, where structurally similar
compounds are often grouped or siRNA libraries, where functionally related reagents
may be located on the same plate. The most frequently used plate based normalization
methods are presented in the following.
(Robust) z-score: The z-score expresses eect strength as a function of the general
variability of the data, i.e.
z   score = xi   x
SDp
(6.3)
where xi corresponds to the sample value, x corresponds to the plate mean and SDp
corresponds to the standard deviation (SD) of plate p. A disadvantage of this method
is that it considers all samples for computing mean and SD . Alternatively, the robust z-
score can be used, where mean and SD are exchanged with median and median absolute
deviation (MAD) respectively. In z-score normalized data, the plate mean is 0 and the
SD is 1. This type of normalization corrects for general dierences in signal intensity
and expresses eect strength in dependence of the general signal variation, thus allowing
for inter-plate comparison.
B-score: A common problem in HTS are positional eects. These can be caused by,
e.g. increased evaporation of the outer wells or by a technical bias introduced in cell
seeding, where each row is typically supplied by a dierent tube. The result of these
eects is a signal bias that is in most cases row and column specic. To mitigate this,
Brideau et al. suggest the B-score [138], which utilizes Tukey's two way median polish to
obtain a signal estimate rijp that is corrected for position specic bias x^jip. It includes
the estimated average of the plate p as x^p, the estimated oset of row i in plate p as R^ip
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and the estimated oset of column j in plate p as C^jp:
rijp = xijp   x^ijp (6.4)
= xijp   (x^p + R^ip + C^jp) (6.5)
Similar to the robust z-score, the B-score can be obtained by dividing the corrected
signal estimate by the MAD of the plate:
B   score = rijp
MADp
(6.6)
The B-score is ideally suited to deal with positional eects, but particularly in 96 well
plates it may introduce an additional bias in case of rows or columns that contain many
active samples.
6.3.2 Quality Control
Quality control (QC) in HTS is imperative to identify batches or individual plates that
did not perform as expected, e.g. if the transfection was inecient or if the cell viability
was aected. Moreover, QC helps to monitor time dependent eects where the quality
typically decreases with each following plate, thus limiting the maximal batch size.
Several parameters of QC can be investigated visually, such as row and column means to
check for positional eects, or scatter plots to investigate the signal distribution. Ideally,
wells with positive and negative controls are available on each plate. Two established
measures that assess how well positive controls can be separated from negative controls
are presented in the following.
6.3.2.1 Strictly Standardized Mean Dierence
Acknowledging that QC measures like the signal-to-noise and signal-to-background ra-
tio fail to capture the variability of the data appropriately, Zhang et al. suggested a
dimensionless parameter called Z-factor [139]. It is dened as the ratio of the dierence
between sample and control mean, and the dynamic range of the signal. This measure,
called Z'-factor when comparing control values, is a widely used QC measure in HTS .
However, Zhang et al. have criticized it for a lack of solid statistical interpretation and
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proposed an alternative score called strictly standardized mean dierence (SSMD) [140],
which is dened as:
SSMD =
1   2p
21 + 
2
2
(6.7)
where 1 and 2 are the means and 1 and 2 the SDs of two populations 1 and 2
4.
Like the Z-factor, the SSMD captures not only the dierence, but also the variability of
both populations. In contrast to the Z-factor, however, the SSMD is easier to interpret.
An SSMD > 3 indicates that the mean dierence is at least three times the SD of the
dierence of the two populations. Moreover, an SSMD > 3 indicates that the probability
that a value from the rst population is larger than a value of the second population is
close to 1 (0.99865), adding a probability interpretation. Following the three sigma-rule
for signicance, a SSMD of 3 is thus a suitable cuto for a pass / fail test in QC .
6.3.3 Hit Detection
The goal of HTS is to identify active samples or reagents in a screen that show an
eect. The threshold at which an observed eect is considered signicant depends on
the variability of the data. Therefore, a common and straight forward approach to detect
hits is to dene a threshold based on k SDs or, to increase robustness, on k MADs.
The factor k is chosen by the user to control the number of hits to be selected. A small
k results in less stringent ltering and is likely to include many false positives, while a
large k will lead to stringent ltering with and lead to many false negatives. In reality,
the choice of k mostly depends on economic considerations, where as many promising
hits as possible are included in a secondary conrmation screen. Therefore, the false
discovery rate (FDR) and its control via multiple testing correction are widely ignored
in primary screening.
6.3.3.1 SSMD for Hit Detection
The intuitive approaches of dening a window based on SD or MAD are often criticized
for being relative arbitrary. Moreover, these approaches are not suited to fully utilize
replicates. An intuitive alternative that is often considered for HTS experiments with
replicates is thus the t-test, which can be used to assign a p-value to the dierence
4Note: populations here can refer to the comparison of two controls or a sample and a control.
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between sample and control replicates. However, Zhang et al. demonstrated the t-
test is in fact an inappropriate measure of eect strength, due to its dependence on
the number of available replicates [141]. A suitable alternative for hit detection that
separates the eect size of the impact of the number of replicate samples, is the SSMD
score described in Chapter 6.3.2.1.
6.3.3.2 Bayesian Hit Detection
The hit discovery methods presented so far can be used to assess and rank the activ-
ity of all samples in a screen. A common disadvantage is that the FDR is unknown
but expected to be inated, since a large number of samples are tested independently.
Moreover, variation between plates and batches is only taken into account on a per plate
basis. While this strategy is generally appropriate, it might lead to misleading results if
individual plates contain clusters of active samples. Zhang et al. therefore propose an
alternative hit discovery based on a Bayesian model [135]. One of the main advantages
of this method is that it calculates eect strength per plate while borrowing information
from the entire experiment. Moreover, this model maintains a balance between contri-
butions of sample wells and control wells. In practice, the experiment-wide information
is used to calculate the priors for the model, while the actual likelihood is calculated
per plate. Another major advantage of this method is that it allows one to eectively
control the FDR via multiple testing correction, e.g. using the method of Benjamini-
Hochberg [142]. Bayesian hit detection thus oers a statistically motivated alternative
for dening a threshold for hit detection. A detailed description of the method, which
was implemented for RNAice by Martin Dissing-Hansen5, is included in Chapter D.1.
The method presented here is more robust to plate-specic signal bias due to its ability
to utilize information of the entire experiment or batch, yet it does not account for
positional eects. Similar to control based normalization methods, its eectiveness de-
pends crucially on the reliability of controls. Pooling the variance of negative controls
across plates, however, allows for this method to be used even if relatively few negative
control wells are included. This is of particular importance for 96 well plates, where
typically only very few controls are available. The result of hit discovery in RNAi or
CRISPR/Cas9 screens is a list of genes that are associated with a particular phenotype.
In contrast, miRNA inhibitor or mimics screens require a list of target genes.
5Computational Biology Group, Department of Mathematics and Computer Science, University of
Southern Denmark
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6.3.4 MicroRNA target genes
MiRNAs operate as key regulators of biological processes by inhibiting the translation
of up to hundreds of genes (Chapter 1.5.1.2). Consequently, the eect of inhibiting or
mimicking a miRNA can only be understood through interrogating the function of the
aected genes. It is therefore imperative to acquire knowledge about miRNA-gene inter-
actions prior to any functional analysis. A number of prediction algorithms have been
developed to solve this problem computationally. Common features considered are the
requirement for a perfect match in the seed region, evolutionary conservation of the tar-
get site sequence, as well as the free binding energy at and the accessibility of a particular
genomic site. More ne-grained strategies exist and have been reviewed exhaustively in
[143, 144]. The predictions of these tools are available through the Bioconductor package
RmiR6, including predicted targets from mirbase [145], targetScan [146], miRanda [147],
miRDB [148], and PicTar [149], as well as experimentally validated targets from tar-
base [150]. In addition, a database of human miRNA targets has been created using
the tool RNAhybrid [151]. RNAhybrid predicts miRNA target interactions via the free
binding energy. The advantage of this database, named RNAhybrid hsa, is that each
miRNA target interaction is associated with a p-value. This allows for controlling the
sensitivity of the target prediction. A general weakness of miRNA target prediction
is the high false positive rate, where a single miRNA is typically predicted to target
hundreds of genes. Controlling this parameter in RNAhybrid hsa is thus advantageous.
Ideally, predicted miRNA target interactions are veried experimentally. Reliable exper-
imental evidence formiRNA target interactions is available through reporter assays [152].
However, this requires experimenters to tediously validate each single interaction. Re-
cently, more systematic approaches such as crosslinking immunoprecipitation (CLIP)
have become available [153]. Here, the miRNA and its target mRNAs are crosslinked
in the RISC complex, which is subsequently extracted via immunoprecipitation. In
CLIP-seq, the degradation of the RISC complex is followed by NGS , which allows for
the identication and conrmation of miRNA targets. However, many potential inter-
actions are likely to be missed, since they can only be detected if both the miRNA and
the corresponding target gene are actively transcribed in abundance [154]. Therefore,
prediction algorithms currently remain the primary source of miRNA target informa-
tion. To accommodate the high false positive rate of these methods, we propose a lter
for high-condence target genes introduced in the following.
6http://www.bioconductor.org/packages/release/bioc/html/RmiR.html
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6.3.4.1 High-Condence miRNA Target Genes
In a typical miRNA experiment, putative target genes are aggregated for all miRNAs
hits using one of the established public databases or prediction methods. The resulting
gene list is then subjected to further analysis (Chapter 6.3.5). However, several stud-
ies demonstrated that functional miRNA target enrichment analysis leads to erroneous
results [155, 156]. Godard et al., for instance, found that pathways are reported as
enriched independent of the disease investigated in the study [155]. This motivated the
authors to investigate and compare lists of randomly selected miRNAs, conrming the
suspicion that miRNA target enrichment is unspecic. We therefore propose to lter
the miRNA hit list to exclude uninformative miRNAs. To this end, we utilize the hy-
pergeometric test to compute the probability of drawing k successes from a population
of size N in n draws, given that there are K success states in the population:
P (X = k) =
 
K
k
 
N K
n k
 
N
n
 (6.8)
This allows us to calculate the probability that k out of n miRNAs target a particular
gene given that this gene is predicted as a target for K out of N total miRNAs. Since
we are in fact interested in the probability of observing at least k miRNAs that target
a particular gene, we can calculate the cumulative probability as:
P (X  k) =
nX
i=k
 
K
i
 
N K
n i
 
N
n
 (6.9)
Genes with a signicant p-value are thus found more frequently as targets in the miRNA
hit list than we would expect by chance. To compute these p-values, we rst needed to
know K for each of the genes. However, for RNAhybrid hsa, the value of K depends
on the p-value threshold selected for miRNA target interactions in the rst place. We
thus added additional tables to RNAhybrid hsa that yield corresponding K values for
p-value thresholds of 0.05, 0.01, 0.001, and 0.0001.
To apply this strategy irrespective of the miRNA target database used, we implemented
a second method based on repeated sampling of miRNA target lists. These lists of equal
length as the original hit list are utilized to extract the putative target genes. In this
way, the average number of miRNAs targeting a particular gene can be computed to
obtain an estimate of K.
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Finally, the resulting p-values from the hypergeometric test are corrected for multiple
testing using the Benjamini-Hochberg method [142]. The remaining target genes that
pass the signicance threshold after this correction are considered as high-condence
target genes for further analysis.
6.3.5 Analysis of Candidate Genes
Both, siRNA and CRISPR/Cas9 screens yield hit lists in the form of genes. Similarly,
the eect of miRNAs and small compounds can be best understood under consideration
of their target genes. It is thus crucial to extend the HTS analysis to the systematic
functional analysis of gene sets. Three popular approaches that have been included in
RNAice are briey discussed in the following.
6.3.5.1 Gene Set Overrepresentation Analysis
Several databases exist that link sets of genes to functional categories in gene set over-
representation analysis (GSOA). One of the most popular providers of gene sets is Gene
Ontology [131], which groups genes across three categories, namely cellular compart-
ment, molecular function, and biological process. Being organized as an ontology, these
so-called GO terms form a hierarchical structure, in which more generalized terms, which
are shared by many genes, are on top, while more specic terms, which are shared by
few genes, are found on the bottom. Other popular databases that link gene sets to
functions are KEGG [157] and Reactome [158], which consider sets of genes as biological
pathways that provide a specic function to the cell or that are related to a specic
disease. Utilizing the hypergeometric test, a probability can be calculated for observing
a given overlap between the genes in the hit list and pre-dened functional gene sets
[159]. Overrepresentation analysis identies gene sets for which signicantly more genes
are found than would be expected by chance.
6.3.5.2 Gene Set Enrichment Analysis
In GSOA analysis, only the membership of a hit gene in a gene set is considered. In
contrast, gene set enrichment analysis (GSEA) takes the rank of a all genes of a set into
account [132]. To this end, an enrichment score (ES) is calculated as a running sum for
each gene set S. The ES is increased if a gene is in S and decreased otherwise. The
magnitude of the increase or decrease depends on the correlation of the gene with the
phenotype, i.e. in case of HTS it is the measured eect strength. By permuting the
phenotype labels repeatedly, a null distribution of the ES can be calculated. This allows
Chapter 6. RNAice 74
for the computation of signicance values for each individual score. In this way, the ES
indicates whether members of a gene set are enriched at either end of the ranked sample
list. GSEA, which is based on the Kolmogorov-Smirnov statistic [160], is generally
considered more powerful than the hypergeometric test described above, but is often
criticized for a lack of sensitivity [161].
6.3.5.3 Network Enrichment Analysis
Tamayo et al. could show empirically that the underlying assumption of GSEA, the
independence of gene eects, does not hold. This indicates a severe bias of the ES due
to frequent gene-gene interactions [162]. Moreover, the results of GSEA as well as GSOA
depend crucially on the selection of the a priori dened gene sets [163]. Both of these is-
sues can be mitigated by network enrichment analysis, which utilizes biological networks
that consist of experimentally validated or predicted interactions between genes and / or
proteins [128, 164, 165]. In contrast to methods based on gene sets, network enrichment
allows for functional pathways or functionally related gene sets to be discovered de novo.
Analyses based on pre-dened gene sets or pathways, such as those found in KEGG or
Reactome, are subjected to a research bias, whereas de novo network enrichment relies
only on knowledge of general interactions between genes or proteins and thus allows
for extracting pathways without this bias. To utilize such methods, gene regulation or
protein-protein interaction networks such as BioGrid are needed. While the resulting
pathways often overlap with the pre-dened ones found in KEGG, for instance, there
are also pathways that have not been formally described and can potentially identify
unknown mechanisms. These can be further investigated and might lead to an expla-
nation of the observed phenotype. Several distinct algorithms and tools are available to
achieve network enrichment [166{168].
We chose to include KeyPathwayMiner (KPM) [166], which features two enrichment
models to extract de novo pathways. KPM operates on a binary indicator matrix of
cases  entities, where cases correspond to samples or patients and entities to genes
or more generally to the nodes of the network. The common goal of both models is
to nd connected components that are enriched for entities that are active in \most"
cases. Individual Node Exceptions (INES) is an enrichment model that introduces two
parameters K and L to control what \most" cases means. K denes entity exceptions,
i.e. in each sub-graph up to K nodes can be inactive. Moreover, L denes case excep-
tions, meaning that an entity is counted as active if it is active in all cases but L. A
consequence of the K parameter is that KPM often reports sub-graphs that are highly
similar and only dier in the up to K nodes that have been added arbitrarily at the
periphery. These so-called border exception nodes can be removed by KPM to avoid
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this issue. One disadvantage of INES is that it tends to use the exibility introduced
by the K parameter to add well connected hub nodes to the sub-graph. Although these
are selected to increase the overall size of the solution, this eect might not always be
desirable. Therefore, an alternative enrichment model called Global Node Exceptions
(GLONE) omits the K parameter in favor of a globally distributed number of case ex-
ceptions dened by L. In other words, all entities in a sub-graph are active in all cases
but L. KPM was selected, since, in contrast to other methods, the parameters are eas-
ily interpretable. Moreover, KPM oers a web service that can be integrated to allow
the user to save time by performing the demanding computations for de novo network
enrichment asynchronously on a powerful server. In this way, the user can conveniently
continue to explore the HTS results while waiting for the results. The sub-graphs re-
vealed by de novo network enrichment are likely to provide new insights into molecular
mechanisms that were aected during the screen and which should be followed up in
further experiments (see Chapter 6.4.2.1 for an example).
6.4 Results
In the following, we describe the user interface and typical work-ow in RNAice, includ-
ing options for data input, data exploration, quality control, normalization, hit discovery,
and functional analysis. This chapter concludes with two application cases that demon-
strate the capabilities of RNAice on previously published RNAi and miRNA mimics
screening data.
6.4.1 User Interface
6.4.1.1 Input
RNAice is exible with regards to the input format (Figure 6.1). The start page of the
application is the \Input" tab, where the user can choose between several options. To get
familiar with RNAice, the user can select one of of several published data sets, including
a miRNA mimics screen of cell viability in human melanoma cells [169], a dierential
genome-wide siRNA screen aimed at identifying modulators of tumor necrosis factor 
(TNF) [170], and a genome-wide siRNA aimed at identifying genes implicated in the
sensitivity of human colon cancer cells to the anti-cancer drug vorinostat. The latter is
complemented by a genome-wide miRNA mimics screen [171]. Alternatively, users can
provide an AID or upload their own dataset. The raw data is shown in a data table at
the bottom of the page. Data tables shown in RNAice are interactive, i.e. the content
can be sorted by column in ascending or descending order. Moreover, the content can
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be searched with a global search box located in the top right corner of the data table
or with column-specic search boxes located at the bottom of each column. Entering a
search term will lter for table rows that match the query.
Subsequent to uploading or selecting a dataset, the respective columns need to be
mapped to properties known to and required by RNAice. This can be achieved by
clicking on a checkbox called \Show le input options", which provides select boxes
for identifying properties, such as plate id, well location, accession number, measured
signal, replicate, experiment and control status of each row, by the column name of
the input data. Moreover, the type of screen, type of accession number, type of well
position as well as specic positive and negative controls need to be selected. The user
can decide to log-transform the data and to include the calculation of B-scores, which
prolongs the run-time considerably due to the complexity of the method. A click on the
button \Process raw data" triggers pre-processing and normalization of the data. Upon
completion, additional options become available in the top menu.
Figure 6.1: A: RNAice guides the user through the analysis of an HTS dataset.
To this end, the functionality is grouped into categories that are accessible through a
navigation menu on top. At rst, only the \Input" tab is available, while additional
functionality becomes available after proper processing of the data. B: As input data,
users can either select one of the included demo data sets, import a dataset by its
PubChem id or upload their own data le. C: Since the composition and properties
of any uploaded les is unknown, a form is provided to enable the user to identify the
required columns and to enter additional information, e.g. about the type of the screen
or the type of accession id provided.
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6.4.1.2 Data
The \Data" tab provides a series of plots to explore the processed data (Figure 6.2). A
table shows the pre-processed data, which now includes columns for (robust) z-score, for
the signal centered by mean or median, and optionally for the B-score and for control
normalized values. Scatter plots show the entire data of the screen and are divided by
experiment and readout. Plates and replicates are distinguished by color and shape,
respectively. In the plots included here, the raw signal can be compared to dierent
normalization methods enabling users to perform a direct comparison of their eect.
Density plots provide an impression of the distribution of the raw data across replicates,
experiments and readouts. A quantile-quantile plot is available to assess if the signal
data is normally distributed. Finally, an interactive plate viewer allows users to select
individual replicate plates for heatmap and scatter plots. The quality of the screen can
be further investigated in the following tab.
6.4.1.3 Quality Control
The \Quality Control" tab depicts the variability of the screen and the performance of
the controls (Figure 6.3). A plot of signal spread across the entire screen consists of box
plots of each plate to demonstrate in how far the quartiles of dierent plates agree. The
replicate correlation plot includes linear regression models and R2 values for all pairwise
combinations of replicates in the screen. A plot dedicated to the spread of control values
consists of a box plot for each control and plate. In this way, problematic controls and
/ or plates can be spotted. The separability of controls is an important indicator for
the quality of a screen, since it indicates the expected sensitivity for hit discovery. As
described earlier (Chapter 6.3.2), the Z'-factor and SSMD are both suitable methods to
quantify separability of samples or controls. Since the SSMD can be considered superior
to the Z'-factor, it is currently the only method included in RNAice. The corresponding
plot depicts the SSMD of all pairs of positive and negative controls across all plates.
Finally, the column and row means are plotted for each replicate plate after centering
the raw signal data with the mean. This plot is particularly suited to spot positional
eects. Here, a characteristic u-shape indicates a signal increase of the outer wells due
to, for instance, increased evaporation. After successful assessment of the quality of the
screen and sources of variation, the user can proceed to hit discovery.
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Figure 6.2: RNAice allows its users to explore screening data by plots such as A:
Scatter plot of samples in the screen ordered by plate (color), replicate (shape) and
well number. B: Signal density plot. C: quantilt-quantile plot. D: Interactive heatmap
of a plate, where the color gradient corresponds to signal strength. E: Interactive scatter
plot of a plate with the well index on the x-axis and the signal strength on the y-axis.
Error bars indicate the standard deviation of the replicates.
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Figure 6.3: RNAice produces a series of plots for quality control. A: Box plots of all
plates and replicates. B: Replicate correlation plot including a linear regression (black
line) with corresponding R2 correlation factor. The grey line indicates the identity. C:
Signal spread of the various controls across all plates. The positive controls rela and
tnfr1 are more robust than the negative controls sicon and lrp5. D: Control separability
measured by SSMD . Here the separability between the negative control lrp5 and the
other controls is shown. The red area indicates bad separability and the orange area
good separability. An SSMD outside of the orange area indicates excellent separability.
E: Plate signal is centered by the mean and subsequently column means are plotted
across all plates and replicates to indicate positional eects typically evident by a u-
shape.
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6.4.1.4 Hit Discovery
The \Hit Discovery" tab is dominated by an options pane, which allows the user to
include one or several experiments and readouts. Moreover, a normalization method
and hit detection method need to be selected together with a sensible margin that is
used to compute thresholds for active samples (Figure 6.4). In case of the Bayes method,
a p-value threshold has to be selected instead. Finally, the user can select whether to
show all hits, or to lter for promoters or suppressors. Sample lter options are provided
to exclude or include specic samples from the nal list. If several experiments and / or
readouts are selected, dierential screening can be selected to use one pair of experiment
and readout as a baseline or reference. Hits discovered in this reference will be removed
from other selected experiments or readouts.
In response to the settings selected above, a list of hits is generated. Depending on the
screen type and the type of accession number, additional information is added, such
as, for instance, entrez gene ids, gene symbols, miRNA ids, or miRNA family ids. An
alternative view of the hits is provided in an interactive scatter plot depicting the hits
of the screen in decreasing order. For a large number of samples, the labels on the x-
axis quickly overlay and thus become unreadable. The user can, however, still move the
mouse cursor over one of the hits to trigger a tooltip with additional sample information.
Finally, a large heatmap of the entire screen is plotted, where hits are indicated through
small black arrows (Supplemental Figure B.6). This form of presentation allows to
quickly assess systematic problems in the hit discovery, e.g. if hits accumulate on a few
plates or if they show a tendency to occur in a specic row or column. In this way,
the user is encouraged to critically review the selected normalization and hit discovery
strategy. However, often none of the available methods seem to be fully convincing, since
they all have their particular advantages and disadvantages. The next tab is therefore
dedicated to comparing multiple methods in simultaneously.
Consensus Hits:
The \Consensus Hits" tab oers to consider several normalization methods in parallel
(Figure 6.5). A consensus hit list is generated based on all selected methods. The user
can dene a minimal number of methods that need to report a particular hit for it to be
included. Similar to the ordinary hit list, the consensus hit list can be viewed as a table
or as a scatter plot. In addition, a Venn diagram shows to what extent the dierent
methods agree and how many of the hits are exclusive. The remaining tabs in RNAice
depend on the screen type and are described in the following.
MicroRNAs: The \MicroRNAs" tab can only be selected after successful identication
of hits in a miRNA screen. Here, additional information is provided for further analyses.
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Figure 6.4: RNAice provides several options for hit discovery. A: The user can choose
to include or exclude samples based on a regular expression. Moreover, dierential
screening is possible, where hits identied in one experiment or readout are removed
from others. B: The user selects which experiments and readouts to consider. C: Several
normalization and hit detection methods are available. A threshold needs to be dened
and optionally a direction of the eect can be selected. D: The result is shown as
either a data table (Hit List), as an interactive plot (Hits Plot), or as a heatmap that
encompasses the entire screen.
Figure 6.5: The problem of experimental variation in the data can be accommodated
by normalization, where each method disqualies some hits while promoting others. A:
This is reected in consensus hit list where several methods can be selected in parallel.
A threshold can be adjusted to include only hits reported by several methods. B: The
consensus hit list can be viewed as a data table or interactive plot. C: A venn diagram
illustrates to what extent the methods agree.
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A table of predicted or experimentally validated miRNA target genes can be generated
using a number of dierent databases (Chapter 6.3.4). Moreover, a miRNA family view
provides an overview of family coverage, i.e. how many members of a miRNA families
appear as hits in this particular screen. Cutos can be selected for family size and
percentage of coverage to lter for interesting families. The idea behind this is that
miRNAs in a family share the same seed sequence and thus a large number of target
genes. Single miRNA hits may be due to an o target eect. In contrast, observing
several miRNA mimics or inhibitors in the hit list that are part of the same miRNA
family is unlikely to be the result of o-target eects.
The eect of miRNAs is attributed to their target genes. RNAice enables users to
select predicted or experimentally validated target genes from a selection of sources. As
discussed in Chapter 6.3.4.1, the list of miRNA targets is likely to contain a large number
of false positives. To mitigate this, high condence target genes can be computed.
Finally, the integration of the miRcancer database [127] points the user to literature of
known associations of the miRNA hits with various types of cancer.
Small Compounds:
Small compound screening aims at identifying drugs that are suitable to inuence cellular
function through so called drug targets, i.e. proteins that interact with a chemical com-
pound. Several million drug target interactions have already been collected in databases
such as STITCH [172]. RNAice uses STITCH to identify possible drug targets of active
compounds found in small compound screens. Subsequent functional analysis on the re-
sulting gene list is suited to reveal if several of these drugs achieve an eect through the
same or associated proteins or molecular functions.
Systematic Functional Analysis on the Gene Level: The systematic functional
analysis of gene lists through GSOA and GSEA (Chapters 6.3.5.1 and 6.3.5.2) is facili-
tated through the integration of the R package HTSanalyzeR [133].In the case of siRNA
or CRISPR/Cas9 screens, either the hit list or the consensus hit list has to be selected.
Alternatively, if a miRNA is analyzed, the choice is between the original miRNA target
list or the high condence miRNA targets. Finally, if a small compound screen is se-
lected, the drug target gene list is pre-selected. The user can choose several gene sets to
be considered, including the three categories of Gene Ontology and KEGG pathways.
Moreover, the p-value cuto, the minimal gene set size, the number of permutations for
GSEA and the selected method for multiple testing correction can be adjusted. The
\Start analysis" button will trigger an analysis. Alternatively, de novo network enrich-
ment analysis (Chapter 6.3.5.3) is available through integration with the web service of
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the KPM web application7. The user can adjust the parameters of KPM and initialize
the analysis remotely by pressing \Start KPM". During the analysis, the user can freely
explore other results provided by RNAice. Upon completion, the key pathways, i.e. gene
sets, provided by KPM will be shown in a graph. In contrast to the result graph shown
in the KPM web application, RNAice will include additional nodes and edges depicting
the miRNAs that share the identied genes as targets.
6.4.2 Application Cases
In the following, we demonstrate how RNAice can be utilized to analyze HTS raw data.
The rst example is a genome-wide siRNA screen aimed at identifying modulators of
tumor necrosis factor alpha (TNF) [170], which is implicated in inammatory diseases
and cancer. Our aim here is to demonstrate the basic data processing and quality control
capabilities of RNAice and to compare our results to the results reported in the study.
We also apply functional enrichment analysis to evaluate the resulting hit list in a wider
biological context. Another example is a synthetic lethal screen in colon cancer cells
aimed at detecting resistance genes for vorinostat, a drug for cancer treatment [171].
In addition to a genome-wide siRNA screen, Falkenberg et al. performed a miRNA
mimics screen. The combination of these two screening types in a single experiment
provides an opportunity to test the miRNA high-condence target method introduced
in Chapter 6.3.4.1.
6.4.2.1 A Genome-Wide RNA Interference Screen Identies Caspase 4 as
a Factor Required for Tumor Necrosis Factor Alpha Signaling
Nickles et al. have performed a genome-wide dierential siRNA screen for genes modu-
lating TNF-, which also aects NFB signaling [170]. The screen includes 56 duplicated
384 well plates. In order to distinguish TNF modulators from genes that aect cell
viability in general, two readouts were performed. A Renilla luciferase acting under
control of a -actin promotor serves as a general reporter of cell viability (channel 1).
In addition, a second reporter plasmid contains eight NFB binding sites that control
the expression of rey luciferase (channel 2). Since the NFB pathway is triggered by
TNF, this allows for the identication of potential modulators. The screen includes the
two negative controls sicon (siCON) and lrp5 (siLRP5) as well as two positive controls
rela (siRELA) and tnfr1 (siTNFR1). Inspecting the raw signal data (Figure 6.2) shows
comparably little variation between individual plates. It is evident from Figure 6.3A
7The KPM web application was developed by Martin Dissing Hansen at the Computational Biology
group, Department of Mathematics and Computer Science, University of Southern Denmark, manuscript
in preparation
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(only channel 2 is shown) that for a number of plates one of the two replicates was
removed, probably due to quality problems. Figure 6.3B shows that the correlation
between the two replicates is satisfactory. Figure 6.3C shows that the positive controls
mostly demonstrate a robust eect while the negative controls vary considerably. This
eect is mirrored in Figure 6.3D, since the SSMD between the negative controls (ex-
emplary shown for lrp5) versus the positive controls varies strongly from plate to plate.
The SSMD for rela is between -3 and -6 qualifying as an acceptable control, while tnfr1
is mostly between -3 and -6 and occasionally <  6. The sicon negative control appears
to produce an elevated signal in channel 2 indicating that it may be aected by TNF
signaling. These ndings are in agreement with Nickles et al., who disregard sicon as
a negative control for the same reason. Moreover, the authors use the Z'-factor to test
the positive controls with the ndings that rela is unacceptable and tnfr1 is acceptable
as positive control. Figure 6.3E shows the column means across dierent plates with
the typical u-shape indicating positional eects. A similar but less pronounced eect is
observed for rows. In conclusion, the inconsistent performance of the controls suggests
to use a plate based normalization method. Moreover, the pronounced positional eects
suggest to apply B-score normalization. The density plots of the two replicates indicate
which of the plate-based normalization methods are eective. The robust z-score and
B-score are most eective in achieving congruence for the two replicate distributions.
The raw data appears skewed towards higher signal intensities, which is partially miti-
gated by the robust z-score and by the B-score. It is noteworthy that the density plots
produced from B-score normalized data do not appear normally distributed. Based on
these results, we chose to continue with z-score, the robust z-score and B-score normal-
ized data, while the original publication used the z-score.
For hit detection (Chapter 6.3.3), we chose median absolute deviation (MAD) with a
typical threshold of 2.5, which led to a reasonable number of 614 hits (3.5% of targeted
genes) in channel 1 and 427 hits (2.4% of targeted genes) in channel 2. Subsequently,
the dierential screening setting was used to remove all hits from channel 2 that were
also reported in channel 1. The remaining 241 hits (1.4% of targeted genes) are thus
exclusive to channel 2 and potential TNF modulators. To our surprise, only some of
the 19 hits were validated in secondary screening and none of the ve genes that were
fully validated by Nickels et al. produced a signicant eect in our results irrespective
of the normalization method applied (Supplemental Table A.7). Nickles et al. selected
hits for follow up studies based on stringent ltering and literature search. However, the
authors did not perform a systematic analysis of the hits that might also help to identify
promising candidate genes. We thus performed gene set analysis (see Chapter 6.3.5) on
the 241 hits we obtained. All conducted tests, i.e. GSOA and GSEA in both Gene
Ontology and KEGG pathways, led to similar results implicating RNA polymerase II
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related functionality and ribosomal activity with very high signicance (Supplemental
Tables A.8 to A.11).
Gene set analysis provided compelling evidence that the hits we obtained were related
to NFB signaling. However, this approach does not lead to the identication of novel
modulators. For this task, de novo pathway enrichment (Chapter 6.3.5.3) is a more ap-
propriate strategy, since it does not rely on pre-dened gene sets and already established
molecular processes. To this end, RNAice constructed an indicator matrix consisting of
a single column in which genes that are a hit are assigned 1 and 0 otherwise. Subse-
quently, we subjected this indicator matrix to KeyPathwayMiner (KPM ). With only a
single column in the indicator matrix, case exceptions (L parameter) become irrelevant.
Consequently, we selected INES as enrichment strategy with K = 1 to allow one addi-
tional gene in the extracted sub-graph. We chose BioGrid [128] as source network for
gene-gene interactions, since it is one of the established standards in the eld. The top 20
solutions that were reported appeared to be variations and subsets of the best solution,
which is shown in Figure 6.6. It contains two known members of the NFB pathway,
one of which is the exception node added to the solution. The remaining members were
not yet implicated in NFB-signaling and thus appeared as promising candidates for
follow-up studies.
POLR2K
CSNK2B
POLR2E
F11R
RELA
POLR2B
POLR2C
ACTL6A
DVL1
CFDP1
IFI16
SSRP1 POLR2A
SUPT5H
POLR2GEIF2B4
EIF2S2 CSNK2A1
CREM
Figure 6.6: The 241 hits were subjected to analysis with the de novo network enrich-
ment tool KeyPathwayMiner. The enrichment strategy INES with K = 1 produced
as best solution a sub-graph containing RELA and CSNK2A1, which are both part
of the KEGG pathway for NFB signaling (indicated by red squares). The red node
corresponds to the exception node, while green nodes were identied as hits.
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6.4.2.2 Genome-Wide Functional Genomics Analysis for Genes Regulating
Sensitivity to Vorinostat
Falkenberg et al. performed a genome-wide RNAi synthetic lethal drug screen to identify
vorinostat sensitivity genes in human colon cancer cells. In addition, they included a
genome-wide miRNA mimics screen under identical assay conditions. The combination
of a RNAi and miRNA screens oered a unique opportunity to study if the observed
eect in miRNA hits can be reproduced by the miRNA high-condence target genes in
the RNAi screen. Both screens were split into a plus and a minus drug arm, where the
minus arm served to identify genes that were lethal by knockdown alone. We focused on
the plus drug arm, which was interrogated for cell death using two dierent readouts. A
cell viability assay was used to assess rapid cell death, while a complementary caspase
activity readout served to assess apoptosis, i.e. slower cell death. We downloaded
the raw data of the primary siRNA screen (PubChem AID 743454) and the miRNA
mimics screen (PubChem AID 743456). Neither the siRNA nor the miRNA screen
included replicates or controls such that only the (robust) z-score or B-score could be
considered. However, since no positional eect was observed, the robust z-score was
chosen as normalization method. For the viability readout (rapid cell death), we chose
a hit selection cuto of 2.5 MAD , which resulted in 32 miRNA hits (3.6% of miRNAs
mimics). Putative miRNA target genes from RNAhybrid hsa were obtained with a p-
value threshold of 0.05. Here, the p-value reects the likelihood of the miRNA-gene
interaction considering the free binding energy determined by RNAhybrid. This lead
to 48,980 possible miRNA-gene interactions. The subsequent lter for high-condence
targets using the hypergeometric test (see Chapter 6.3.4.1) with a p-value cuto of
0.05 after multiple testing correction produced a single gene, CSDC2, which was also
identied as a signicant hit in the primary siRNA screen by Falkenberg et al.. We
repeated the same procedure with the miRNA hits identied via the alternative readout
of caspase activity (slow cell death through apoptosis) using a threshold of 4 MAD ,
which yielded 34 miRNA hits (3.8% of miRNA mimics). The resulting list of 39,498
putative miRNA-gene interactions was ltered as described above, but did not yield
any signicant results. Next, we relaxed the multiple testing cuto to 0.2, allowing for
more false positives. This lead to 127 high-condence targets found in the cell viability
screen, out of which 6 were signicant hits in the primary screen. Moreover, a single
gene, TRIM27, was found in the caspase activity screen, which, however, was not a hit.
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6.5 Discussion & Conclusion
HTS is an indispensable tool for drug target discovery and for functional genomics. A
major concern in the eld is assay robustness [173]. In primary screening thousands
of samples are included in experiments that span over dozens of plates with only few
replicates per sample, if any. Data normalization and hit detection are utilized to re-
move known sources of variation such as plate or batch eects. However, validation
of hits in secondary screening is costly due to an increased number of replicates and
through the inclusion of other cell lines to be tested. Therefore, only a limited number
of hits from the primary screen can be selected and consequently, it is imperative to se-
lect the most promising ones. Sophisticated methods for quality control, normalization
and hit discovery can help to better accommodate the characteristics of a particular
screen. Here, the user has the choice between control and plate based normalization
techniques and also needs to decide whether to correct for positional eects or not. The
availability of replicates and suitable controls motivates the choice of a suitable hit de-
tection method. Here, the SSMD and Bayesian hit detection method are available as
robust alternatives to the traditional thresholds based on SD or MAD . The R packages
RNAither and cellHTS2 provide excellent features for data visualization and processing
of RNAi data. HTML reports and a web service for cellHTS2 allow non-expert users to
perform data analysis independently. However, to be able to make an informed decision
about the best possible data processing strategy, a non-expert user needs to be able
to directly compare the eect of dierent data processing strategies interactively and
with as little friction as possible. RNAice facilitates this in an interactive web applica-
tion, where parameters can be quickly changed without the need to repeat the entire
analysis. Moreover, RNAice provides a consensus approach to combine dierent nor-
malization strategies. While RNAice already supports a large number of normalization
and hit detection methods, there are additional methods that should be considered and
integrated in the future. Examples are the aforementioned quantile normalization, as
well as Li-Wong rank normalization, loess regression, or bivariate regression, which are
found in cellHTS2 and RNAither. Another noteworthy method that should be included
is the spatial correction method implemented in SbacHTS [174].
An important aspect for assessing the quality of hits from the primary screen is system-
atic functional analysis. While this is mostly covered by the HTSanalyzeR R package,
only RNAice provides full integration of its functionality directly in the web interface.
RNAi screens are currently the most popular choice for HTS experiments in academia,
yet there are other popular types of screens that are not covered suciently by existing
solutions. CRISPR/Cas9 screens yield comparable data and can utilize existing work-
ows for data analysis. Other types of screens, however, require dedicated features.
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The analysis of small compound screens in RNAice benets from the integration of the
drug target database STICH to identify genes of interest. Unfortunately, at the time of
writing, no small compound screen was available to serve as an application case. While
a large number of small compound screens have been deposited in public databases such
as PubChem, they lack raw signal data as well as plate id and well location for each
sample. Other databases such as ChemBank8 provide this information but do not con-
tain the PubChem identiers necessary to identify the compounds in the available drug
target databases. In theory, chemical structures represented by SMILES notation [175]
could be used to identify matching compounds via structural similarity search. This
approach, however, is computationally demanding and not feasible in an interactive web
application such as RNAice.
To accommodate miRNA screens, RNAice provides access to putative and experimen-
tally validated miRNA target genes for identied hits. This allows subsequent analysis
with HTSAnalyzeR for gene sets and with KPM for de novo network enrichment. It
should be noted that two recent studies indicate that GSOA and GSEA do not lead to
valid results when applied to lists of miRNA target genes [155, 156]. This is likely due
to the fact that miRNAs target a large number of genes and thus have a high proba-
bility to always target a large number of important pathways. Therefore, we suggested
a probability ltering step for high-condence miRNA target genes that were targeted
by more miRNAs than would be expected by chance. To evaluate the results of this
method, we analyzed a coupled genome-wide RNAi and miRNA mimics screen [171].
Our hypothesis that miRNA high condence target genes would also be active samples
in the RNAi screen could not be proved, since only a single signicant high-condence
target gene was found. Nevertheless, the identied gene was a promising hit in the
primary siRNA screen. Relaxing the p-value cuto for multiple testing from 0.05 to 0.2
increased the number of high-condence genes to 128, out of which only 6 were hits in
the primary screen (4.7% hit rate versus 3.4-3.9% hit rate in the two readouts of the
primary screen). A possible explanation for the low success rate could be the polygenic
nature of miRNA regulation, in which an eect is likely to be caused by down-regulation
of several genes, whereas the primary siRNA screen is limited to observing the eect
of a single gene at a time. Nevertheless, additional work in this direction is needed to
rene the method, e.g. by improving the ltering strategy to produce and validate a
larger number of hits. It would also be worthwhile to use only experimentally validated
miRNA targets instead of predicted ones to test this approach.
As another application case, we selected a genome-wide RNAi screen aimed at identifying
modulators of TNF and NF-B signaling [170]. Here, we found that the robust z-
scores computed by the authors dier from our results. We thus compared the data
8http://chembank.broadinstitute.org/ (access date: 06/01/2015)
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processing strategy and identied a possible explanation in the use of shorth and quantile
normalization prior to calculating the robust z-scores. Since the signal distribution was
indeed skewed, such a normalization might lead to a more balanced detection between
promoters and suppressors in a screen. This has to be considered carefully, however,
since the normalization might also do harm in cases where more hits are expected in one
of the two extremes due to the experimental design. One example is a caspase assay,
which serves to detect apoptosis and thus is likely to include more promoters than
suppressors in an experiment aimed at killing cells. In general, the dierences found
between our hit list and the hit list reported by Nickles et al. highlight the impact of
comparing dierent normalization strategies.
A subsequent functional analysis of the screening hits, which was not performed by
Nickles et al., implicated known functions of the NFB signaling pathway (Supplemen-
tal Tables A.8 to A.11). De novo network enrichment with KPM identied two central
elements of this pathway, namely RELA and CSNK2A1. The latter was selected as
an exception node, connecting other genes that were identied as hits and which are
not known to play a role in NFB signaling. This highlights the potential of de novo
enrichment analysis with KPM to suggest promising candidates for secondary screening
and functional characterization.
In conclusion, RNAice enables biologists with little or no experience in R to analyze
complex HTS data. The user is supported with various plots to allow for informed
choices about the appropriate data processing strategy. Sources of variation can be
spotted and accommodated before the hit list is produced. Moreover, dierent nor-
malization methods can be compared conveniently. As a novelty, RNAice specically
supports the analysis of miRNA and small compounds screens, making RNAice the most
comprehensive open-source tool for HTS data analysis currently available.

Chapter 7
MIRACLE: Microarray R-based
Analysis of Complex Lysate
Experiments
z
Objective of this Chapter
Development of a sample management and data analysis tool for reverse-
phase protein array (RPPA) data, including
 virtual spotting to track samples from plates to RPPAs.
 user-friendly sample editor.
 quality control and visual inspection of the data.
 normalization of raw data to account for uneven staining.
 quantication to obtain single protein concentration estimates from
dilution series.
 normalization for total protein amount.
While high-throughput screening (HTS ) is an ideal strategy for the identication of
potential drug targets, it provides limited insight into the underlying biological mech-
anisms. A secondary readout on the protein level using reverse-phase protein array
(RPPA) is suitable to increase the amount of information gained from a single HTS
experiment manifold. RPPAs are nitro-cellulose covered glass slides that can carry sev-
eral thousand of samples of tissue or cell lysates. Since RPPAs are typically spotted in
many copies, each copy can be stained with a dierent antibody, which is subsequently
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linked to a biotin-complex. This enables uorescence based measurement of protein ex-
pression levels [60]. See Chapter 1.7 for more details. Following image acquisition with
a suitable scanner, commercial tools such as MicroVigener can be used to measure the
foreground and background signal intensity for each spot on an RPPA. The position
of a spot is typically recorded as the combination of block number, row number, and
column number, where each block originates from a single pin of the extraction head
of the spotter. The extraction head has typically far fewer pins than there are wells on
the source plates. Consequently, several extraction steps are necessary to transfer the
samples of an entire plate onto a slide. Moreover, the distance between individual pins is
relatively large, reecting the distance of the wells on the plates. To t as many samples
as possible on a slide, the space between the pins is utilized by depositing subsequent
extractions of the source plates with a minimal shift of the extraction head. In this way,
samples that were taken up by the same pin will be placed next to each other, giving
rise to the aforementioned blocks on the slide. However, with this strategy, the original
order of samples in the source plates is lost, making it dicult to re-locate the samples
on the slide. This is further complicated by the fact that samples are often spotted in
various dilutions and with varying number of depositions, meaning that a single sample
is represented by several spots distributed across a slide. The entire spotting process
is shown in more detail in Supplemental Figure B.8. In the following, we will present
RPPA specic requirements R1-R17 in sample tracking as well as in data processing
and analysis and evaluate to what degree available tools are suited to fulll these (Sup-
plemental Table A.12). Subsequently, we will briey describe the methods employed in
RPPA analysis and present MIRACLE , a web application that is intended as a user-
friendly end-to-end solution for RPPA data. This chapter is mostly based on [176], in
which MIRACLE was rst published.
7.1 Requirements
7.1.1 Sample Management
To deal with the challenges introduced by the spotting process, an ecient and user-
friendly sample management solution is necessary. Ideally, such a system is open source
(R1) and accessible through a graphical user or web interface (R2). Sample tracking
should be supported on the level of both, the microtiter plates used as source (R3)
and the RPPAs generated from them (R4). To increase productivity, slides and plates
should be organized in experiments or projects (R5). This extends to the fact that
typically each slide is spotted in several slide copies (R6), where each one is stained
with a dierent antibody. Moreover, the same slide may yield several readouts that
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need to be tracked (R7). It would be advantageous to also include plate readouts to be
able to utilize RPPA technology as a secondary readout to HTS experiments (R8). To
optimally track samples between the source plates and the RPPAs, the sample spotting
process should be modeled in silico in so-called virtual spotting (R9). To facilitate this,
an appropriate RPPA sample tracking software must be customizable with respect to
the plate format being used and the size of the extraction head, which may vary from
spotter to spotter.
7.1.2 Analysis
Initially, visual inspection of the data can help to determine quality problems (R10).
After background correction, the signal of the spots needs to be further processed.
The rst step is typically the correction for bias introduced through uneven staining
(R11) [177]. Another concern is the dynamic range of signal detection, which can be
described as a sigmoidal curve due to limitations in sensitivity in the lower range and
signal saturation in the upper range [178]. Through adjusting each sample for the total
protein amount a priori, measurement is possible in the linear range of this curve.
However, this is often not feasible for high-throughput experiments, due to the trade-o
between large sample numbers, feasibility, and costs. In order to overcome this problem,
samples are typically spotted multiple times in a dilution series to cover a broad dynamic
range of protein concentrations, where each sample gives rise to a response curve. In a
process called quantication (R12), an estimate of relative protein abundance is created
by merging these values (Supplemental Figure B.9). The resulting relative concentration
estimates still need to be normalized for the total amount of protein (R13), before they
can be evaluated statistically to assess the signicance of relative dierences in protein
amount (R14). In addition, it is also of interest to correlate these values to plate based
readouts obtained, for instance, from HTS experiments (R15). Finally, it would be
desirable to include support for timecourse studies (R16) and network analysis (R17).
7.2 State of the Art
A single RPPA experiment may comprise thousands of samples distributed over large
slide sets. Precise sample tracking is a challenge that grows with the number, size and
complexity of the RPPA experiments. To date, the only documented solution to address
this critical issue is an integrated platform called RIMS [179], which provides features
for uploading and annotating sample information, data visualization, correlation and
pathway analysis. Notably, the authors also propose an XML standard called RPPAML
to overcome the lack of a data exchange format for RPPA data and a standardized
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annotation. Unfortunately, however, none of the project URLs are accessible (last access
attempt 06/01/2015), indicating that the project is no longer under active development
and has not been adapted by the community. Being implemented for the commercial
softwareMATLAB, RIMS also lacks integration of R methods commonly used for RPPA
analyses. Finally, RIMS only supports sample tracking at the slide level and not at the
level of the plate formats that form the basis for all experimentation. This leaves the
most dicult step of sample tracking to the user.
Implementations for both, parametric and non-parametric methods for quantication
of protein concentration estimates from serial sample dilutions are available through
the R packages SuperCurve [180] and RPPanalyzer [181]. These packages thus allow
for the analysis of RPPA data. A major challenge here is, however, that end users
are often not familiar with R. SuperCurve overcomes this problem partly by oering
an tcl/tk -based graphical user interface, making both analysis and experimental design
more accessible. Sample management on a larger scale, however, is neglected. RIMS
addresses some of these issues, but does not cover more complex data analysis. See
Supplemental Table A.12 for a feature comparison.
7.3 Methods
Before RPPA data can be used to compare protein expression levels of dierent samples,
a number of processing steps are necessary, including data normalization, quantication
and loading control normalization. The most common methods have been implemented
in MIRACLE and are briey introduced in the following.
7.3.1 Raw Signal Normalization
As customary for all microarray data, the background signal is determined for each spot
and subtracted from the foreground signal. This approach, however, does not correct
for signal bias due to uneven antibody staining, which is an issue specic to RPPA
technology. Positive control spots on the slide can be utilized for creating a smoothing
surface mirroring the staining bias. A correction factor can then be calculated from a
generalized linear model for each individual spot (Supplemental Figure B.11) [177].
7.3.2 Quantication
Mircean et al. proposed a linear model [69] for merging the signal originating from
individual response curves. One drawback of this approach is that a linear model cannot
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deal with samples close to saturation or close to the detection limit. Consequently,
Tabus et al. compared a variety of parametric models and found that a logistic model
was most suitable to reect the sigmoidal shape of the response curve. Furthermore,
a joint response curve based on all samples increased the condence of the model t,
since similar chemistry can be assumed for all samples [178]. Hu et al. showed that
a more exible non-parametric model yields more accurate estimates at the cost of
robustness [180]. Finally, Zhang et al. proposed a simplied robust parametric model
called serial dilution curve based on the Sips model for DNA binding. In contrast to
other parametric models, this method is based on meaningful and intuitive parameters
like the detection limit, the dilution factor and the saturation level [182].
7.3.3 Loading Control Normalization
If the total protein amount of each sample is not determined a priori, protein levels
have to be normalized, in order to guarantee a meaningful comparison between samples.
This can be achieved by either normalizing to a slide stained for total protein with, for
instance, Sypro Ruby [60] or Fast Green [183], or by using additional antibody stainings.
For the latter approach, one can rely on either a selection of housekeeping proteins that
are assumed to be constantly expressed or on incorporating the entire panel of antibody-
generated signals, where all antibodies are rst centered and scaled before the median
value is used for normalization. This so-called median loading normalization has been
improved by Neeley et al. in a method called variable slope normalization [184]. Here,
a correction factor is included to take into account that additional bias arises due to
independent slide measurements.
7.4 Results
The lack of a comprehensive and user-friendly solution for RPPA sample management
and data analysis motivated us to develop MIRACLE , an open-source web application
providing an end-to-end solution covering experimental design, sample tracking, data
processing, normalization, as well as visualization and statistical analysis of the results.
MIRACLE conveniently keeps track of sample information, starting with the source
plates, throughout array generation and down to the signal data, in a process called
virtual spotting.
MIRACLE allows biological researchers without any knowledge of R to process and ana-
lyze RPPA data eciently, grasping back to established methods by interacting directly
with R in the background. This interface will also allows future methods to be added
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Figure 7.1: Schematic exemplary work-ow of RPPA construction and analysis via
MIRACLE . (A) Larger sample sets are stored in multiple source plates, with individual
and partly complex sample information. Optionally primary plate readout data can be
included. (B) The individual sample lysates are diluted (indicated by the color gradient)
in a rst reformatting step and subsequently spotted onto slides in a customized pattern.
(C) Multiple array copies are generated and stained with dierent antibodies, adding
to the sample tracking demands. (D) An array scanner yields signal intensities for all
spots, which need to be further processed to obtain the nal results. Taken from [176].
in a straight-forward fashion. Results are directly visualized and can be investigated
interactively with regards to statistical signicance, as well as to correlation to primary
plate based readout data.
MIRACLE is designed with user approachability in mind, but also supports R data
analysts by oering a convenient data export/import interface with R. While the data
analysis part of MIRACLE is particularly laid out for handling RPPA data, the sample
management functionality is suitable for any kind of customized array design.
With its deep integration of sample management and data analysis,MIRACLE separates
itself from existing solutions (Supplemental Table A.12) that only cover parts of the
RPPA work-ow shown in Figure 7.1.
7.4.1 Sample Management
7.4.1.1 Plate and Slide Layouts
In a typical RPPA experiment, lysate samples are stored in a 96-well or 384-well mi-
crotiter plate, before they are subjected to microarray generation using a bioarrayer,
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Layer 1: Cell line
Layer 2: Inducer
Layer 3: Spot type
Layer 4: Seeded cell no.
Layer 6: Sample type
Cell line1, Inducer4, SpottypeB, Density1, Treatm2, A_NC1
Layer 5: Treatment
Figure 7.2: Sample management of plate layouts illustrated for an exemplary 96-well
plate layout. Several layers of information are accessible. Taken from [176].
-printer or -spotter. Already at this stage, MIRACLE supports experimental design
by oering an interactive web interface for creating so-called plate layouts. To avoid
cryptic and long sample names, several layers of information can be included, for in-
stance regarding cell material, treatments, applied compounds, lysis conditions, etc.
(Figure 7.2). A lot of this information is shared by samples and is therefore redundant.
MIRACLE stores information in relational databases, where each layer corresponds to
a single property, keeping the data concise through use of ids and mapping tables. By
relying on linked tables of a relational database, changes of layout properties are imme-
diately available to all samples and experiments, thereby ensuring data consistency and
comparability in the analyses. MIRACLE shares plate and sample related functionality
with SAVANAH (see Chapter 8.1.3.3 for details), allowing both applications to remain
compatible to each other and to share a single database. The latter guarantees that
sample and plate information entered in HTS experiments can be conveniently reused
in RPPA experiments and vice versa.
Similar to plate layouts, users can also dene slide layouts, in which sample properties
for each individual spot of the slide can be edited using the aforementioned sample
layers. The format of the slide is determined through specifying the number of rows and
columns, as well as blocks where applicable, e.g. when using spotters, where each pin of
the extraction head gives rise to a dierent block.
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7.4.1.2 Virtual Spotting
As previously mentioned, it is not always trivial to determine the location of a sample on
the slide, since a large number of samples originate from dierent plates. Furthermore,
repetitive spotting of samples with various dilutions and varying number of depositions
per spot has to be considered, as well as the format of the extraction head. MIRACLE
addresses this issue in a feature called virtual spotting, where previously created plate
layouts are combined with information about the operation mode of the spotter, such
as format of the extraction head, column or row-wise extraction, top-to-bottom or left-
to-right spotting, to determine the nal layout. The selection and order of the plates
can be manipulated via drag-and-drop and for each plate individual extractions can
be excluded. If a so-called deposition pattern is used, in which several adjacent spots
originate from the same sample, but are spotted with varying depositions, the layout
can be simplied. Since these samples are otherwise identical, the respective columns of
the layout can be merged.
7.4.1.3 Projects and Experiments
MIRACLE enables users to locate sample information quickly using full text search.
However, to keep experimental data organized, projects and experiments can be created,
linked to layouts and subsequently be used for ltering. As mentioned before, the
shared database between MIRACLE and SAVANAH (Chapter 5) allows projects and
experiments to be dened in either of the two applications, thus avoiding overhead
and ensuring that data stemming from related high-throughput experiments is properly
linked to each other.
7.4.2 Data Processing
7.4.2.1 Slides
Slide layouts can be linked to an arbitrary number of slides, which correspond to the
copies created during spotting. For each slide, additional information such as a barcode,
the antibody that was used for staining and scanner settings, such as the wavelength
of the readout, can be specied. Three types of les can be uploaded, including the
output le from the scanner containing signal intensities, an image of the slide and an
experimental protocol.
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7.4.2.2 Supported File Formats
The experimental protocol can be of any le type (e.g. DOC, PDF or TXT), while
for images the most common le types, such as JPG, PNG and TIFF, are supported.
MIRACLE processes each image into the Microsoft R deep zoom format. In this format,
an image is split into a number of tiles that provide the same resolution on a smaller
part of the original image. These les are stored individually and split continuously
until several levels of these splits are available. This leads to a hierarchy of tiles with the
advantage that images can be zoomed to detail without requiring the entire image to
be loaded at the full resolution. This is ideal for visual detection of quality issues, such
as clogged tips, scratches or uneven stainings and also allows MIRACLE to eciently
handle the large image les of more than 100MB that are normally produced by array
scanners. With regards to the numeric output of the array scanner, MIRACLE is not
limited to certain le types, but has a exible system supporting import of comma, semi-
colon, tab-separated or Microsoft Excelr les without requiring a specic format. This
is facilitated by allowing the user to map columns of the input le to known properties
in MIRACLE . This mapping can also be stored as a so-called ResultFileCong.
7.4.2.3 Processing Raw Data
After successfully reading the scanner le, MIRACLE will oer to add all spots to the
database. During this process, the signal of each spot is linked to the sample information
stored in the slide layout. Subsequently, users can create heatmaps to visualize the data
to detect quality problems. One example are block shifts introduced by the scanner
software that can then be corrected for (Supplemental Figure B.10).
7.4.2.4 Plates and Readouts
Similar to how slides can be added to slide layouts, plates can be added to plate layouts,
where additional information, such as plate and well type, barcode and replicate number
are stored. Often a plate readout is performed spotting, using, for example, uorescence-
based measurement of cell viability or colorimetric analysis of total protein amount.
MIRACLE allows for adding these results for each plate, utilizing the aforementioned
le upload mechanism. This mechanism is identical to the one used in SAVANAH
(Chapter 5) and allows for uploaded plate readouts to be used in either of the systems.
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7.4.3 Data Analysis
When sample management and data processing are complete, users can begin with data
analysis. After selecting a slide layout, the user is presented with a list of all slides linked
to this layout. In case the slide layout was created through virtual spotting, readouts
linked to the source plates are also shown. By starting the analysis, the user will be
forwarded to an R-based web application called Rmiracle, which will automatically begin
to fetch the selected slide and plate readouts from the database.
7.4.3.1 Processing of Raw Signal:
Rmiracle oers data analysis in several steps (Figure 7.3):
 A heatmap for visual inspection and correction of block shifts.
 Positive control spots can be used to correct for uneven staining using the method
proposed by Neeley et al. [177].
 If a dilution series has been spotted, a quantication method can be selected
for merging these samples. Rmiracle currently supports SuperCurve, as well as
implementations of a logistic model [178], serial dilution curve [182] and a non-
parametric model [180].
 Slides can be normalized for total protein amount by selecting between median
loading, variable slope [184] or housekeeping normalization. For the latter, one or
several of the slides have to be marked as loading controls.
 Signicance of relative sample dierences can be assessed by selecting a sample
reference for performing Dunnett's test [185].
7.4.3.2 Protein Concentration Estimates and Sample Grouping
With the above settings, Rmiracle computes protein concentration estimates that allow
assessment of relative dierences between samples. To this end, we grasp back to the
multi-layer sample information model of MIRACLE to group samples. Users can select
horizontal and vertical grouping categories, for example cell lines tested or treatments
applied, which will then be reected by dierent facets of a bar plot. Users can also
select an additional category called \ll" for separating bars by color to achieve a third
grouping dimension to compare, for instance, replicates with dierent numbers of depo-
sitions. The results are also shown in tabular form, including a download option, and are
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Figure 7.3: Processing of raw data in Rmiracle: Signal intensities are displayed in
heatmaps (A) for visual inspection. Subsequently, a surface adjustment based on control
spots may be performed to correct for uneven staining (B). In case of serial sample
dilutions, quantication can be applied (C) to obtain a single protein concentration
estimate (D). Furthermore, data can be normalized to negative controls (A NC1) and
total protein amount, e.g. using protein data from separate slides, which enables the
identication of eector samples (E, depicted by arrows added to the plot). Signicance
of the sample dierences is nally assessed in comparison to a selected negative control
by applying Dunnett's test (F). Taken from [176].
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further accompanied by diagnostic plots specic for the selected quantication method.
Figure 7.4 depicts the user interface of the Rmiracle analysis. Beyond data visualization
and computation of protein concentration estimates, the analysis comprises additional
features introduced below.
7.4.3.3 Comparison across Slides and Readouts
The comparison tab provides a bar plot (Figure 7.4F), in which an average is calculated
for the previously selected color ll category, since colors are here reserved for comparing
protein concentration estimates across slides. It is also possible to include plate readouts.
7.4.3.4 Correlation with Primary Readout
An important aspect of quality control is signal correlation. Since we expect the raw
signal and protein concentration estimates to follow a normal distribution, we use the
Pearson correlation coecient in the correlation tab (Figure 7.4G) to compare both,
protein concentration estimates and raw signal intensities. These are presented as a
heatmap and are also shown between slides and plate readouts. This can be an important
factor, e.g. in case a plate-based readout provides information about the total protein
amount and should therefore correlate with the RPPA signal used for normalization.
7.4.3.5 Signicance Testing
The signicance of relative dierences between samples or between samples and a control
is of great interest for experimental researchers. Traditionally, t-tests are used to obtain
the necessary p-values, often neglecting multiple comparisons correction and issues aris-
ing from low replicate numbers. To address these issues, MIRACLE applies Dunnett's
test (Figure 7.4H), which is a t-statistic based multiple comparison method designed to
keep the family-wise error below a threshold . In Dunnett's test, each sample is com-
pared with a pre-dened control. In contrast to other methods, the variance is pooled
across all samples, thereby dealing with low replicate numbers [185].
7.4.3.6 Import and Export
Convenient import functions allow experienced R users to download RPPA data directly
from MIRACLE by specifying ids or barcodes, respectively. R methods to process or
visualize these data are directly available, allowing data analysts to perform deeper
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Figure 7.4: Typical analysis using Rmiracle: A heatmap visualizes dierent slide
properties, such as signal intensities (A). Users can change various parameters, for
example inclusion of surface adjustment, selection of methods for quantication and
normalization for total protein amounts. Specic samples can be selected and grouped
based on dierent properties of the data set (B). Depending on the quantication
method, diagnostic plots are shown (C). The results are displayed in an interactive
table and in a bar plot (D,E). A global overview of protein concentration estimates is
available for all slides and plate-based readouts (F). Pearson correlation coecients are
calculated for all slides, as well as for plate-based readouts (G). Signicance is assessed
by comparing sample groups to negative controls through Dunnett's test (H). Taken
from [176].
analysis not covered by the proposed work-ow. Each slide, as well as the resulting
protein concentration estimates can be downloaded as tab- or comma-separated le, in
which all layout information is included.
7.5 Discussion & Conclusion
RPPAs are a promising technology that nds growing application in both, basic and
clinical research. While many of the challenges of this technology are similar to those
of traditional microarrays, RPPA-specic challenges arise and have to be addressed.
Especially when considering this technology as secondary readout to high throughput
genome-wide RNAi screens, comprehensive tools incorporating all necessary tasks, such
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as experimental design, sample tracking and data analysis, are essential. To ll this
gap, we developed MIRACLE , a web-based application with deep integration of R for
ecient data analysis.
With regards to sample management, both the SuperCurve package and RIMS provide a
graphical user interface for specifying slide layouts, but it does not address sample track-
ing from plate to slide level and does not allow for multiple levels of sample information.
Moreover, they lack the virtual spotting and layout editing features of MIRACLE that
enable researchers to enter all sample-related information already on the plate level and
before the complexity of the layout is increased by the array generation. This saves a
signicant amount of time and eectively avoids mistakes due to manual data processing.
The R packages SuperCurve and RPPanalyzer provide experienced R users with a wealth
of options to analyse RPPA data. The results of these methods are relative protein
concentration estimates. A logical next step could be to investigate how signicant
relative dierences in protein levels are and how well results correlate, e.g. between
slides used for normalization or between individual slides and plate-based readout. Only
RPPanalyzer reports on slide to slide correlation [181]. Signicance analysis is not
part of any existing solution. Moreover, replicates are typically merged during data
processing to increase condence of the results, thereby making them unavailable for
subsequent signicance analysis. In contrast, Rmiracle processes replicates individually
and oers a comprehensive evaluation of signicance and correlation. A number of
analysis methods, such as serial dilution curve [182] have been published as R code, but
have not been adapted to a user-friendly format, thereby limiting their application for
experimental researchers. Experienced R users, on the other hand, need the exibility
of the R environment to perform deeper analysis of the data. Rmiracle strives to serve
both target groups by incorporating a broad number of published methods on RPPA
data analysis in both, command line and web interface. Additionally, Rmiracle can
be used completely independently of the MIRACLE web application, requiring only a
local installation of R together with the required packages. To this end, data stored in
MIRACLE can imported on the R command line either via user authentication or using
a unique access token generated for each slide.
Notably, the web application RIMS followed similar goals as MIRACLE , but did not
include scenarios where more sophisticated data processing, e.g. quantication and
normalization of the signal intensities, is necessary [184]. Moreover, RIMS is not actively
developed or available at the moment, stressing the need for a solution like MIRACLE .
In recent years, the application of RPPA technology has matured considerably. Along
with this progress, suitable computational methods have been developed to address
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issues in data processing. To further promote acceptance of this technology, fully in-
tegrated tools like MIRACLE are indispensable. Furthermore, it can be expected that
standardization of RPPA data in a common framework can substantially aid the devel-
opment of novel algorithms and allow better integration at the level of network biology
and other multi-OMICS data. Finally, the integration of SAVANAH and MIRACLE
provides a solid basis to couple two eective high-throughput methods, namely HTS and
RPPA, not only on the experimental side, but also on the data management side. This
reduces unnecessary eort for entering sample information and guarantees consistency.
Finally, linking samples across OLF, SAVANAH and MIRACLE allows for these tools
to be used eciently in a drug target discovery platform.

Chapter 8
Implementation
z
Objectives of this Chapter
 Application development using the Grails web application framework.
 Concept behind the modular design of OpenLabFramework.
 Use of web services and secure tokens.
 Digital signature mechanism implemented in OpenLabNotes.
 Integration of SAVANAH and MIRACLE through a shared plug-in.
 Application development in R shiny.
8.1 Grails Applications for Sample Management
OLF (Chapter 3), SAVANAH (Chapter 5) andMIRACLE (Chapter 7) were built based
on the same technologies and concepts, which are introduced in the following.
8.1.1 Grails Web Application Framework
We considered the JavaTM based framework Grails1 to be the most promising candidate
for building a web-application. Grails is an open source project and former VMWare R
product that was built on the company's experience in industry-standard frameworks
such as Hibernate2 and Spring3, which also form the core of Grails. A plethora of
1https://grails.org/ (access date: 06/01/2015)
2http://hibernate.org/ (access date: 06/01/2015)
3https://spring.io/ (access date: 06/01/2015)
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open source plug-ins are available to deliver high-quality solutions for non-trivial web
application tasks, e.g. database search (Compass and Apache Lucene4), spreadsheet
im- and export (Apache POI 5) and a user / security management (SpringSecurity6).
Grails embraces the paradigms convention over conguration and separation of concerns
to keep the code concise and clean. Furthermore, Grails hides the complexity of data
persistence with an object relational modeling technique, which encapsulates all database
interactions and models them through Java domain classes. These characteristics allow
rapid application development and facilitate the integration of new features built on top
of reliable and robust technologies. Grails follows an extended Model View Controller
(MVC) model, which depends on the following types of classes.
8.1.1.1 Domain Classes
Domain classes are used to dene the data persistence layer of the application, i.e.
they represent the model in the MVC pattern. Domain class instances are objects that
represent rows in a relational database table, where each property corresponds either to a
column of the row or to an association with another table / domain class. Java collections
such as sets or lists allow setting up one-to-many and many-to-many associations, which
are handled automatically on the database level through mapping tables that are used
for joins. Associating database tables in this fashion raises the question of cascading
behavior. Consider an example, where a class Library has a one-to-many relationship
with another class Plate. If an instance of Library is deleted, one needs to decide
whether associated instances of Plate should also be deleted. This cascading behavior
can be dened in Grails by adding a \belongsTo" property to the domain classes. If, for
instance, the class Plate is declared with a \belongsTo Library" statement, all associated
Plate instances would be deleted along with the Library instance.
8.1.1.2 Controller and Service Classes
In the MVC pattern, the controller acts as the interface of the model and the view
and implements the application logic. Grails deviates slightly from this pattern by
splitting this functionality into two parts. Controller classes accept user input from the
view and access the model to prepare and deliver a response. However, anything more
complex than a simple information retrieval should ideally be outsourced to so-called
service classes. This has the advantage of clearly separating the negotiation between
model and view from the application logic, which in this way also becomes reusable and
4http://www.compass-project.org/ (access date: 06/01/2015)
5https://poi.apache.org/ (access date: 06/01/2015)
6http://projects.spring.io/spring-security/ (access date: 06/01/2015)
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can be shared by dierent controllers. Moreover, the default behavior of a service is
transactional, i.e. any database manipulation will roll back if something goes wrong,
thus protecting the integrity of the database.
8.1.1.3 Groovy Server Pages
Grails relies on Groovy Server Pages to realize the view part of MVC . A view is created
as a mixture of normal HTML code, which can also include java script, and java code.
When preparing a response, the embedded java or groovy code is evaluated prior to
nalizing the HTML document. Templates can be used to make parts of a view reusable.
Moreover, layouts can be dened to factor out common parts of the view. In addition, a
large number of Grails-specic or customized tags allow accessing data provided by the
server. Any dependencies, such as CSS or javascript les, are dened on the server side
as so-called resources, which then only need to be declared to be included in a view.
8.1.2 Application Security
All Grails web applications presented here utilize the SpringSecurity plug-in to restrict
access to the system. A role based access model has been established in which general
functionality is available to members of \ROLE USER", while administrative tasks are
only accessible to members of \ROLE ADMIN". To dene access rules, two dierent sys-
tems are utilized. OLF denes access rules for controllers and actions on the database
level through so-called request maps. In contrast, SAVANAH and MIRACLE use an-
notations of controllers and actions to establish access rules already on the level of the
source code. Either approach is appropriate, but annotations are easier to manage.
8.1.2.1 Data Export to R via Web Service
Data export to R is realized through Representational State Transfer (REST) web ser-
vices, in which R scripts and applications can request data from a Grails application
using HTTP requests. These can be submitted, for instance, using the RCurl R package.
The server will reply by delivering the requested content in the light-weight JavaScript
Object Notation (JSON) format, which can be processed in R using, for instance, the
package RJSONIO. The ecient conversion between database content and JSON ob-
jects is facilitated with the Jackson7 library. However, as mentioned before, access to
Grails managed content is restricted to authenticated users. To authenticate via R,
users can use Rcurl to facilitate a user login. Example code is shown in Listing D.1.
7https://github.com/FasterXML/jackson (access date: 06/01/2015)
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However, to facilitate direct integration of R shiny applications (Chapter 8.2.1) with
Grails applications, an alternative access system had to be devised. To this end, all
exportable domain classes are equipped with a security token, which is a randomly
generated universal unique identier that can not be guessed. The same concept is
found throughout the internet, where content is often shared with other users through
secure links that are based on such identiers. If a Grails web service receives a request,
it will rst check if the user is authenticated. Alternatively, the service will check if
a security token has been supplied. These are generated automatically for exportable
objects in MIRACLE and SAVANAH such as slides and plate readouts and are oered
to authenticated users for export (Figure 8.1).
Figure 8.1: Grails managed content can be exported to R via a web service. Since
access to these resources is restricted, two access models are available. Either, the
user is authenticated via username and password or a resource-specic security token
is utilized.
8.1.3 Implementation Details
8.1.3.1 OpenLabFramework
As illustrated in Figure 3.1, OLF has a modular structure, in which a back-end plug-in
provides the necessary base classes, as well as user, project and security management.
Content plug-ins can then add arbitrary classes and view templates, and integrate with
other plug-ins. All plug-ins are nally merged in the front-end application, which utilizes
the scaolding mechanism of Grails to dynamically create views.
The two most important base classes are called MasterDataObject and DataObject (Fig-
ure 8.2). MasterDataObjects can be extended by classes representing master data. This
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represents content that is maintained by system administrators, e.g. wildtype cell lines
or vector systems in the OpenLabGeneTracker module, or freezers and storage locations
in the OpenLabStorage module. More dynamic content is expressed through DataObject
classes, which can be created and modied by regular users, e.g. genes or genetically
engineered cell lines in the OpenLabGeneTracker module, or StorageElements in the
OpenLabStorage module, which represent location data through a xed position in an
associated storage box, which is in turn associated with a freezer. This hierarchy makes
OLF highly generic, but also allows ne-grained interactions between more specialized
classes. Finally, any OLF module can serve as a content provider for other modules or
the front-end. Templates for building additional tabs, menus, or add-ins can be added.
MasterData 
Object 
… Cell-Line Vector 
DataObject 
Cell 
Recombinant 
Gene Gene+Vector … 
Backend 
GeneTracker Module 
Storage 
Element 
Freezer … 
Storage Module 
… 
Figure 8.2: The back-end of OLF provides two classes MasterDataObject (MDO)
and DataObject (DO) that are extended by the dierent modules. MDOs can only
be created by administrators, whereas DOs can be created by any user. Existing DOs
and MDOs can be combined freely by module developers in order to build complex
hierarchies.
REST web service:
To allow other applications to access information maintained in OLF , a REST web
service has been implemented (Listing 8.1). Here, DataObjects in OLF can be searched
and extracted given that a so-called app access token is provided. These tokens can be
generated in the admin area of OLF with an optional expiration date. Access to the
web service is limited to secure https connections to prevent hackers from intercepting
the tokens or the content.
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1 https : // . . . / r e s t f u l / search ? query=$fqueryg&type=$ftypeg&token=$ftokeng
https : // . . . / r e s t f u l / get ? id=$f idg&token=$ftokeng
Listing 8.1: Two REST web services are available in OLF . The rst one allows for
searching DataObjects matching a query in OLF (line 1). Optionally, the type of
DataObject can be specied, e.g. gene, or cellLine. The second method can be used
to request detailed information on a particular DataObject via its id (line 2). Both
methods require an app access token that has to be provided to gain access.
8.1.3.2 OpenLabNotes
The use of base classes introduced in OLF enables modules such as OpenLabFileAt-
tachments to accommodate the additional domain class NoteItem that is introduced
by OpenLabNotes without requiring any changes. Vice versa, OpenLabNotes allows
samples to be linked to DataObjects that are generated by modules such as OpenLab-
GeneTracker. Moreover, the NoteItem class is immediately recognized by the Compass
search engine, enabling full text search on all database elds.
Frontend 
GeneTracker 
Module 
File 
Attachments 
Module 
Electronic 
Laboratory 
Notebook 
Module 
Data 
Objects 
Data 
Objects 
Data 
Objects 
Figure 8.3: Integration of OpenLabNotes in OLF. To maintain its exiblity, OLF
keeps track of arbitrary domain classes that extend a common class DataObject. This
allows for complex interactions between modules. OpenLabNotes, for instance, gen-
erates DataObjects representing experimental notes and links them to other DataOb-
jects, such as samples generated by OpenLabGeneTracker. The OpenLabFileAttachment
module can generate DataObjects encapsulating uploaded documents and links them
to either DataObjects irrespective of whether they represent samples or ELN notes.
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Digital Signatures:
ELNs are expected to comply with regulations for eective data protection. This implies
that access is generally limited to authorized users. In addition, documents need to be
digitally signed to guarantee origin, authenticity and integrity. Hash functions, such
as SHA-1, can be used to generate unique identiers of an input string representing
a document. Hash functions are one-way functions that produce a dierent output if
the input string is changed. In this way, scientic fraud can in principle be detected.
This, however, does not establish a sucient level of protection, since the hash string
in the database can simply be recomputed based on the modied document. Thus,
the hash string is protected through asymmetric public-key cryptography (Figure 8.4).
First, a public/private key pair needs to be generated for each user. When a user signs
a document, the private key, together with a password, is used to generate a digital
signature. Subsequently, a public key can be used by any user to decrypt the digital
signature and to validate the integrity of the signed document. Digital signatures are
typically embedded in a document. However, both the author and a supervisor can sign
a document, which would thus be stored redundantly in the database. We thus decided
to generate detached signatures that are kept in addition to the original document. We
apply the Digital Signature Algorithm (DSA), which is an ocially recognized standard
based on a variant of the ElGamal digital signature [120], which in turn is based on
Die-Hellman key exchange method [186]. To add DSA capabilities to OpenLabNotes,
the Bouncy Castle Java library8 was added. Apart from the document itself, it is
imperative to protect timestamps, such as the creation date and the date of signing.
Therefore, this information is included when creating the digital signature and for the
validation.
8.1.3.3 Shared Functionality between SAVANAH and MIRACLE
Both, MIRACLE and SAVANAH deal with sample information and readout data re-
lated to microtiter plates. Therefore, shared functionality is factored into a separate
Grails plug-in called HTSbackend (Figure 8.5). This does not only lead to better main-
tainability of the code, but also facilitates the integration of the two systems. This is
desirable, since RPPA technology can be used as a secondary readout for HTS . Using a
shared database, MIRACLE and SAVANAH can access and maintain the same informa-
tion and users can enter and access plate level data in any of the systems. HTSbackend
does not only provide domain classes, but also controllers and views, such that changes
on any level are automatically available in both applications. Finally, HTSbackend en-
ables the user to link cell lines created in MIRACLE or SAVANAH to cell line samples
8http://www.bouncycastle.org (access date: 06/01/2015)
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A 
B 
þ
þ
Public key 
Private key 
Detached 
signature 
Figure 8.4: Digital signatures require a pair of asymmetric keys that is generated by
OpenLabNotes for each user. A: The author uses his private key, his password and a
timestamp to sign a note. A second signature is added by the supervisor or a colleague
based on his private key, the current timestamp and the timestamp of the author. The
result is a detached signature for the author and the supervisor, respectively. B: The
public keys of the author and the supervisor, together with the original note and the
original timestamps can be used to validate the signatures.
maintained in OLF using a REST web service. This allows genetically engineered cell
lines that were used in an HTS screen and subsequent RPPA readout to be traced back
to earlier functional genomics experiments and to the current physical location of the
sample.
Library 
Diluted Library 
Plate Layout Library Plate 
Diluted Library 
Plate 
Plate 
Readout 
Slide Layout 
Slide 
Experiment 
Project 
Figure 8.5: The HTSbackend (middle) is a Grails plug-in that provides functionality
shared between SAVANAH (left) and MIRACLE (right), such as project and experi-
ments as well as management of plate level data.
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8.1.3.4 Plate and Slide Layouts
As described in Chapters 5 and 7, sample data of plates and RPPAs is divided into
layers and collected in plate- and slide layouts, respectively. To this end, plate layouts
are associated with a collection of well layouts, whereas slide layouts are associated
with a collection of spot layouts. Apart from its position, each well and spot layout is
associated with a number of attributes corresponding to the various sample properties.
Finally, all sample properties are independent domain classes and thus changes to a
sample property are automatically propagated to all plates and slides that use it.
8.1.3.5 Plates and Slides
Similar to plate and slide layouts, plates and slides are associated with a collection
of wells or spots, respectively. Each spot is linked to a spot layout and holds the
foreground and background values of the measured signal intensity. In contrast, the
measurement data of wells is stored in associated well readouts. Moreover, well readouts
are represented as a collection in a readout, which in turn is associated with a plate.
8.1.3.6 Layout Editor
Experimenters typically use spreadsheets to track the sample layout of a plate. To
provide them a similar or even better experience, the layout editor was developed. As
shown in Figures 5.2 and 7.2, the user can select one of the sample properties that is
then shown as a grid representing the plate or slide. Due to their size, slide layouts are
split into groups of blocks represented by tabs. The grid is implemented as an HTML
table combined with a java-script listener that monitors if a table cell is clicked on. The
user can select several cells for updating a sample property by drawing a box. When
the user presses the save button, the HTML table is submitted as a form, where table
cells that were altered are used to update the corresponding database entries for well or
spot layouts, respectively.
8.1.3.7 Grails OpenSeaDragon Plug-in
In order to eciently deal with large image les in MIRACLE, we created the Grails
OpenSeaDragon plug-in. The plug-in provides functionality to convert images to tiles
according to the pyramide representation dened in the Microsoft R deep zoom format.
Moreover, the OpenSeadragon java-script library is utilized to display these images pro-
viding a smooth zooming experience to the users of the system.
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8.2 R shiny Applications for Data Analysis and Visualiza-
tion
SAVANAH and MIRACLE provide sample management to HTS and RPPA data re-
spectively. Their capabilities for data analysis, however, is limited to rudimentary data
visualization. R is a language and data analysis software that is valued for its rich plug-
in ecosystem, providing powerful packages for statistics and visualization. This makes R
ideally suited to provide analysis and advanced visualization for HTS and RPPA data.
A pitfall of R, however, is that its not very user-friendly. To overcome this hindrance,
two web applications were developed in R shiny, namely RNAice for HTS data and
Rmiracle for RPPA data.
8.2.1 R shiny
R shiny is an R package that enables developers to create web applications using R
code. In this way, R packages and scripts used to analyze and visualize data can be
transformed into a more accessible web interface. Moreover, R shiny applications can
be deployed to a server, such that a user is not forced to maintain a local installation of R.
This is particularly useful considering the complexity of package dependencies, which is a
general issue for R users. The reactive programming paradigm underlying R shiny makes
it particularly useful for setting up a data processing pipeline. In reactive programming,
computationally expensive operations are encapsulated as reactive elements, which will
only be recomputed if their input changes (Figure 8.6).
Pre-processing 
Step 1 
Pre-processing 
Step 2 
Plots 
Data Tables 
Filter / Sort 
Plotting options 
Input B Input A 
Figure 8.6: Reactive programming with R shiny. Changing Input B in the user
interface will trigger a re-computation of data processing step 2, which depends on it.
However, the potentially expensive computation in processing step 1 is only repeated
if Input A is changed. Finally, the re-computation of processing step 1 will also trigger
processing step 2, which depends on step 1.
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8.2.2 Plotting
One of the most powerful plotting libraries available in R is ggplot2 9, which is used
extensively in both RNAice and Rmiracle. Developing the analysis pipelines described
above as web applications, however, suggests to utilize java-script to produce interactive
rather than static plots to improve the user experience. To this end, several java-
script libraries are available, such as highcharts10 or polycharts11, which were integrated
through the rCharts12 package.
8.2.3 Code Structure
R shiny applications typically consist of merely two les. The ui.R denes the user
interface and layout of the application, while the server.R is responsible for the applica-
tion logic and for performing computations, producing plots, etc. The server.R consists
mainly of reactive expressions that are coupled to each other, to input elements repre-
senting user interactions, and to output elements, such as plots or data tables. It can
be imagined that developing a complex application with only two les results in code
that is dicult to maintain. We realized this issue during the development of Rmiracle,
which, however, is dwarfed in complexity by RNAice. This motivated us to devise rules
for structuring R shiny code that is logical and facilitates better maintainability in the
development of RNAice.
First of all, the application logic in server.R is split into individual les. Each le delivers
either a set of related functions (similar to methods in a service class) or a set of related
output to be delivered to the ui.R. Functional code is located in a folder called server,
while output generating code is located in a sub-folder server/output. Where applicable,
complex code is factored out into separate functions located in a folder called source.
Moreover, the ui.R is split into individual les that each describe the makeup of a single
tab. These les are stored in a folder ui. Finally, all data les are located in a data
folder, while additional java-script and CSS les are located in a folder named www.
Following this scheme, server.R and ui.R merely import other les and thus remain
concise and readable. This allows developers to quickly assess in which les specic
functions are located, contributing decisively to the maintainability of the project.
9http://ggplot2.org/ (access date: 06/01/2015)
10http://www.highcharts.com/ (access date: 06/01/2015)
11http://www.polychartjs.com/ (access date: 06/01/2015)
12http://rcharts.io/ (access date: 06/01/2015)
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Discussion and Conclusion
Breast cancer is a global burden that aects women in developed as well as in developing
countries. Despite of improvements in diagnosis and therapy, it is the most common
cause of death in women [187]. Determining the optimal treatment strategy for a breast
cancer patient is complicated by the heterogeneous nature of the disease. Cancer in
general is characterized by a failure in cellular regulation and initially triggered by
point mutations in important genes. These mutations, known as driver mutations, may
occur in dierent genes participating in the same biological function and thus lead to
a similar outcome. This makes cancer a disease of pathways rather than genes [6].
Moreover, a sub-population of tumor cells, cancer stem cells (CSCs) are implicated in
treatment resistance, metastatic spread and tumor relapse (Chapter 1.2.3). In deed,
the existence of highly resilient CSCs can explain many of the properties observed in
tumors. Some commonalities that are crucial for cancer development in general have
been established in the so-called hallmarks of cancer [7]. These are caused by mutations
in cancer cells that aect a series of oncogenes, which become hyperactive and are
essential for maintaining the unnatural growth pattern of the tumor. This phenomenon,
called oncogene addiction, can be exploited for cancer specic treatment in synthetic
lethality (Chapter 1.4). Knowledge about synthetic lethal target genes can be used in
precision medicine (Chapter 1.3), which aims at optimizing the treatment of patients by
taking the molecular properties of the disease into account.
In breast cancer, several clinically relevant subtypes exist that mirror the dierent stages
of dierentiation in the normal development of mammary tissue (Chapter 1.2.2). The
relation of these subtypes to the CSC model remains unclear, but it can be suspected
that the breast cancer subtype is mostly determined by the dierentiation stage of the
founder cell. Subsequently, some tumor cells may acquire CSC characteristics. A rst
step in applying the principles of precision medicine to breast cancer patients, is the
119
Chapter 9. Discussion and Conclusion 120
successful classication of breast tumors into clinically relevant subtypes.
9.1 Classication of Breast Cancer Subtypes by Combin-
ing Gene Expression and DNA Methylation Data
Breast cancer subtype classication is currently based exclusively on histopathological
proling and on gene expression proling tests. However, the widespread availability of
other types of OMICS data in public resources such as TCGA [67] suggests an integrated
approach to improve the prediction performance of statistical learning models and to
discover novel biomarkers. In an initial project in the frame of this thesis, we thus rst
explored how the combination of two types of OMICS data, namely gene expression
and DNA methylation data, could help to improve the classication of breast cancer
subtypes (Chapter 2).
Briey, a machine learning strategy using random forests was applied to build three
statistical models. A gene expression model, a DNA methylation model, and a combined
model based on the feature sets of gene expression and DNA methylation data. The
performance of these models was compared to a control model based on the PAM50
genes that served as a gold standard to dene the subtypes of the TCGA samples.
Moreover, the robustness of these methods was assessed using .632 bootstrapping and
the accuracy was determined using the average AUC (AAUC ), which is an appropriate
measure in multi-class problems. As a result, the DNA methylation model was clearly
outperformed by both, the gene expression model and the combined model. To our
surprise, however, the combined model did not utilize a single feature from the DNA
methylation data. This suggests that the DNA methylation data is not suited for this
task and led us to speculations about the fairness of the comparison, since the class
labels were already based on gene expression data. This is also demonstrated in the
original TCGA publication on breast cancer, where it is shown that DNA methylation
data aggregates into ve clusters that do not overlap with the subtypes investigated
here [67].
The features we identied as relevant had only a small overlap with lists of known breast
cancer genes. This indicates that most of the known breast cancer genes might not be
promising candidates for subtype classication, since they are likely a common factor
across subtypes. Moreover, the discordance of features lists, where only a few genes such
as ESR1 clearly stand out, suggests that the issue that many genes have a moderate but
signicant contribution to the classication performance, might not be fully mitigated
by the recursive feature elimination strategy we applied.
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Nevertheless, we consider further investigation in the use of DNA methylation data
for breast cancer subtype classication worthwhile. It remains unclear, for instance,
if an improved pre-processing of the data might not lead to better results. The DNA
microarrays applied in this study contain an average of 17 probes per gene, which are
typically, but not exclusively, located in the promoter region of the gene. The strategy
of using the median probe signal as a representative value for each gene signicantly
reduces the size of the feature data, but might not always be appropriate in cases where
the signal varies signicantly between probes.
Moreover, alternative methods for classication might still benet from features with
moderate predictive qualities. A novel strategy currently explored by PhD candidate
Nicolas Alcaraz1, for instance, attempts to utilize pathways rather than individual genes
as features for random forest. Here, DNA methylation might contribute to a model based
on both data sets, since features are evaluated in combination, i.e. as gene sets, rather
than individually.
Most importantly, we consider the denition of subtype labels via the gene expression
based PAM50 standard as a major problem in the TCGA data set. We could already
demonstrate that some of the labels might be incorrect, which might be potentially
harmful to any attempt of including alternative OMICS data, such as DNA methylation,
miRNA expression of copy number variation data in the classication task. Alternative
independent data sets, in which subtypes have been assigned using histopathological
methods, should be included for further investigations in this direction and for model
validation.
Despite its moderate performance, the DNA methylation model results contained a num-
ber of interesting genes such as Sorcin, which warrants further investigation. In general,
OMICS data are well suited to generate sets of candidates that can then be function-
ally characterized through functional genomics. Using advanced cell manipulation tech-
niques to systematically study large sets of potential biomarkers, however, leads to a
large number of samples and demands the use of a LIMS for sample management.
9.2 OpenLabFramework: A Laboratory Information Man-
agement System with Focus On Functional Genomics
In order to retain an overview over large sample libraries typically found in nowadays
laboratories, an ecient system for management and tracking of samples is required. A
1Computational Biology Group, Department of Mathematics and Computer Science, University of
Southern Denmark
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large number of LIMS have been developed in the past, none of which, however, could
fulll the requirements we dened as essential for a productive LIMS in the eld of
functional genomics. We were thus motivated to develop OpenLabFramework (OLF )
to ideally support this important research eld in the construction and maintenance
of large libraries of vector construct and genetically modied cell lines (Chapter 3).
OLF covers most of the requirements any sample management system should fulll.
Most importantly, this includes a physical sample tracking solution that guarantees that
researchers do not waste time trying to retrieve samples that were once deposited in an
unknown location. Moreover, we implemented a mechanism for printing and reading
machine and human readable barcode labels to solve the issue of unidentiable samples.
To keep related results and documentation retrievable, OLF allows les to be uploaded
and linked to samples. To bring physical and virtual sample management closer to
each other, OLF supports mobile devices, allowing researchers to update the sample
status right away after dealing with a sample. Some of the requirements we identied
were concerned with deployment and support. Even a perfect LIMS would be of no
use if the system cannot be installed in a particular laboratory. Limitations in the
availability of a suitable server or to a certain database management system thus should
be overcome. Therefore, OLF supports a large variety of deployment scenarios and
comes with a thorough online documentation. Finally, OLF strives to overcome the
limitation of most LIMS to their respective eld of research. To this end, it is built
in strictly modular fashion and with abstract classes that allow arbitrary modules to
interact irrespective of the type of sample data. The implementation of a REST web
service allows for other applications to integrate sample information maintained in OLF
and is a signicant step towards an integrated drug discovery platform (Chapter 8.1.3.1).
Using a database-driven web application, such as OLF , for sample management oers
a number of advantages. Due to relational tables, all data are kept in a concise and
consistent format, where changes and updates are automatically propagated. In contrast
to le-based storage solutions, no experimental information is lost upon turnover of
laboratory sta and no problems arise from cryptic and inconsistent sample terminology.
Collaboratively creating experimental data is signicantly more convenient in web-based
applications, since concurrency issues, such as le locks, can be avoided. In addition, all
information can be located quickly, using full text search, which additionally increases
eciency.
OLF currently provides rudimentary data export capabilities for all types of samples
and for a number of dierent le types. These reporting capabilities, however, could be
drastically improved by introducing support for customized reports, where information
from several instances is pooled. A well known library that could be utilized to this
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end is JasperReports2. Moreover, the use of the mobile view dedicated to smartphones
and tablets could be improved signicantly by implementing a dedicated app for mobile
platforms, such as Android or iOS. A current limitation of the system, for instance, is
that barcodes have to be scanned with a third party app on the device, while a dedicated
mobile app could accommodate this directly.
Despite our best eorts, the deployment of OLF remains challenging for biologists.
Moreover, they can not easily adapt the system to their particular research require-
ments without the assistance of a software developer. It would thus be advantageous
to devise a mechanism that allows administrators of the system to dene new sample
types on the y in the running system. The use of the label printing mechanism is
currently limited to Dymo R label printers, which creates a quite strict and unwanted
dependency on the products of this company. Therefore, support for alternative label
printers should be added in the future. Finally, two requirements we proposed remain
unfullled by OLF . We suggested that integrating data analysis tools would be advan-
tageous to enable users to deal with uploaded result les appropriately. An example for
this is the OpenLabTaqMan plug-in that is currently under development. In functional
genomics, quantitative real-time polymerase chain reaction (qRT-PCR) is regularly per-
formed to measure the relative expression level of genes in samples. The intention of
OpenLabTaqMan is to process raw data uploaded by the user to provide the possibility
to retrieve, visualize, and compare several of these result les conveniently within OLF .
Finally, the requirement of audit-logging to better monitor changes to the entries in the
database and to establish a sample history remains an open challenge. A general labora-
tory task that was not covered in OLF until recently is the experimental documentation
in an ELN .
9.3 OpenLabNotes: An Electronic Laboratory Notebook
Extension for OpenLabFramework
Electronic laboratory notebooks (ELNs) provide several advantages over paper laboratory
notebooks (PLNs), such as full text search and data security. However, a major concern
in the transition from paper-based to electronic documentation of experiments is the legal
perspective. For a long time, only PLN were accepted as legal documents suitable to
protect the interest of researchers and their institutions in legal disputes over patenting.
Meanwhile, regulations for electronic data storage exist, which require that information
entered by the user is protected to prevent scientic fraud. While many ELNs and
general note-taking tools are available, none of the existing free solutions deals with
2http://community.jaspersoft.com/project/jasperreports-library (access date: 06/01/2015)
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this issue. This motivated us to develop OpenLabNotes, which is a module contributing
ELN functionality to OLF . It includes a rich text editor to provide researchers the
text editing experience they are accustomed to from popular oce software. Moreover,
documents can easily be shared between users and collected in shareable notebooks. In
addition, documents can be exported to DOCX or PDF formats. As a unique feature,
OpenLabNotes provides a sophisticated digital signature mechanism based on a state-
of-the-art Java security library. This enables the author of a note and an appointed
supervisor to use their secret passwords to digitally sign a note, which cannot be altered
anymore after this point. A timestamp is included in each signature to protect not
only the document itself, but also the time of signing, which would be crucial in a law
case. Finally, being an integrated part of OLF oers additional benets, such as the
possibility to upload and link arbitrary documents or to link the documentation to the
samples that were used in a particular experiment.
Some features are missing in the current version that we would like to implement in
the future. The introduction of user groups would make it more convenient to share
documents with several users. In addition, it would be advantageous to add an audit
logging system that could track dierent versions of a document. This would allow
for specic versions to be signed, while the document would remain editable for future
versions, thus limiting one of the current limitations of the system. Furthermore, the
digital signature only extends to the documents and embedded images, but not to les
that are uploaded and linked. Extending the signature mechanism to these les would
be benecial to allow scientists to use these les as proof for their invention. Finally, an
open issue is the exact legal status of documents maintained in OpenLabNotes. While
the implementation is open source and utilizes an established security library as well
as an accepted standard for digital signatures, it lacks formal approval by the Federal
Drug Administration, which dened the guidelines we adhere to. Further eort is thus
needed to achieve ocial recognition.
9.4 SAVANAH: Sample Management and Visual Analysis
of High-Throughput Screens
Recent advances in high-throughput functional genomics techniques and in the automa-
tion and miniaturization of high-throughput screening (HTS ) have enabled researchers
to study complex diseases, such as breast cancer, in a systematic fashion [29, 38]. More-
over, the HTS technology is ideally suited for drug target discovery [188]. Here, genes
can be identied, for instance, that cause vulnerability of cells subsequent to a partic-
ular treatment, or discover scenarios of synthetic lethality, which can be exploited to
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specically target diseased cells. HTS is typically performed using molecular libraries,
which include, for instance, small compounds that potentially act as a drug, siRNAs or
shRNAs to facilitate a gene knock-down (RNAi), sgRNAs to facilitate a gene knock-out
(CRISPR/Cas9 ), or miRNA inhibitors or mimics to perturb cellular regulation on a
higher level. The production and maintenance of such libraries is elaborate and costly,
Such that they are delivered in a set of microtiter plates in highly condensed form to
allow for several screens to be performed. Prior to a screen, these library plates need
to be diluted in several steps. This leads to a challenge in tracking various plates at
dierent dilution stages.
To enable researchers to tackle this challenge eectively, we have developed Sample
Management and Visual Analysis of HTS (SAVANAH ) (Chapter 5). SAVANAH allows
molecular libraries to be added to the system in a le upload. Subsequently, users
can browse the content of the library, search for specic samples, and create a series
of virtual diluted copies. Each library copy contains also copies of all library plates
together with their corresponding barcodes. These are automatically created to identify
the physical plates unambiguously. A number of diluted libraries can be selected in a
step-by-step guide in preparation of a screening experiment. These diluted libraries serve
as replicates and are associated through a common plate layout, which is created from
the respective library plate and additional experimental information provided by the
user. Each plate can be linked to several readouts, which can be uploaded individually
or as a batch. Finally, SAVANAH allows these data to be exported along with the
sample information for further analysis in RNAice (Chapter 6). The convenient plate
editor that displays sample information across several layers can not only be used to edit
the plate layouts used in large-scale library screens, but is also ideally suited to manually
design experiments in a smaller scale. This makes SAVANAH an attractive tool for HTS
facilities as well as for laboratories that perform a large number of plate-based assays.
There are, however, several features that would make SAVANAH more applicable for
certain use cases. While data processing and analysis is addressed by RNAice, it would
be advantageous if researchers could upload the results of the analysis to SAVANAH ,
similar to how this is handled in competing tools such as Screensaver [125]. Docu-
menting the analysis would allow for results to be retrieved more easily and would thus
improve the overall documentation. Small compound screens would benet from features
utilizing the structural information known about the tested molecules, e.g. by includ-
ing a visualization of the chemical structure based on the SMILES representation [175].
Moreover, the current focus on SAVANAH is either on primary screening or on small
customized experiments. It would be advantageous if the user was assisted in secondary
conrmation screens, where plate layouts need to be created based on a given hit list
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from the primary screen. Automated plate randomization could be oered to better ac-
commodate clustered libraries. In addition, dedicated support of deconvolution screens
would be benecial, where samples that were pooled in the primary screen are tested
individually. Information across dierent screens could be utilized, e.g. by monitoring
the performance of individual samples to determine o-target eects or other quality
problems [189]. To further increase the accessibility of the system, im- and export of
plate layouts in XLSX or CSV format should be included. SAVANAH currently ac-
commodates various types of high-throughput screening (HTS ) data, but could in the
future be extended to support high-content screening (HCS ) data. Finally, SAVANAH
could achieve broader applicability by explicitly supporting time course or dose response
studies.
9.5 RNAice: High-Throughput RNAi and Compound Screen
Evaluation for R
A single HTS screen may include several thousand of experiments, which are typically
spread across dozens of microtiter plates and which are often seeded from dierent cell
batches (Chapter 1.6). While the simple numerical output of most readouts can in
theory be evaluated relatively easily, there are numerous technical and biological factors
that introduce a signicant amount of variation, which are reviewed in [56]. A straight
forward solution to this issue is to increase the number of biological and / or technical
replicates to reduce the variation of the experimental data to a tolerable level. Moreover,
replicate plates can be randomized to reduce the eect of positional bias. However, the
signicant costs and eorts associated with these experiments do often not permit such
strategies. In consequence, primary screens are often conducted in triplicates, duplicates
or without replicates. Alternatively, one can rely on computational methods to normalize
the data for known sources of variation to increase the quality of the results.
Several strategies have been proposed in the past, reaching from control-based normal-
ization methods that utilize positive and negative controls placed on each plate. Since
controls may not always be reliable and are also limited in replicate number, plate-
based normalization is an attractive alternative, which operates under the assumption
that most of the samples in a plate do not exhibit any eect and can thus contribute
to a virtual negative control. Plate-based normalization methods can be simple, like
the z-score, which takes only the variation of all samples into account, or more com-
plex such as the B-score, which uses a two-way median polish to deal with row- and
column-specic eects. To utilize replicate data, the SSMD is useful, since it considers
the variation of the sample and the negative controls independently. The recognition
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of hits can be based on any of these methods in combination with a xed threshold, a
multiple of the SD or MAD , or based on a Bayesian model. The latter utilizes negative
control wells of the individual plates and across the experiment, as well as the variation
of the sample itself.
The success of each of these methods, which can realistically only be assessed through
the conrmation rate observed in secondary screening, depends on several factors. This
includes the quality of negative and / or positive controls, the availability and agreement
of replicates, and the magnitude of batch, plate, and positional eects. The choice of
the appropriate data processing strategy is thus not trivial. This motivated us to de-
velop RNAi and Compound Screen Evaluation (RNAice) (Chapter 6), a web application
implemented in R shiny, which in contrast to existing analysis packages for HTS data
provides a high degree of exibility in comparing dierent data processing strategies. A
rich visualization of raw data, hits, and possible indicators of variation, make RNAice
the most user-friendly HTS non-commercial analysis software currently available.
In addition to its guidance in the hit discovery process, RNAice also supports the user
in the down-stream evaluation of potential hits. This support extends to RNAi or
CRISPR/Cas9 screens, small compound screens, and, as a novelty, to miRNA inhibitor
and mimics screens. In practice, hits from small molecule or miRNA screens are mapped
to putative or known targets genes. Consequently, each of the three screen types provides
a list of genes that can be analyzed using gene set overrepresentation analysis (GSOA),
gene set enrichment analysis (GSEA) or de novo network enrichment analysis in order
to investigate these hits in the light of established biological knowledge.
Finally, RNAice allows to compare several readouts of the same screen or several screens
of the same library with dierent experimental parameters, e.g. comparing dierent
cell lines or to compare the eect of a specic treatment. Here, one of the screens
or readouts needs to be selected as a reference, i.e. hits from this screen or readout
are generally excluded from the hit lists. Subtracting such a baseline screen allows to
remove hits with unspecic eects, such as general toxicity from hits with specic eects,
such as a treatment response. This option is currently very rudimentary and provides
several angles for future improvements. It should, for instance, be possible to select
dierent normalization and hit detection methods for each of the considered screens,
since each of them might be aected from dierent sources of variation to a varying
degree. Moreover, the dierences in signal distribution between dierent readouts and
screens suggest turning towards rank-based solutions. This could be, for instance, the
use of rank products [136]. Moreover, RNAice does currently not provide any means to
eectively compare primary and secondary screening data. It should be mentioned that
in absence of raw data from small compound screens, this particular use case could not
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be tested appropriately. We are, however, currently in the process of requesting suitable
data from authors of corresponding studies.
The HTS community continues to propose new and eective normalization strategies
that can deal with known sources of variation. Such methods need to be included into
RNAice to allow for a comprehensive comparison. In this way, RNAice could in the
future not only serve as a data analysis tool, but also as a benchmark tool for method
development. In this way, it would allow for assessing the eect of various normalization
methods, such as quantile normalization. Finally, a major problem in the successful
adaption of RNAice is the absence of plate-level information from public databases such
as PubChem. This poses a signicant issue in establishing the trustworthiness of pub-
lished results, which are often based on simple and potentially ineective normalization
methods. In comparison, other research methods, such as microarray expression data,
have overcome this issue. Most journals now require that such data is deposited in
public databases such as GEO [190]. The availability of increasing amounts of HTS
data suggests to interrogate these data in conjunction through so-called meta-analysis.
However, the absence of raw data eectively prevents such studies.
9.6 MIRACLE: Microarray R-based Analysis of Complex
Lysate Experiments
In recent years, the application of RPPA technology has matured considerably. Along
with this progress, suitable computational methods have been developed to address
issues in data processing. This includes spatial correction of staining eects, the quan-
tication of signal data stemming from dilution series, and the normalization of protein
concentration estimates for the total amount of protein in a sample. However, the issue
of sample management has been widely ignored, preventing the successful application
of this technology for high-throughput scenarios.
This motivated us to developMicroarray R-based Analysis of Complex Lysate Experiments
(MIRACLE ) (Chapter 7), which is the rst open-source sample management system
dealing with bioinformatics challenges inherent to RPPA experiments. A common issue
of managing RPPAs data is the large number of sample spots for which several prop-
erties need to be tracked across dozens of slide copies. Moreover, individual slides can
be scanned with dierent settings, further increasing the number of data points. The
information for each sample spot typically includes details about the sample itself, its
treatment, and the estimated amount of cells, as well as spot specic information such
as its position on the slide, foreground and background signal, dilution, and number of
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depositions. MIRACLE provides a slide layout editor that allows users to assign and
modify these sample properties conveniently for an entire slide. To make use of the fact
that samples with varying deposition numbers are typically spotted next to each other,
MIRACLE asks the user to dene a deposition pattern. In this way, several columns or
rows of the layout can be merged, since the remaining sample properties are identical.
This simplies editing the slide layout, which is shared by all spotted copies. To further
reduce the eort for dening a slide layout, MIRACLE supports management of plate
level data. This functionality, which is shared with SAVANAH (Chapter 5), enables
users to enter sample information prior to the spotting. At this point, the location
of samples is easier to oversee for the experimenter, since the spotting process often
leads to a seemingly randomized distribution of samples across the slide. This process
is mirrored in silico by MIRACLE and referred to as virtual spotting.
Most available analysis packages for RPPA data are dicult to use for biologists without
experience in R. To mitigate this, the SuperCurve R package provides a graphical user
interface. The installation of SuperCurve, however, is extremely complex due to the
use of non-standard repositories. The R package that is part of MIRACLE has similar
issues, but can be deployed centrally thanks to R shiny. Here, data analysis is performed
remotely on a server and accessed through a web browser. Moreover, MIRACLE facil-
itates the direct export of selected RPPA slide and accompanying plate readout data
directly to the R shiny application, where it can be analyzed. This part of MIRACLE ,
called Rmiracle, also provides rich visualizations and a statistical evaluation of dier-
ences in protein amount between dierent samples. In conclusion, MIRACLE provides
a seamless transition from sample management to data analysis and supports the user
in every aspect of RPPA data handling. Possible improvements to MIRACLE include
implementing options for im- and export of plate and slide level information directly
from XLSX spreadsheets and the possibility to add the results of the analysis conducted
in Rmiracle to MIRACLE itself to allow storing this information in the database for
future reference.
To further promote acceptance of RPPA technology, fully integrated tools like MIRA-
CLE are indispensable. It can be expected that standardization of RPPA data in a
common framework can substantially aid the development of novel algorithms and al-
low for better integration at the level of network biology and other multi-OMICS data.
The Minimum Information About a Micorarray Experiment (MIAME) standard [191]
and platforms like GEO [190] oer an eective method for standardized data exchange
of gene expression array data. In GEO, users can export data to R or utilize a web-
based application called GEO2R3 for basic analysis. MIRACLE has the potential to
deliver similar features to the RPPA community in the form of an RPPA web portal for
3https://www.ncbi.nlm.nih.gov/geo/geo2r/ (access date: 06/01/2015)
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published data, similar to what has already been achieved for RNAi HTS through the
GenomeRNAi database [192]. In addition, we envision that MIRACLE could serve as a
framework for comparing the performance of various methods for RPPA data process-
ing. Finally, it is imperative to add capabilities for easier down-stream analysis on the
pathway level, for instance, by integrating with third party tools like RPPApipe [193].
9.7 An Integrated Functional Genomics Platform for Drug
Discovery
Advances in cell manipulation techniques in functional genomics allow for targeted ma-
nipulation of the genome. With this, ne grained studies of wildtype genes and / or
their mutated variants is feasible on a large scale. In high-throughput genomics, an
entire panel of isogenic cell lines is created, which can be eciently characterized using
HTS . In this way, the eects of gene perturbation can be studied on the genome level,
making such an experimental setup ideal for discovering disease vulnerability genes or
to uncover scenarios of synthetic lethality. However, the information gained by HTS ex-
periments is quite limited. While dierential HTS can identify eects that are specic
to the perturbed gene, it remains often unclear how this eect can be explained in the
frame of established knowledge of a disease. In particular in cancer research, there are
many known disease genes that could possibly be involved and deliver an explanation for
the observed eect. Therefore, RPPA technology is an appropriate secondary readout
to HTS screens that allows measuring the eect of genome perturbation on the protein
expression of known disease markers. The combination of functional genomics, HTS
and RPPAs thus constitute an eective platform for drug discovery.
A major goal of the project underlying this thesis was to develop the necessary bioinfor-
matics tools to optimally support the three integral parts of the drug target discovery
platform described above. OLF was developed to handle the sample management chal-
lenges of creating and maintaining large panels of isogenic cell lines and associated vector
constructs. SAVANAH was created to deal with the challenges of dealing with molec-
ular libraries used in HTS and to deal with the large number of diluted library plates
and assay plates that are created in the process. To provide user-friendly access to the
processing and analysis of such data, RNAice was developed. Finally, the development
of MIRACLE allowed researchers to deal with the particular challenges of RPPA data
that were introduced by the spotting process and by the necessity to spot samples in
serial dilutions. Moreover, MIRACLE provides capabilities for analyzing these data in
a user-friendly fashion. Another goal of this project was to integrate these tools to fur-
ther increase productivity in sample management and data handling and in this way,
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to complement the experimental drug target discovery platform with a corresponding
integrated bioinformatics platform. This goal could be achieved through a number of
mechanisms. The REST web service that was implemented in OLF is currently utilized
by both, SAVANAH and MIRACLE to link plate based samples to cell line samples
in OLF . Moreover, SAVANAH and MIRACLE share a common database and all plate
specic functionality, allowing researchers to generate and access assay plate and read-
out data in either of the two applications. This also guarantees that plates produced in
SAVANAH in an HTS experiment can be further processed in MIRACLE to produce
slide layouts needed for managing RPPA data. In conclusion, this establishes a thread
reaching from functional genomics, via the primary readout in HTS to the secondary
readout in RPPAs.

Chapter 10
Outlook
A central goal of the project underlying this thesis was to develop user-friendly and
eective tools for sample management and data analysis for functional genomics, HTS
and RPPAs. These tools have the potential to create an impact in each of their respec-
tive research elds. A common issue found in all of the tools developed here, however, is
the complex deployment, which might prevent other researchers from using these tools
successfully. Grails applications can be delivered as self-contained and executable JAR
les. The R shiny applications introduced here, however, require an R installation and
depend on a large number of R packages originating from several repositories, includ-
ing CRAN1, Bioconductor [194] and github2. In addition, it is quite likely that future
updates of R and / or related packages may break essential functionality of these appli-
cations. In consequence, dependent tools such as SAVANAH and MIRACLE will also
be aected. To mitigate this, we plan to release all of the software tools described here
as self-contained Docker3 images.
Docker provides an abstraction layer of the operating system and thus a novel approach
to virtualization. This allows running software through so-called docker containers,
which are light-weight and particularly suited to deliver complex systems such as the
ones described in this thesis. Containers are executed based on images, which include the
software and all of its dependencies. In this way, the software can easily be maintained
and updated through subsequent image releases. Moreover, Docker containers can share
le directories and use network ports of the host system, allowing web applications
to be deployed as if they were hosted in an ordinary way. Containers can also be
linked, thus facilitating a modular deployment of the dierent parts of the drug target
discovery platform introduced in this thesis. Finally, the light-weight abstraction model
1http://cran.r-project.org/ (access date: 06/01/2015)
2https://github.com/ (access date: 06/01/2015)
3https://www.docker.com/ (access date: 06/01/2015)
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of Docker provides nearly the same performance as a native installation, in contrast to
the considerable overhead that would be introduced by a virtual machine approach.
Another open challenge is the integration of the data analysis tools, which should be
further improved. A major goal of the drug target discovery platform described in
Chapter 1.8 is to evaluate samples with signicant eect in HTS in the context of the
observed protein expression of disease markers. However, while Rmiracle, the analysis
part of MIRACLE , can already deal with plate readouts, it does currently not benet
from the data normalization and hit discovery capabilities provided in RNAice. Con-
sequently, further eorts are necessary to better link the results of these two tools. In
addition, it remains unclear how these data can be optimally analyzed together. More re-
search in this direction is necessary, yet a straight-forward approach would be to subject
these data to de novo network enrichment to uncover the potential relationship between
disease markers and the hit genes. More sophisticated techniques may be necessary
though, such as the Bayesian network inference approach for RPPA data suggested by
Hill et al. [195].
It can be expected that the drug discovery platform described in this thesis will be ex-
tended with additional high-throughput technologies in the foreseeable future. Some of
these technologies already impact current research. It is, for instance, widely acknowl-
edged that the development of targeted therapeutics requires a better understanding of
within-tumor heterogeneity [196]. This is feasible through advances in NGS technology
that enable single cell sequencing. This has great potential to unravel the mutation
patterns leading to cancer cell dierentiation and to CSC development [197]. More-
over, this technology can be used to study the properties of metastatic cells in the
blood stream [198]. The sequencing data generated in this process will introduce new
challenges in data management, processing and integration that have to be addressed.
Moreover, recent advances in microuidics allow HTS experiments to be performed on
the single cell level [199]. The use of microuidics technology will likely require the
integration of new methods for data processing and sample tracking.
Established HTS applications such as RNAi screening might in the near future become
possible through more sophisticated technologies that enable these experiments to be
performed at a fraction of the costs. An example for this is pooled shRNA screening,
in which NGS is used to perform genome-scale RNAi in a single experiment [75]. Even
though the advance of such technologies challenge the traditional HTS platforms, it can
be expected that the unique exibility and throughput of traditional HTS will lead to
new applications. This has recently been demonstrated by the availability of genome-
wide miRNA inhibitor and mimics libraries. In conclusion, it is imperative that the
bioinformatics drug discovery platform presented in this thesis continuously evolves to
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adapt to new technologies and to new types of high-throughput applications.
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Supplemental Tables
Project Name Main purpose Built with
EnzymeTracker [104] Result & sample management, data analysis PHP
SIGLa [115] Customized experimental work-ows Java
iLAP [114] Data management, analysis, protocol design Java
BIKA [200] Whole lab work-ow for clinical studies Python
FreeLIMS [201] Sample management, reports Java
PARPs DB [110] Protein-protein interaction & data-mining Perl/Java
YourLabData [202] Sample tracking and lab notebook -
LabStoRe [203] Chemical lab stocks PHP
LabLog [204] Project Documentation Java
Open-LIMS [205] Work-ow, sample & document management PHP
ProteinTracker [109] Protein production & purication Java
AGL-LIMS [106] Genotyping work-ow Java
SMS [107] Gene mutation screening & biobanking Java
MMP-LIMS [105] Genome mapping in maize Java
LIPAGE [111] 2D gel electrophoresis based proteomics PHP
MicroGen [116] Mircoarray information and work-ow MS-Access
LISA [112] Protein crystallography PHP
MolabIS [118] Molecular genetics data Perl
SIMBioMS [117] Linking patient and high-throughput data Java
OpenFreezer [113] Sample management & tracking PHP/Python
PiMS [108] Sample tracking for protein production Java
Table A.1: A large number of open-source LIMS solutions have already been devel-
oped. However, LIMS are often customized towards a very specic type of research
data. This is an overview of existing browser-based LIMS solutions, not claiming to be
exhaustive.
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Requirements Enzyme
Tracker
Free
LIMS
SLIMS YourLab
Data
Open-
LIMS
Protein
Tracker
AGL-
LIMS
SMS Molab-
IS
SIMBio
MS
Open
Freezer
PiMS OLF
Open-source R1 3 3 3 7 3 3 3 3 3 3 3 3 3
Modularity R2 7 7 7 7 3 7 3 7 3 3 3 7 3
Sample Management R3 3 3 3 3 3 3 3 3 3 3 3 3 3
Sample Tracking R4 7 7 o 3 7 7 7 3 3 7 3 3 3
File Management R5 7 7 7 3 3 7 3 7 7 3 7 7 3
Reports R6 3 3 3 7 7 3 3 3 3 7 7 7 3
Multiple DB Support R7 7 7 7 7 7 7 3(2) 7 7 3 7 3(2) 3
Local Deployment R8 7 7 7 7 7 7 7 7 3 3 7 7 3
Cloud Deployment R9 7 7 7 7 7 7 7 7 7 7 7 7 3
Barcode Generation R10 3 7 7 7 7 7 7 3 7 7 7 7 3
Label Printing R11 7 7 7 7 7 7 7 3 7 7 7 7 3
Mobile Devices R12 7 7 7 7 7 7 7 7 7 7 7 7 3
Documentation R13 3 7 3 o 3 3 7 3 3 3 3 3 3
Data Analysis R14 3 7 7 7 o 7 7 7 7 7 7 7 7
Audit-Logging R15 3 7 3 7 7 7 7 o 7 7 7 7 7
Table A.2: Depending on its purpose, each LIMS has to fulll a dierent set of requirements. Here, we list all those requirements (R1 - R15)
that are common for all LIMS where sample management on a large scale is involved. Existing LIMS fulll these requirements to a varying degree,
including OLF. Note: o depicts limited fulllment. See Supplemental Table A.1 for references.
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Requirements IARC ELN OpenLabNotes
Userstamp and timestamp R1 3 3
Digital signing (author) R2 7 3
Digital cosigning (supervisor) R3 7 3
Notebooks R4 3 3
Projects R5 7 3
Share with specic user R6 3 3
Share with user groups R7 3 7
Comments / annotations R8 3 7
File attachments R9 3 3
Navigation interface R10 3 3
Rich text editor R11 3 3
Editor templates R12 3 7
Sort by title or date R13 3 3
Search by key words R14 3 3
Full text search R15 7 3
Export to PDF R16 3 3
Export to DOCX R17 7 3
Integration with LIMS R18 7 3
Table A.3: Feature comparison between the IARC ELN and OpenLabNotes. Here,
we list requirements (R1 - 18) that we identied as important for an ELNs.
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Requirements Mscreen Screensaver SAVANAH
Open Source R1 7 3 3
User Roles R2 3 3 3
Screening libraries R3 3 3 3
Track library plate dilutions R4 7 3 3
Control wells R5 3 3 3
Plate reformatting R6 3 7 7
Well volumes R7 7 3 7
Well deprecation R8 7 3 3
Active wells R9 3 7 7
Multi-layer plate editor R10 7 7 3
Plate Readouts R11 3 3 3
Experiment Meta Data R12 3 3 3
Cherry Picking R13 3 3 7
Plate layout randomization R14 7 3 7
Dose response curves R15 3 7 7
RNAi reagents R16 3 3 3
Chemical compounds R17 3 3 3
miRNA reagents R18 7 7 3
Full text search R19 3 3 3
External databases R20 7 3 3
Heatmap R21 3 3 3
Scatter plot R22 3 7 3
Quality Control R23 3 7 3(RNAice)
Data normalization R24 3 7 3(RNAice)
Hit discovery R25 o(SD/MAD) o 3(RNAice)
Dose response R26 3 7 7
Time series R27 7 7 7
Array-based readouts R28 7 7 3(MIRACLE)
Table A.4: Feature comparison between SAVANAH and comparable open source
solutions for managing HTS data. The identied requirements are listed here as R1 -
R28.
Plate Well.positionCatalog.Nr Probe.ID Sample.Name Accession Comment
1 A1 410007-00 34143 hsa-mir-384 MIMAT1075 NA
1 A2 410008-00 34144 hsa-mir-515-5p MIMAT2826 NA
... ... ... ... ... ... NA
Table A.5: Screening libraries can be added to SAVANAH via tab delimited les with
a specic header.
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Requirements CellHTS2 RNAither RNAice
Data Input Column Mapping R1 3 7 3
Well format conversion R2 7 7 3
PubChem AID R3 7 7 3
Quality Control Visual Inspection R4 3 3 3
Z'-factor R5 3 3 7
SSMD R6 7 7 3
Normalization Percentage of control R7 3 3 3
NPI R8 3 3 3
z-score R9 3 3 3
Robust z-score R10 3 3 3
Center by mean R11 3 3 3
Center by median R12 3 3 3
Center by shorth R13 3 7 7
B-score R14 3 3 3
Bivariate regression R15 3 7 7
Loess regression R16 3 3 7
Li-Wong rank R17 7 3 7
Quantile R18 3 3 7
Hit Detection +/- k SD R19 3 3 3
+/- k MAD R20 3 3 3
Bayes R21 7 7 3
SSMD R22 7 7 3
Data Export R23 3 3 3
Static Plots R24 3 3 3
Interactive Plots R25 7 7 3
Dierential screening R26 3 7 3
Consensus hit list R27 7 3 3
Downstream
Analysis
miRNA families R28 7 7 3
miRcancer database R29 7 7 3
miRNA targets R30 7 7 3
Chem. structure plot R31 7 7 7
Similar structures R32 7 7 7
Drug targets R33 7 7 3
GSOA R34 HTSAnalyzeR 3 HTSAnlayzeR
GSEA R35 HTSAnalyzeR 7 HTSAnlayzeR
Network enrichment R36 HTSAnalyzeR 7 KPM
Graphical or
Web interface
Data Input R37 3 7 3
Result browser R38 3 3 3
Reactive Design R39 7 7 3
Data Input
Quality Control
Normalization
Hit Discovery
Downstream
Analysis
Graphical or
Web Interface
Table A.6: Feature comparison between RNAice and other open source solutions
for analyzing HTS data across requirements previously identied as R1 - R39. Some
functionality is provided by external tools such as HTSAnalyzeR or KeyPathwayMiner
(KPM). Abbreviations: Negative percentage inhibition (NPI); Standard deviation (SD);
Median absolute deviation (MAD); Chemical (Chem.).
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Gene Symbol robust z-score
(Nickles et al.)
z-score robust
z-score
B-score
CKB -4.24 -2.13 -2.55 -2.44
CCL25 -3.24 -1.44 -1.64 -1.98
CKAP5 -3.79 -3.06 -3.87 -3.73
KIAA0999 -3.44 -1.39 -1.49 -0.64
NOP17 -3.13 -1.22 -1.35 -1.10
SEZ6L2 -2.95 -1.73 -1.86 -0.85
GPR119 -2.78 -1.90 -2.27 -2.00
KIF2B -2.75 -1.72 -1.96 -1.47
MS4A4A -2.93 -1.71 -2.11 -1.25
CLTC -2.74 -1.56 -1.88 -1.38
ITGB4BP -2.67 -1.61 -2.18 -2.06
CASP4 -2.56 -1.39 -1.59 -1.42
GH2 -2.57 -1.48 -1.59 -0.03
MEN1 -2.55 -1.37 -1.56 -1.46
C10orf64 -3.11 -2.01 -2.35 -1.82
PRO1855 -3.04 -2.14 -2.65 -2.30
FLJ10980 -2.63 -1.83 -2.29 -1.13
PTK9 -2.89 -1.76 -2.13 -1.49
ROBO4 -2.56 -1.27 -1.45 -0.74
Table A.7: The 19 suspected TNF modulators that were subjected to secondary
screening. The robust z-score obtained by Nickels et al. in comparison to z-score,
robust z-score and B-score normalized values in RNAice.
GO id Gene Set Term GSOA p adj. GSEA p adj.
GO:0003899 DNA-directed RNA polymerase activ-
ity
0 0
GO:0003735 structural constituent of ribosome 1.88e-08 0
GO:0044822 poly(A) RNA binding 1.17e-06 0
GO:0019843 rRNA binding 0.01 0.05
Table A.8: GO molecular function terms found to be signicantly overrepresented
or enriched in hits found in RNAi screening for TNF modulators. Only those results
are shown, where the adjusted p-value (Benjamini-Hochberg) was signicant in both
gene set overrepresentation analysis (GSOA) and gene set enrichment analysis (GSEA).
The minimal gene set size was 10 and the number of permutations for GSEA was 1000.
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GO id Gene Set Term GSOA p adj. GSEA p adj.
GO:0022627 cytosolic small ribosomal subunit 9.11e-14 0
GO:0005665 DNA-directed RNA polymerase II,
core complex
6.96e-08 0
GO:0015935 small ribosomal subunit 1.88e-06 0
GO:0005730 nucleolus 5.83e-05 0
GO:0005829 cytosol 0.028 0
GO:0005840 ribosome 0.01 0
Table A.9: GO cellular compartment terms found to be signicantly overrepresented
or enriched in hits found in RNAi screening for TNF modulators. Only those results
are shown, where the adjusted p-value (Benjamini-Hochberg) was signicant in both
gene set overrepresentation analysis (GSOA) and gene set enrichment analysis (GSEA).
The minimal gene set size was 10 and the number of permutations for GSEA was 1000.
GO id Gene Set Term GSOA p adj. GSEA p adj.
GO:0016032 viral process 1.77e-13 0
GO:0000184 nuclear-transcribed mRNA catabolic
process, nonsense-mediated decay
1.44e-09 0
GO:0019083 viral transcription 1.53e-11 0
GO:0006413 translational initiation 1.53e-11 0
GO:0006415 translational termination 2.80e-11 0
GO:0010467 gene expression 3.29e-11 0
GO:0006414 translational elongation 1.45e-10 0
GO:0019058 viral life cycle 8.35e-10 0
GO:0006614 SRP-dependent cotranslational protein
targeting to membrane
9.10e-10 0
GO:0016071 mRNA metabolic process 2.78e-09 0
GO:0016070 RNA metabolic process 1.15e-08 0
GO:0006412 translation 3.27e-07 0
GO:0006370 7-methylguanosine mRNA capping 6.20e-07 0
GO:0050434 positive regulation of viral transcrip-
tion
4.23e-07 0
GO:0006368 transcription elongation from RNA
polymerase II promoter
1.94e-05 0
GO:0044267 cellular protein metabolic process 3.79e-05 0
GO:0006367 transcription initiation from RNA
polymerase II promoter
0.01 0
Table A.10: GO biological process terms found to be signicantly overrepresented
or enriched in hits found in RNAi screening for TNF modulators. Only those results
are shown, where the adjusted p-value (Benjamini-Hochberg) was signicant in both
gene set overrepresentation analysis (GSOA) and gene set enrichment analysis (GSEA).
The minimal gene set size was 10 and the number of permutations for GSEA was 1000.
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KEGG id Gene Set Term GSOA p adj. GSEA p adj.
hsa03010 Ribosome 2.58e-11 0
hsa03020 RNA polymerase 8.24e-06 0
Table A.11: KEGG pathways found to be signicantly overrepresented or enriched
in hits found in RNAi screening for TNF modulators. Only those results are shown,
where the adjusted p-value (Benjamini-Hochberg) was signicant in both gene set over-
representation analysis (GSOA) and gene set enrichment analysis (GSEA). The mini-
mal gene set size was 10 and the number of permutations for GSEA was 1000.
Requirements SuperCurveRPPanalyzer RIMS MIRACLE
Open source R1 7 7 7 3
User interface R2 3 7 3 3
Plate Layouts R3 7 7 7 3
Slide Layouts R4 7 7 7 3
Projects R5 7 7 7 3
Slide copies R6 7 7 3 3
Multiple readouts R7 7 7 - 3
Plate Readouts R8 7 7 7 3
Virtual Spotting R9 7 7 7 3
Visualization R10 3 3 3 3
Surface adjustment R11 3 7 7 3
Quantication R12 3 3 7 3
Normalization R13 7 3 7 3
Signicance R14 7 7 7 3
Correlation R15 7 3 7 3
Timecourse
Analysis
R16 7 3 7 7
Network nalysis R17 7 7 3 7
Sample
Manage-
ment
Data
Analysis
Table A.12: Features of MIRACLE and other open source solutions for processing
RPPA data. Typical requirements in the eld of RPPA sample management and data
analysis are listed as R1 - R17.
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Figure B.4: The .632 bootstrap error over 10 iterations (left), the average AUC
(AAUC ) (middle), and the distribution of the number of variables across bootstrap
iterations (right) after applying random forests to the dierent models. Here, samples
labeled as normal have been excluded from model creation. For comparison, the AAUC
of the control model is also shown. Taken from [80].
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Figure B.5: The classication and out-of-bag error (OOB) of each subtype for the
control model (A), the gene expression model (B), the methylation model (C) and the
combined model (D) excluding samples labeled by PAM50 as normal and depending on
the number of trees already created in the feature selection process. Taken from [80].
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Figure B.6: Example of a heatmap covering all plates in a screen. The plot is divided
into facets, where each facet corresponds to a particular plate. The color gradient
indicates the normalized signal value. Black arrows indicate samples that are considered
as hits with the selected criteria.
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Figure B.7: A: The raw data of the dierential screen for TNF. Channel 1 depicts a
general readout of cell viability, while channel 2 corresponds to an indirect reporter of
TNF activity. The signal density plots of the two dierent replicates do not agree and
are skewed towards promoting activity in both channels. B: A z-score normalization
yields a better congruence of the density plots. C: The robust z-score achieves a nearly
perfect congruence of the density plots, which appear less skewed. D: The B-score also
achieves nearly perfect congruence and eliminates the skewing problem. However, the
density plots do not appear to follow the Gaussian distribution any more.
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Figure B.8: A: Several microtiter plates can serve as source for a single RPPA slide. B:
Each plate is subjected to multiple extractions, depending on the size of the extraction
head. C: Each extraction is deposited on the slide and the extraction head is moved
slightly to place samples next to each other. This gives rise to as many sample blocks
as there are pins on the extraction head. D: Samples are previously diluted to allow
measurement in a dynamic range. In addition, samples are spotted with varying number
of depositions.
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Figure B.9: To cover a broad dynamic range, samples are typically spotted in a
dilution series on an RPPA. Subsequently, the individual spots have to be merged into
a single representative value in a process called quantication. Taken from [176].
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Figure B.10: In some cases, a block shift is introduced during spot recognition of
RPPAs (A). As a consequence, a false signal intensity is associated with a given sample.
MIRACLE can correct this by shifting the signal intensities to their intended position
(B). Taken from [176].
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Figure B.11: Surface normalization in Rmiracle using positive control spots. A:
RPPA slide with quality problems shows uneven antibody staining. B: Positive control
spots are included at the beginning and the end of each block. C: These can be used
to calculate a generalized additive model reecting a smoothing surface. From this, an
individual correction factor can be calculated for and applied to each single spot.
Appendix C
Availability
C.1 Version Control System and Public Code Repository
Git was chosen for managing the source code produced during this thesis. This allows
storing source code in github 1, which is currently developing into the de facto standard
for open source projects in general and in the scientic community in particular. All
source code described in this thesis is available through the github accounts NanoCAN
and mlist. More detailed URLs (last access 06/05/2015) follow below.
C.2 Open Source License
The Gnu Public License v3 (GPLv3) was chosen as open-source license for the code
produced in this thesis. It is a common choice for non-commercial open-source code
that can be freely distributed, altered and re-used as long as the original source is
referenced. The GPLv3 further prohibits the commercial use of this source code by any
entity.
1http://www.github.com (accessed 06/04/2015)
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C.3 Classication of Breast Cancer Subtypes By Combin-
ing Gene Expression and DNA Methylation Data
The source code used to download and process the input data, to apply random forest
with recursive feature elimination (using the varSelRF R package) and parallelization,
as well as all the code used to produce the gures and tables for Chapter 2 is available
at
https://github.com/mlist/IB2014
C.4 OpenLabFramework
The source code for OLF is divided into several repositories reecting the modular
nature of the program.
 OpenLabBackend: https://github.com/NanoCAN/OpenLabBackend
 OpenLabGeneTracker: https://github.com/NanoCAN/OpenLabGeneTracker
 OpenLabStorage: https://github.com/NanoCAN/OpenLabStorage
 OpenLabBarcode: https://github.com/NanoCAN/OpenLabBarcode
 OpenLabAttachments: https://github.com/NanoCAN/OpenLabAttachments
A live demo of OLF can be accessed at http://www.nanocan.dk/openlabframework/
demo (username: admin, password: demo0815).
Further documentation can be found at https://github.com/NanoCAN/OpenLabFramework/
wiki
C.5 OpenLabNotes
The original implementation of OpenLabNotes was created by Michael Franz during an
individual study activity. The source code can be found at:
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https://github.com/michaelfranz89/OpenLabNotes
The source code was subsequently extended to provide additional features, such as de-
tached signatures or notebooks, and to better integrate with existing OLF functionality,
such as linking to samples, projects, and uploaded les. The source code described in
this thesis can be found at:
https://github.com/NanoCAN/OpenLabNotes
OpenLabNotes is part of OLF and uses the same documentation and demo installation
as described above.
C.6 HTSbackend
As described in Chapter 8, SAVANAH and MIRACLE share common functionality,
i.e. they both operate with sample information with regards to microtiter plates. To
avoid code redundancy and to increase maintainability, this common functionality was
factored into a separate code repository that can be integrated as a Grails plug-in. This
source code can be found at:
https://github.com/NanoCAN/HTSbackend
C.7 SAVANAH
The source code for SAVANAH will be available at this URL after its public release:
https://github.com/NanoCAN/SAVANAH (username: demo, password: demo0815)
A live demo that can interact with the live demo of OLF is available at:
http://www.nanocan.org/savanah/demo
A detailed user manual is in preparation.
C.8 RNAice
The source code for RNAice will be available at this URL after its public release:
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https://github.com/NanoCAN/RNAice
A demo installation is hosted at:
http://www.nanocan.org/rnaice/demo
A detailed user manual is in preparation.
C.9 MIRACLE
The source code for MIRACLE can be found at:
https://github.com/NanoCAN/MIRACLE
The code for Rmiracle, the R shiny application that integrates with MIRACLE and
allows processing and analysis of RPPA data, is found at:
https://github.com/NanoCAN/Rmiracle
MIRACLE allows creating zoomable views of slides using the OpenSeaDragon javascript
library. To optimally utilize this functionality, a Grails plug-in was developed and
contributed to the community. The source code can be found at:
https://github.com/mlist/grails-openseadragon-plugin
The plug-in is listed at the Grails project page:
http://grails.org/plugin/open-seadragon
A user manual for MIRACLE can be found at the project page:
http://nanocan.github.io/MIRACLE/
A live demo application that interacts with the SAVANAH and OLF demo applications
can be accessed at:
http://www.nanocan.org/miracle/demo (username: demo, password: demo0815)
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D.1 Details on Bayesian Hit Detection
Zhang et al. have proposed two dierent Bayesian models for hit discovery based on the
concept of borrowing strength across the entire experiment (Chapter 6.3.3.2). Model 1
relies only on negative control wells, while model 2 relies on negative as well as positive
control wells. Since model 2 has more parameters than model 1 and since it is, according
to Zhang et al. outperformed by model 1, we focus solely on the description of model 1.
Likelihood:
Let X1; X2;    ; Xk be log transformed signal values. For calculating the likelihood, we
assume that each sample well follows a standard distribution
Xiji  N(i; 2) (D.1)
where i denotes the center of the distribution of sample i and 
2 denotes the variance.
The following hypotheses can be tested:
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H0 : sample i 2 fno eectg (D.2)
H1 : sample i 2 factivation eectg (D.3)
H2 : sample i 2 finhibitor eectg (D.4)
Prior:
The prior distribution is dened as
i  N(0; 2) (D.5)
where 0 denotes the center and 
2 denotes the variance of the negative control. For the
negative control wells, we assume independence and equal distribution
XijN  N(N ; 2) (D.6)
where N is the mean of the negative control. The variability of the negative control
can be assumed to be identical across plates and is thus pooled.
For each plate, the negative control wells are denoted as Yij , where i denotes the index of
the negative control and j denotes the plate number. Each negative control Yij deviates
by dij from the plate-wise mean of the negative controls denoted as Yj
dij = Yij   Yj (D.7)
The estimate of the variance ^2 of the negative control is calculated as
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^2 =
P
i
P
j d
2
ijP
j nj  A
(D.8)
Assuming that samples Xi have the same variance in a given plate, we can calculate
V ar(Xi) based on the variance of the negative control plus additional variance estimated
from the sample itself, denoted as dV ar(Xi).
V ar(Xi) = ^
2 + 2 (D.9)
2 = max
hdV ar(Xi)  ^2; 0i (D.10)
Posterior: The prior mean of sample i is Yw, where w denotes the plate index of i.
The prior variance is denoted as 2. The posterior distribution is then
ijXi  N

20 + 
2Xi
2 + 2
;
22
2 + 2

(D.11)
 N

2Yw + 2Xi
V ar(Xi)
;
22
V ar(Xi)

(D.12)
where 0 is given by Yw.
Bayesian hypothesis testing: The Bayesian framework allows to detect hits based
on the signal Xi of a sample and the center of the distribution of the negative reference
0 and is weighted by the variability of both, the sample (V ar(Xi)) and the negative
control (). The p-values under the dierent hypotheses introduced above are calculated
as follows:
P (H1jXi) = P (i   0 >  jXi) (D.13)
P (H2jXi) = P (i   0 <   jXi) (D.14)
P (H0jXi) = P (ji   0j   jXi) (D.15)
= 1  P (H1jXi)  P (H2jXi) (D.16)
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Based on these p-values, the FDR can be calculated and controlled via multiple testing
correction using, for instance, the Benjamini-Hochberg method [142].
D.2 Authentication to Grails Applications in R
authent i ca t e . to . g r a i l s <  f unc t i on ( baseUrl="http :// l o c a l h o s t :8080/MIRACLE/"
, user , password , verbose=F) f
2 r e qu i r e (RCurl )
l o g i nUr l = paste ( baseUrl , " l o g i n /auth" , sep="" )
4 authent i ca t eUr l = paste ( baseUrl , " j sp r ing s e c u r i t y check" , sep="" )
6 cat ( paste ( " t ry ing to authent i ca t e user " , user ) )
agent="Moz i l l a /5 .0 "
8
#Set RCurl parameters
10 cu r l = getCurlHandle ( )
cur lSetOpt ( s s l . v e r i f y p e e r=FALSE, timeout=60, c o o k i e f i l e=t emp f i l e ( ) ,
c o o k i e j a r=t emp f i l e ( ) , useragent = agent , f o l l ow l o c a t i o n = TRUE, cu r l=
cur l , verbose=verbose )
12
#Open l o g i n page
14 getURL( log inUr l , c u r l=cu r l )
16 #Post l o g i n form
postForm ( authent i cateUr l , . params= l i s t ( j username=user , j password=
password ) , c u r l=cur l , s t y l e="POST" )
18
re turn ( cu r l )
Listing D.1: R method to authenticate to a Grails web application
